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A B S T R A C T
Background
Steroid-sparing strategies have been attempted in recent decades to avoid morbidity from long-term steroid intake among kidney
transplant recipients. Previous systematic reviews of steroid withdrawal after kidney transplantation have shown a significant increase
in acute rejection. There are various protocols to withdraw steroids after kidney transplantation and their possible benefits or harms
are subject to systematic review. This is an update of a review first published in 2009.
Objectives
To evaluate the benefits and harms of steroid withdrawal or avoidance for kidney transplant recipients.
Search methods
We searched the Cochrane Kidney and Transplant Specialised Register to 15 February 2016 through contact with the Information
Specialist using search terms relevant to this review.
Selection criteria
All randomised and quasi-randomised controlled trials (RCTs) in which steroids were avoided or withdrawn at any time point after
kidney transplantation were included.
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Data collection and analysis
Assessment of risk of bias and data extraction was performed by two authors independently and disagreement resolved by discussion.
Statistical analyses were performed using the random-effects model and dichotomous outcomes were reported as relative risk (RR) and
continuous outcomes as mean difference (MD) with 95% confidence intervals.
Main results
We included 48 studies (224 reports) that involved 7803 randomised participants. Of these, three studies were conducted in children
(346 participants). The 2009 review included 30 studies (94 reports, 5949 participants). Risk of bias was assessed as low for sequence
generation in 19 studies and allocation concealment in 14 studies. Incomplete outcome data were adequately addressed in 22 studies
and 37 were free of selective reporting.
The 48 included studies evaluated three different comparisons: steroid avoidance or withdrawal compared with steroid maintenance,
and steroid avoidance compared with steroid withdrawal. For the adult studies there was no significant difference in patient mortality
either in studies comparing steroid withdrawal versus steroid maintenance (10 studies, 1913 participants, death at one year post
transplantation: RR 0.68, 95% CI 0.36 to 1.30) or in studies comparing steroid avoidance versus steroid maintenance (10 studies,
1462 participants, death at one year after transplantation: RR 0.96, 95% CI 0.52 to 1.80). Similarly no significant difference in graft
loss was found comparing steroid withdrawal versus steroid maintenance (8 studies, 1817 participants, graft loss excluding death with
functioning graft at one year after transplantation: RR 1.17, 95% CI 0.72 to 1.92) and comparing steroid avoidance versus steroid
maintenance (7 studies, 1211 participants, graft loss excluding death with functioning graft at one year after transplantation: RR 1.09,
95% CI 0.64 to 1.86). The risk of acute rejection significantly increased in patients treated with steroids for less than 14 days after
transplantation (7 studies, 835 participants: RR 1.58, 95% CI 1.08 to 2.30) and in patients who were withdrawn from steroids at a
later time point after transplantation (10 studies, 1913 participants, RR 1.77, 95% CI 1.20 to 2.61). There was no evidence to suggest
a difference in harmful events, such as infection and malignancy, in adult kidney transplant recipients. The effect of steroid withdrawal
in children is unclear.
Authors’ conclusions
This updated review increases the evidence that steroid avoidance and withdrawal after kidney transplantation significantly increase the
risk of acute rejection. There was no evidence to suggest a difference in patient mortality or graft loss up to five year after transplantation,
but long-term consequences of steroid avoidance and withdrawal remain unclear until today, because prospective long-term studies
have not been conducted.
P L A I N L A N G U A G E S U M M A R Y
Steroid avoidance or withdrawal for kidney transplant recipients
What is the issue?
Each year more than 28,000 kidney transplants are performed globally. Kidney transplantation is the treatment of choice for eligible
people who have lost kidney function. Most kidney transplant recipients receive corticosteroids as part of their immunosuppression
treatment. Steroids are effective in preventing acute rejection, which is a major problem in the early period after kidney transplantation.
However, steroids can also lead to serious side effects when taken long-term. This review looked at two strategies to reduce steroid
administration after kidney transplantation: either discontinuing steroids soon after transplantation (within 14 days) or stopping steroid
treatment later.
What did we do?
We searched the literature up to February 2016 and identified 48 studies (7803 patients) that were evaluated in this review. Only three
studies included children. This is an update of a review that was last published in 2009.
What did we find?
Our review looked at data relating to 7803 kidney transplant recipients. We assessed the risk of bias in all studies and found that most
were unblinded, about half did not report funding sources or how they randomised and allocated study participants.
We found that the risk of acute rejection significantly increased with both steroid-reducing treatments among adults who received
kidney transplants. There was no little or no difference in the numbers of deaths or loss of transplanted kidneys for both steroid-
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reducing strategies within five years after kidney transplantation. Side effects, such as infection, cancer or diabetes after transplantation
did not differ between groups of patients whose steroids were discontinued compared with those who continued to take steroids. The
effect of steroid withdrawal in children is unclear.
Conclusions
There was no evidence to suggest a difference in patient mortality or graft loss up to five year after transplantation, but longer-term
consequences of steroid avoidance and withdrawal still remain unclear.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Steroid withdrawal versus steroid maintenance for kidney transplant recipients
Patient or population: kidney transplant recipients
Intervention: steroid withdrawal
Comparison: steroid maintenance
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Steroid maintenance Steroid withdrawal
M ortality
Follow-up: 1 year
22 per 1000 15 per 1000
(8 to 29)
RR 0.68
(0.36 to 1.3)
1913 (10) ⊕⊕©©
low1,2
Graft loss (excluding
death)
Follow-up: 1 year
32 per 1000 38 per 1000
(23 to 62)
RR 1.17
(0.72 to 1.92)
1817 (8) ⊕⊕©©
low2,3
Acute rejection
Follow-up: 1 year
152 per 1000 268 per 1000
(182 to 396)
RR 1.77
(1.2 to 2.61)
1913 (10) ⊕⊕⊕©
moderate1
NODAT
Follow-up: 5 years
57 per 1000 44 per 1000
(28 to 69)
RR 0.77
(0.49 to 1.21)
1439 (6) ⊕⊕©©
low2,4
CM V infection
Follow-up: 5 years
100 per 1000 104 per 1000
(80 to 137)
RR 1.04
(0.8 to 1.36)
1758 (5) ⊕⊕©©
low2,5
* The assumed risk is the baseline risk in the control group treated with steroid maintenance. The corresponding risk (and its 95% conf idence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io; NODAT: new-onset diabetes af ter transplantat ion; CMV - cytomegalovirus
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Most studies were unblinded (9 studies) and did not report details about random sequence generat ion or allocat ion
concealment or both (8 studies). One study had inappropriate random sequence generat ion. Four studies were industry
sponsored. ITT analysis was unclear in four.
2 Total number of events were fewer than 300.
3 Most studies were unblinded (7 studies) and did not report details about random sequence generat ion or allocat ion
concealment or both (6 studies). One study had inappropriate random sequence generat ion. Four studies were industry
sponsored. ITT analysis was unclear in two.
4 Most studies were unblinded (5 studies) and did not report details about random sequence generat ion or allocat ion
concealment or both (5 studies). Three studies were industry sponsored. ITT analysis was unclear in three studies. One study
had select ive outcome report ing.
5 Most studies were unblinded (4 studies) and did not report details about random sequence generat ion or allocat ion
concealment or both (4 studies). Three studies were industry sponsored. ITT analysis was unclear in two studies. One study
had select ive outcome report ing.
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B A C K G R O U N D
Description of the condition
Patients with end-stage kidney disease (ESKD) have to undergo
renal replacement therapy which is available either as dialysis
or kidney transplantation. Kidney transplantation is the pre-
ferred treatment for eligible patients with ESKD, because it of-
fers a nearly normal life and is associated with better survival
and quality of life compared to dialysis treatment. More than
16,000 kidney transplants are currently performed annually in
the USA (OPTN/SRTR 2014) and more than 12,000 in Europe
(ERA-EDTA 2013). Despite kidney transplants from live donors,
organ demand exceeds organ availability worldwide and the num-
ber of patients wait listed for kidney transplantation continues to
rise (ANZDATA 2012; ERA-EDTA 2013; OPTN/SRTR 2014).
Although short-term outcomes of kidney transplantation have
continuously improved since the 1980s, long-term results have
only marginally improved until today. Death with a functioning
graft and chronic allograft nephropathy are the most important
causes of graft loss (Pascual 2002). Thus, strategies that prolong
patient survival and graft patency have become a priority in kidney
transplantation.
One of the key factors that influence transplant outcomes is im-
munosuppression which prohibits progressive immune mediated
injury of the allograft. Standard immunosuppressive protocols
nowadays consist of an initial induction treatment followed by
a maintenance regimen. Immunosuppression is induced by an
intensive treatment for the initial days after transplantation ei-
ther with higher dosages of the immunosuppressive drugs or by
adding an additional immunosuppressive agent, such as anti-T-
cell antibodies or interleukin 2 receptor antibodies. Maintenance
immunosuppression usually comprises a combination of three
drug groups: calcineurin inhibitors, such as cyclosporin (CsA) or
tacrolimus (TAC), anti-proliferative agents, such as azathioprine
(AZA) or mycophenolate mofetil (MMF) and corticosteroids,
such as prednisolone.
Corticosteroids are long known for their anti-inflammatory and
immunosuppressive properties and have been used to prevent re-
jection since the early days of kidney transplantation. Although
steroids are effective in preventing acute rejection, chronic steroid
use may be an important cause of morbidity and mortality (Opelz
2005). Steroids exhibit a wide range of adverse effects, such as
skin fragility, bodyweight gain, osteoporosis and cataracts, can ad-
versely affect important cardiovascular and metabolic risk factors
including hypertension, hyperglycaemia and dyslipidaemia and
may contribute to an increased risk of infection (Coutinho 2011;
Czock 2005; Matas 2005; Patel 2001). A literature review on the
safety of low dose glucocorticoid treatment in rheumatoid arthri-
tis suggested that the toxicity of steroids is overestimated, because
adverse effects of chronic low dose steroid treatment (≤ 10 mg/
d prednisolone equivalent) were found to be modest and rarely
statistically significantly different from placebo (Da Silva 2006).
Description of the intervention
With the aim to reduce the adverse effects of long-term corticos-
teroid therapy, there has been much effort to limit the exposure
of kidney transplant recipients to steroids. Lessening exposure to
steroids can be achieved by either steroid avoidance or steroid
withdrawal. In steroid avoidance, steroids are either avoided com-
pletely or withdrawn within the first days after kidney transplanta-
tion and steroid withdrawal refers to discontinuation of steroids at
a certain time point in the later post-transplant phase. This review
evaluated all steroid avoidance or withdrawal strategies in kidney
transplant recipients.
How the intervention might work
Steroids show adverse cardiovascular and metabolic effects and
therefore discontinuing steroid treatment may take effect by a
decrease in this accelerated cardiovascular risk. However, while
steroid avoidance and withdrawal potentially reduces post-trans-
plant atherosclerosis, ischaemic heart disease, post-transplant di-
abetes and death, it may significantly increase the risk of acute
rejection. Acute rejection is associated with late graft loss, espe-
cially if rejection episodes are severe, followed by impaired kidney
function, occur late and affect arteries (Basadonna 1993; Massy
1996). The new immunosuppressants TAC and MMF have led
to important declines in the incidence of acute rejection and may
provide a more potent substrate to attempt safe steroid-free im-
munosuppression or steroid withdrawal.
Why it is important to do this review
It is important to reduce the cardiovascular risk in kidney trans-
plant recipients, who area population at increased cardiovascular
risk, but at the same time it is important to avoid rejection and
graft loss. Steroids have been associated with increased cardiovas-
cular risk in kidney transplant recipients, but long-term benefits
and harms of steroid discontinuation have not yet been estab-
lished with controlled long-term data (Knight 2010). Prednisone
was perceived as the least effective and least favoured immuno-
suppressive drug compared to calcineurin inhibitors, MMF and
AZA in a survey amongCanadian kidney transplant recipients and
the majority of US transplant physicians and surgeons stated that
steroid-free immunosuppression was a goal for future organ trans-
plant recipients (Hricik 2002; Prasad 2003). Steroid use varies
largely in clinical practice around the globe.While steroids are dis-
continued in many centres worldwide, they are at the same time
frequently used for long-term treatment in kidney transplant re-
cipients to protect the allograft. There is no consensus whether
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discontinuation of steroids is safe, what type of patients benefit
from steroid discontinuation and at what time point after trans-
plantation steroids are best stopped. A number of RCTs evaluat-
ing steroid avoidance or withdrawal at various time-points after
kidney transplantation with different immunosuppressive regimes
have been performed during the last decades and were first system-
atically reviewed in 2009 (Pascual 2009). Steroid avoidance and
steroid withdrawal strategies in kidney transplantation were not
associated with increased patient mortality or graft loss, despite an
overall higher incidence of acute rejection for steroid withdrawal
strategies compared with steroid maintenance. The aim of this re-
view was to update the benefits and harms of steroid withdrawal
and avoidance in kidney transplant recipients with new evidence
from RCTs.
O B J E C T I V E S
To evaluate the benefits and harms of steroid withdrawal or avoid-
ance for kidney transplant recipients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs or quasi-RCTs (in which allocation to treatment was
obtained by alternation, use of alternate medical records, date of
birth or other predictable methods), whether published or un-
published, in which steroids were avoided or withdrawn at any
time point after kidney transplantation were eligible for inclusion.
RCTs evaluating any other steroid-sparing strategy (i.e. dose re-
duction) or attempting other interventions in addition to steroid
withdrawal (i.e. switch from AZA to MMF, induction treatment
in addition to steroid withdrawal) were excluded in this review.
Types of participants
Adult and paediatric recipients of a first or subsequent kidney
transplant from a cadaveric or living donor. Recipients of mul-
tiorgan transplants (kidney-pancreas, kidney-liver, kidney-heart)
were excluded.
Types of interventions
• Steroid avoidance, defined as steroid use during less than 14
days after kidney transplantation versus steroid maintenance
• Steroid withdrawal, defined as steroid use for more than 14
days after transplantation versus steroid maintenance
• Steroid avoidance versus steroid withdrawal.
Types of outcome measures
Outcome measures used by transplant registries to report patient
and graft survival were selected for this review. Outcome events
were assessed within the first year and up to five years after kidney
transplantation. A secondary outcome looking at infection has
been amended for this update to specify cytomegalovirus (CMV)
infection.
Primary outcomes
1. All-cause mortality
2. Graft loss or death with a functioning graft; and graft loss
censored for death with a functioning graft (loss of graft function
resulting in either return to dialysis or retransplantation)
3. Acute rejection (clinically suspected and treated) and
biopsy-proven acute rejection.
Secondary outcomes
1. Cardiovascular events
2. New-onset diabetes after transplantation (NODAT)
3. Malignancy
4. Infection and CMV infection
5. Kidney function measures (serum creatinine (mg/dL);
creatinine clearance (mL/min)).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Specialised
Register up to 15 February 2016 through contact with the In-
formation Specialist using search terms relevant to this review.
The Specialised Register contains studies identified from several
sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the
proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of Cochrane Kidney and Transplant. Details of these
strategies, as well as a list of handsearched journals, conference
7Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
proceedings and current awareness alerts, are available in the Spe-
cialised Register section of information about Cochrane Kidney
and Transplant.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and
clinical practice guidelines.
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategies described was used to obtain title and ab-
stracts of studies relevant to this review. Three authors indepen-
dently screened titles and abstracts, and discarded reports that were
not applicable. Studies and reviews that might include relevant
data or information on studies were retained initially and two au-
thors independently assessed retrieved abstracts and, if necessary
the full text, of these studies to determine which studies satisfied
the inclusion criteria. Disagreement about inclusion was resolved
by discussion with a third author.
Data extraction and management
Two authors independently carried out data extraction using stan-
dard data extraction forms. Studies reported in non-English lan-
guage journals will be translated before assessment. Where more
than one report of a study existed, reports were grouped together
and the publication with the most complete data was used in the
analyses. We examined any prior or subsequent report for sup-
plementary outcomes or data to ensure the inclusion of all rel-
evant information. If data were unclear, ambiguous or missing,
authors were contacted for further information and any provided
additional data was included in the review. Whenever necessary,
disagreements were resolved by discussion.
Assessment of risk of bias in included studies
Two authors independently assessed the following items using the
risk of bias assessment tool (Higgins 2011) (see Appendix 2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study?
◦ Participants and personnel (performance bias)
◦ Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes resultswere expressed as risk ratio (RR)
with 95% confidence intervals (CI). Where continuous scales of
measurement were used to assess the effects of treatment, themean
difference (MD) was used, or the standardised mean difference
(SMD) if different scales had been used.
Unit of analysis issues
The unit of analysis was the study participant and not the events;
that is the number of study participants with an acute rejection
rather than the number of episodes of acute rejection.
Dealing with missing data
Any further information required from the original author was
requested by written correspondence (e.g. emailing corresponding
author) and any relevant information obtained in this manner was
to be included in the review. Evaluation of important numerical
data such as screened, randomised patients as well as intention-to-
treat, as-treated and per-protocol population will be carefully per-
formed. Attrition rates, for example drop-outs, losses to follow-up
and withdrawals were investigated. Issues of missing data and im-
putation methods (for example, last-observation-carried-forward)
were critically appraised (Higgins 2011). If standard deviation was
not available, it was estimated using standard error (if provided)
(Higgins 2011).
Assessment of heterogeneity
Heterogeneity was analysed using a Chi2 (on N-1 degrees of free-
dom, with an alpha of 0.05 used for statistical significance) and
with the I2 statistic, calculated to measure the proportion of total
variation in the estimates of treatment effect that was due to het-
erogeneity beyond chance (Higgins 2003). I2 values of 25%, 50%
and 75% correspond to low, medium and high levels of hetero-
geneity.
Assessment of reporting biases
We assessed publication bias by constructing funnel plots for pri-
mary outcomes if there was sufficient data available to enable this
analysis (at least 10 included studies in the meta-analysis).
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Data synthesis
Data were pooled for summary estimates using the random-effects
model but the fixed-effect model was also to be used to ensure
robustness of the model chosen and susceptibility to outliers. Re-
sults reported used the random-effects model because this is more
conservative in the presence of known or unknown heterogeneity
(Deeks 2001).
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were used to explore possible sources of het-
erogeneity and potential effect modifiers were defined a priori.
The main source of heterogeneity among participants could be re-
lated to age, therefore adults and children who were kidney trans-
plant recipients were analysed separately. Heterogeneity in treat-
ments could be related to duration of steroid therapy and con-
comitant immunosuppressants. Therefore subgroup analysis was
undertaken using stratified meta-analysis for type of calcineurin
inhibitor, type of antimetabolite and whether an induction treat-
ment was administered.
Sensitivity analysis
Sensitivity analysis was performed to demonstrate that final results
did not vary where low quality studies were included or excluded.
Low quality studies were defined based on publication type (con-
ference abstract or peer reviewed journal) andmethodological con-
duct (whether intention-to-treat analysis was assessed as adequate
or inadequate/unclear).
R E S U L T S
Description of studies
Results of the search
A search in 15 February 2016 identified 151 reports. Additionally
three previously excluded studies were re-evaluated and included;
these had been incorrectly excluded for reasons of insufficient data
(Aswad 1998; Kacar 2004; Pisani 2001). All three are published
as abstract only. Pisani 2001 contributed data for the meta-analy-
sis. We also re-evaluated three previously included studies and ex-
cluded them because they had been incorrectly included despite a
wrong co-intervention (CARMEN Study 2005; Tarantino 1991;
terMeulen 2002). In CARMENStudy 2005 and terMeulen 2002
induction treatment with daclizumab was only given to patients
in the steroid withdrawal group and in Tarantino 1991 AZA was
given solely to patients in the steroid maintenance group. We in-
cluded 21 new studies (59 reports) that involved 1854 partici-
pants, two of these new studies (seven reports) concerned chil-
dren. We found that 88 new reports were additional reports of
previously included studies. This update includes 48 studies (224
reports) that involved 7803 participants, including three studies
(11 reports) that involved 346 children. See Figure 1.
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Figure 1. Study flow diagram.
Included studies
See Characteristics of included studies.
The 48 included studies were published in 22 different journals
and seven had preliminary abstract data only available (Aswad
1998; Burke 2000; del Castillo 2005; INFINITY Study 2013;
Kacar 2004; Kim 2002; Pisani 2001).The effect of steroid with-
drawal compared versus steroid maintenance was investigated in
26 studies (4022 participants) and the effect of steroid avoidance
compared versus steroid maintenance was investigated in 19 stud-
ies (3401 participants). We identified three studies (380 partici-
pants) that evaluated the effect of steroid avoidance compared ver-
sus steroid withdrawal. Numbers of participants per study varied
from 21 (Aswad 1998) to 560 patients (THOMAS Study 2002).
It is noteworthy that 25 studies randomised fewer than 100 par-
ticipants, 15 studies included between 100 and 300 participants,
and eight studies randomised more than 300 participants.
Trials in adult kidney transplant recipients
This update included 45 studies (208 reports, 7457 participants)
of steroid withdrawal or avoidance in adult kidney transplant re-
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cipients.
Participants
Trials recruited participants who were older than 18 years of age,
except two studies which recruited participants older than 12
years (Stiller 1983) or between five and 62 years (Nagib 2015).
In 14 studies the age range was not further specified (Albert
1985; Aswad 1998; Gulanikar 1991; INFINITY Study 2013;
Isoniemi 1990; Johnson 1989a; Kacar 2004; Kim 2002; Ratcliffe
1993; Schulak 1989; Smak Gregoor 1999; Sola 2002; THOMAS
Study 2002; Zhu 2008a).The majority of studies included ca-
daveric and living kidney transplant recipients (25 studies: Ahsan
1999; ATLAS Study 2005; Boletis 2001; Boots 2002; Burke 2000;
DOMINOSStudy 2012; EVIDENCEStudy 2014; Farmer 2006;
FREEDOM Study 2008; Gulanikar 1991; Jankowska-Gan 2009;
Kim 2002; Kumar 2005; Laftavi 2005; Lebranchu 1999; Matl
2000; Montagnino 2005; Nott 1985; Pelletier 2006; Schulak
1989; Stiller 1983; Smak Gregoor 1999; THOMAS Study 2002;
Vincenti 2003a; Woodle 2005). Kidney transplantation was lim-
ited to cadaveric donor sources in 11 studies (Bouma 1996; De
Vecchi 1986; FRANCIA Study 2007; Isoniemi 1990; Johnson
1989a; Maiorca 1988; Ponticelli 1997; Ratcliffe 1993; Sandrini
2009; Sola 2002; Zhu 2008a) and to living donors in four stud-
ies (Aswad 1998; Nagib 2015; Nematalla 2007; Park 1994) In
17 studies first or subsequent kidney transplant recipients were
eligible (Boots 2002; Bouma 1996; DOMINOS Study 2012;
EVIDENCE Study 2014; Farmer 2006;Gulanikar 1991; Johnson
1989a; Lebranchu 1999; Montagnino 2005; Nott 1985; Pisani
2001; Ponticelli 1997; Ratcliffe 1993; Schulak 1989; Stiller 1983;
THOMAS Study 2002;Woodle 2005), while in 19 studies limited
participants to recipients of first kidney transplants (Ahsan 1999;
ATLAS Study 2005; Boletis 2001; Burke 2000; del Castillo 2005;
FRANCIA Study 2007; FREEDOM Study 2008; INFINITY
Study 2013; Isoniemi 1990; Kumar 2005; Laftavi 2005; Maiorca
1988; Matl 2000; Nagib 2015; Nematalla 2007; Park 1994;
Pelletier 2006; Sandrini 2009; Vincenti 2003a).
Study comparisons
The 45 included studies evaluated three different comparisons in
adults.
• Steroid withdrawal compared versus steroid maintenance
was investigated in 24/45 studies in adult patients (Ahsan 1999;
Albert 1985; Aswad 1998; Boletis 2001; Bouma 1996; Burke
2000; del Castillo 2005; EVIDENCE Study 2014; Farmer 2006;
Gulanikar 1991; Isoniemi 1990; Jankowska-Gan 2009; Kacar
2004; Lebranchu 1999; Maiorca 1988; Matl 2000; Park 1994;
Pelletier 2006; Pisani 2001; Ratcliffe 1993; Smak Gregoor 1999;
Sola 2002; THOMAS Study 2002; Zhu 2008a). Steroids were
withdrawn three months after transplantation in eight studies
(Ahsan 1999; EVIDENCE Study 2014; Gulanikar 1991;
Isoniemi 1990; Lebranchu 1999; Park 1994; Sola 2002;
THOMAS Study 2002); six months after transplantation in
eight studies (Albert 1985; Aswad 1998; Boletis 2001; Burke
2000; del Castillo 2005; Pisani 2001; Smak Gregoor 1999; Zhu
2008a); one year after transplantation in one study (Matl 2000),
and beyond one year after transplantation in six studies (Bouma
1996; Farmer 2006; Jankowska-Gan 2009; Kacar 2004; Maiorca
1988; Ratcliffe 1993). In one study, steroids were withdrawn at
different time points after transplantation and the time point of
withdrawal was not reported, but all patients had steroids for
more than 14 days (Pelletier 2006).
• Steroid avoidance compared versus steroid maintenance was
investigated in 18/45 studies in adult kidney transplant
recipients (ATLAS Study 2005; De Vecchi 1986; FRANCIA
Study 2007; FREEDOM Study 2008; Nott 1985; INFINITY
Study 2013; Johnson 1989a; Kim 2002; Kumar 2005; Laftavi
2005; Stiller 1983; Montagnino 2005; Nagib 2015; Nematalla
2007; Ponticelli 1997; Schulak 1989; Vincenti 2003a; Woodle
2005). In two studies steroids were not given at any time point
before, during or after transplantation (FREEDOM Study 2008;
Stiller 1983). Steroids were withdrawn until day seven after
transplantation in 12 studies (ATLAS Study 2005; De Vecchi
1986; FRANCIA Study 2007; Nott 1985; Johnson 1989a; Kim
2002; Kumar 2005; Laftavi 2005; Montagnino 2005; Nematalla
2007; Ponticelli 1997; Vincenti 2003a) and between day 8 and
day 14 in two studies (Schulak 1989; Woodle 2005).
• Steroid avoidance was compared versus steroid withdrawal
in 3/45 studies with adults (Boots 2002; DOMINOS Study
2012; Sandrini 2009). In all of these three studies, steroids were
withdrawn until day seven after transplantation in the avoidance
group and between three to six months after transplantation in
the withdrawal group.
Immunosuppression
CsA was used in 34 studies evaluating steroid withdrawal or
steroid avoidance (Ahsan 1999; Albert 1985; Boletis 2001;
Bouma 1996; Burke 2000; del Castillo 2005; De Vecchi 1986;
DOMINOSStudy 2012; EVIDENCEStudy 2014; Farmer 2006;
FRANCIA Study 2007; FREEDOM Study 2008; Gulanikar
1991; INFINITY Study 2013; Isoniemi 1990; Jankowska-Gan
2009; Johnson 1989a; Kim 2002; Kumar 2005; Lebranchu 1999;
Maiorca 1988; Matl 2000; Montagnino 2005; Nott 1985; Park
1994; Pelletier 2006; Pisani 2001; Ponticelli 1997; Ratcliffe 1993;
Sandrini 2009; Schulak 1989; Smak Gregoor 1999; Vincenti
2003a). TAC was used in 10 studies investigating steroid with-
drawal or steroid avoidance (Aswad 1998; ATLAS Study 2005;
Boots 2002; Laftavi 2005; Nagib 2015; Nematalla 2007; Sola
2002; THOMAS Study 2002; Woodle 2005; Zhu 2008a). One
study provided no information about the baseline immunosup-
pression used (Kacar 2004).Of the three studies comparing steroid
avoidance with steroid withdrawal, two used a CsA-based im-
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munosuppression (DOMINOS Study 2012; Sandrini 2009) and
one used a TAC-based immunosuppression (Boots 2002).
Five studies investigated steroid withdrawal compared versus
steroid maintenance in patients without an additional antiprolif-
erative immunosuppressant (either MMF or enteric-coated my-
cophenolate sodium or AZA or mTOR-inhibitor) (Albert 1985;
Bouma 1996; Gulanikar 1991; Maiorca 1988; Park 1994) and
five studies investigated steroid avoidance compared versus steroid
maintenance without an additional antiproliferative (De Vecchi
1986; Johnson 1989a; Nott 1985; Stiller 1983; Ponticelli 1997).
Steroid avoidance compared versus steroid withdrawal in patients
without an antiproliferative was investigated in Boots 2002. An
immunosuppressive regimen including an additional antiprolifer-
ative agent was used in 18 studies that investigated steroid with-
drawal compared versus steroid maintenance (Ahsan 1999; Aswad
1998; Boletis 2001; Burke 2000; del Castillo 2005; EVIDENCE
Study 2014; Farmer 2006; Isoniemi 1990; Jankowska-Gan 2009;
Lebranchu 1999;Matl 2000; Pelletier 2006; Pisani 2001; Ratcliffe
1993; Smak Gregoor 1999; Sola 2002; THOMAS Study 2002;
Zhu 2008a). Of these 18 studies, 12 used MMF (Ahsan 1999;
Boletis 2001; del Castillo 2005; Burke 2000; Jankowska-Gan
2009; Pelletier 2006; Pisani 2001; Smak Gregoor 1999; Sola
2002; THOMAS Study 2002; Lebranchu 1999; Zhu 2008a),
five used AZA (Aswad 1998; Farmer 2006; Isoniemi 1990; Matl
2000; Ratcliffe 1993), and one used Everolimus (EVIDENCE
Study 2014). Steroid avoidance compared versus steroid main-
tenance using an additional antiproliferative immunosuppressant
was used in 13 studies (ATLAS Study 2005; FRANCIA Study
2007; FREEDOM Study 2008; INFINITY Study 2013; Kim
2002; Kumar 2005; Laftavi 2005; Montagnino 2005; Nagib
2015; Nematalla 2007; Schulak 1989; Vincenti 2003a; Woodle
2005).Of these, nine usedMMF (ATLASStudy 2005; FRANCIA
Study 2007; Kim 2002; Kumar 2005; Laftavi 2005; Nagib 2015
Nematalla 2007; Vincenti 2003a; Woodle 2005), two used en-
teric-coated mycophenolate sodium (FREEDOM Study 2008;
INFINITY Study 2013), one used AZA (Schulak 1989), and one
used everolimus (Montagnino 2005). Steroid avoidance compared
versus steroid withdrawal in patients treatedwith an additional an-
tiproliferative was investigated in two studies (DOMINOS Study
2012; Sandrini 2009). One study used enteric-coated mycophe-
nolate sodium (DOMINOS Study 2012) and one used sirolimus
(Sandrini 2009) as the third immunosuppressant.
Induction treatment was administered in 17 studies with adult
kidney transplant recipients in three studies comparing steroid
withdrawal with steroid maintenance (EVIDENCE Study 2014;
Pelletier 2006; Pisani 2001), in 12 studies comparing steroid
avoidance with steroid maintenance (FRANCIA Study 2007;
FREEDOM Study 2008; INFINITY Study 2013; Kim 2002;
Kumar 2005; Laftavi 2005; Montagnino 2005; Nagib 2015;
Nematalla 2007; Schulak 1989; Vincenti 2003a; Woodle 2005),
and in two studies comparing steroid avoidance with steroid with-
drawal (DOMINOS Study 2012; Sandrini 2009). In 12 stud-
ies an IL-2 receptor antagonist was used for induction treatment
(DOMINOSStudy 2012; EVIDENCEStudy 2014; FREEDOM
Study 2008; INFINITY Study 2013; Kim 2002; Kumar 2005;
Montagnino 2005; Nagib 2015; Nematalla 2007; Pisani 2001;
Sandrini 2009; Vincenti 2003a), in three studies an anti-lym-
phocytic depleting antibodies was used (FRANCIA Study 2007;
Laftavi 2005; Schulak 1989) and two studies allowed the type
of induction treatment to be chosen by the investigator (Pelletier
2006; Woodle 2005).
Studies in child kidney transplant recipients
This update included three studies (11 reports, 346 participants)
of steroid withdrawal or avoidance in child kidney transplant re-
cipients (Benfield 2005; Höcker 2009; Mericq 2013).
Participants
Studies recruited participants who were younger than 20 years of
age. All three studies included cadaveric and living kidney trans-
plant recipients. In Benfield 2005 andMericq 2013 only first kid-
ney transplant recipients were eligible; in Höcker 2009 first or
subsequent kidney transplantation was included.
Study comparisons
The three studies evaluated two different comparisons in children.
Benfield 2005 and Höcker 2009 investigated steroid withdrawal
versus steroid maintenance; Mericq 2013 investigated steroid
avoidance versus steroid withdrawal.
Immunosuppression
All three studies used a calcineurin inhibitor-based immunosup-
pressive regimen including an additional antiproliferative agent.
Höcker 2009 used CsA and MMF, Benfield 2005 allowed either
CsA or TAC to be used with sirolimus andMericq 2013 used TAC
in combination with MMF. Benfield 2005 and Mericq 2013 also
used basiliximab for induction treatment, but Benfield 2005 was
terminated early when theData SafetyMonitoringBoard noted an
excess risk of post-transplant lymphoproliferative disease in both
treatment groups.
Reported outcome measures
The reporting of outcome measures varied across studies. Of the
45 included studies, 34 reported patientmortality and 23 reported
acute rejection (see Figure 1). Reporting of harms was more lim-
ited and inconsistent among studies (six studies reported cardio-
vascular events with varying definitions of cardiovascular events or
definitions not reported). Frequently, studies reported incomplete
data for harm outcomes or expressed their results as ’episodes’,
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which complicated meaningful use of such data in the meta-anal-
ysis.
Excluded studies
We excluded a total of 48 studies because studies: were not ran-
domised (12), concerned ineligible populations (3), involved in-
eligible interventions ( 11) or ineligible co-interventions (22).
Risk of bias in included studies
Reporting of details of study methodology regarding design and
conduct of the study was incomplete in most studies. The assess-
ment of risk of bias is shown in Figure 2 and Figure 3. Figure 2
shows the risk of bias indicators for individual studies. Figure 3
shows the proportion of studies assessed as low, high or unclear
risk of bias for each risk of bias indicator.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
Allocation
Random sequence generation was judged to be at low risk of bias
in 19 studies (Ahsan 1999; ATLAS Study 2005; Benfield 2005;
DOMINOS Study 2012; EVIDENCE Study 2014; FRANCIA
Study 2007; FREEDOM Study 2008; Gulanikar 1991; Höcker
2009; Johnson 1989a; Kumar 2005; Laftavi 2005; Mericq 2013;
Montagnino 2005; Nematalla 2007; Ponticelli 1997; Schulak
1989; Stiller 1983; Woodle 2005) and considered at high risk
in two studies (Aswad 1998; Matl 2000). Randomisation meth-
ods were not reported in 27 studies (Albert 1985; Boletis 2001;
Boots 2002; Bouma 1996; Burke 2000; del Castillo 2005; De
Vecchi 1986; Farmer 2006; INFINITY Study 2013; Isoniemi
1990; Jankowska-Gan 2009; Kacar 2004; Kim 2002; Lebranchu
1999;Maiorca 1988; Nagib 2015; Nott 1985; Park 1994; Pelletier
2006; Pisani 2001; Ratcliffe 1993; Sandrini 2009; Smak Gregoor
1999; Sola 2002; THOMAS Study 2002; Vincenti 2003a; Zhu
2008a).
Allocation concealment was assessed to be at low risk of bias in
14 studies (ATLAS Study 2005; Boots 2002; De Vecchi 1986;
DOMINOS Study 2012; Farmer 2006; FRANCIA Study 2007;
Gulanikar 1991; Isoniemi 1990;Mericq 2013;Montagnino 2005;
Nematalla 2007; SmakGregoor 1999; Stiller1983;Woodle 2005);
no study was judged to be at high risk of bias. Methods used for
allocation concealment were unclear in the remaining 34 studies
(Ahsan 1999; Albert 1985; Aswad 1998; Benfield 2005; Boletis
2001; Bouma 1996; Burke 2000; del Castillo 2005; EVIDENCE
Study 2014; FREEDOM Study 2008; Höcker 2009; INFINITY
Study 2013; Jankowska-Gan 2009; Johnson 1989a; Kacar 2004;
Kim 2002; Kumar 2005; Laftavi 2005; Lebranchu 1999; Maiorca
1988; Matl 2000; Nagib 2015; Nott 1985; Park 1994; Pelletier
2006; Pisani 2001; Ponticelli 1997; Ratcliffe 1993; Sandrini
2009; Schulak 1989; Sola 2002; THOMAS Study 2002; Vincenti
2003a; Zhu 2008a).
Blinding
Participants and investigators were blinded in only five studies (
Ahsan1999; Benfield2005; Burke 2000;Gulanikar 1991;Woodle
2005). The absence of blinding was judged as high risk of bias
because clinical management could be influenced by knowledge of
treatment group. Blinding of outcome assessment was considered
as low risk of bias because outcomes were objective and therefore
more robust against influence by knowledge of treatment group
(e.g. death, graft loss, serum creatinine).
Incomplete outcome data
Incomplete outcome data was judged to be at low risk of bias in 22
studies (Ahsan 1999; ATLAS Study 2005; Benfield 2005; Boots
2002; Bouma 1996; del Castillo 2005; DOMINOS Study 2012;
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FRANCIA Study 2007; FREEDOM Study 2008; Gulanikar
1991; Höcker 2009; Isoniemi 1990; Kumar 2005; Matl 2000;
Montagnino 2005; Ponticelli 1997; Ratcliffe 1993; Schulak 1989;
Smak Gregoor 1999; THOMAS Study 2002; Vincenti 2003a;
Woodle 2005). Exclusion of participants after randomisation and
attrition were considered at high risk in four studies (Boletis 2001;
Burke 2000; De Vecchi 1986; Nagib 2015). Methods for ad-
dressing incomplete outcome data remained unclear in 22 stud-
ies (Albert 1985; Aswad 1998; EVIDENCE Study 2014; Farmer
2006; INFINITY Study 2013; Jankowska-Gan 2009; Johnson
1989a; Kacar 2004; Kim 2002; Laftavi 2005; Lebranchu 1999;
Maiorca 1988; Mericq 2013; Nematalla 2007; Nott 1985; Park
1994; Pelletier 2006; Pisani 2001; Sandrini 2009; Sola 2002;
Stiller 1983; Zhu 2008a).
Selective reporting
Selective outcome reporting was judged as low risk in 37 studies
(Ahsan 1999; Aswad 1998; ATLAS Study 2005; Benfield 2005;
Boots 2002; Bouma 1996; del Castillo 2005; De Vecchi 1986;
DOMINOS Study 2012; EVIDENCE Study 2014; FRANCIA
Study 2007; FREEDOM Study 2008; Höcker 2009; INFINITY
Study 2013; Isoniemi 1990; Jankowska-Gan 2009; Kacar 2004;
Kumar 2005; Lebranchu 1999;Maiorca 1988;Matl 2000;Mericq
2013; Montagnino 2005; Nagib 2015; Nematalla 2007; Park
1994; Pelletier 2006; Pisani 2001; Ponticelli 1997; Sandrini 2009;
Schulak 1989; Smak Gregoor 1999; Sola 2002; Stiller 1983;
THOMAS Study 2002; Vincenti 2003a; Woodle 2005). Eleven
studies did not report all hard clinical outcomes that were consid-
ered primary outcomes for this review and were assessed as high
risk of bias for selective outcome reporting (Albert 1985; Boletis
2001; Burke 2000; Farmer 2006; Gulanikar 1991; Nott 1985;
Johnson 1989a; Kim 2002; Laftavi 2005; Ratcliffe 1993; Zhu
2008a).
Other potential sources of bias
Funding from academic independent sources was considered
as low risk of bias in four studies (De Vecchi 1986; Isoniemi
1990; Matl 2000; Mericq 2013). In 16 studies a pharmaceuti-
cal company was reported as funding source, which was judged
as high risk of bias (Ahsan 1999; ATLAS Study 2005; Benfield
2005; Bouma 1996; DOMINOS Study 2012; FRANCIA Study
2007; FREEDOMStudy 2008; Kumar 2005; Montagnino 2005;
Gulanikar 1991; Smak Gregoor 1999; Stiller 1983; THOMAS
Study 2002; Vincenti 2003a). In 27 studies funding sources
were not disclosed (Albert 1985; Aswad 1998; Boletis 2001;
Boots 2002; Burke 2000; del Castillo 2005; EVIDENCE Study
2014; Farmer 2006; Höcker 2009; INFINITY Study 2013;
Jankowska-Gan 2009; Johnson 1989a; Kacar 2004; Kim 2002;
Laftavi 2005; Lebranchu 1999; Maiorca 1988; Nematalla 2007;
Nott 1985; Park 1994; Pelletier 2006; Pisani 2001; Ponticelli
1997; Ratcliffe 1993; Sandrini 2009; Schulak 1989; Sola 2002;
Woodle 2005; Zhu 2008a). Publication bias was assessed by con-
structing funnel plots for three comparisons that included at least
10 studies in the meta-analysis (death and acute rejection for
steroid withdrawal versus steroid maintenance and acute rejection
for steroid avoidance versus steroid maintenance). All funnel plots
are symmetric and do not indicate publication bias (see Figure 4).
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Figure 4. Funnel plot of comparisons that included at least 10 studies in the meta-analysis
Effects of interventions
See: Summary of findings for the main comparison Steroid
withdrawal versus steroid maintenance for kidney transplant
recipients; Summary of findings 2 Steroid avoidance versus
steroid maintenance for kidney transplant recipients
Studies in adults with kidney transplant recipients
Steroid withdrawal versus steroid maintenance
Steroid withdrawal may lead to little of no difference in patient
mortality at either one year (Analysis 1.1.1 (10 studies, 1913 par-
ticipants): RR 0.68, 95% CI 0.36 to 1.30; I2 = 0%) or one to five
years post transplantation (Analysis 1.1.2 (7 studies, 1118 par-
ticipants): RR 1.26, 95% CI 0.73 to 2.17; I2 = 0%). Likewise
steroid withdrawal may lead to little or no difference in graft loss
excluding death at either one year (Analysis 1.1.5 (8 studies, 1817
participants): RR 1.17, 95% CI 0.72 to 1.92; I2 = 0%) or one
to five years post transplantation (Analysis 1.1.6 (7 studies, 1092
participants): RR 1.61, 95% CI 0.98 to 2.64; I2 = 0%).
The risk of acute rejection significantly increased by 77% in pa-
tients withdrawn from steroids compared versus patients main-
tained on steroids within the first year after transplantation
(Analysis 1.2.1 (10 studies, 1913 participants): RR 1.77, 95% CI
1.20 to 2.61; I2 = 54%), but there was no difference in the inci-
dence of biopsy-proven acute rejection (Analysis 1.2.2 (5 studies,
1292 participants): RR 1.32, 95% CI 0.78 to 2.22; I2 = 65%).
The incidence of NODAT (Analysis 1.3.1 (6 studies, 1439 par-
ticipants): RR 0.77, 95% CI 0.49 to 1.21; I2 = 0%) as well as
the incidence of cardiovascular events (Analysis 1.3.2 (2 studies,
607 participants): RR 0.98, 95% CI 0.42 to 2.33; I2 = 0%) up to
five years after transplantation were not significantly different be-
tween groups, mainly because of the low number of studies report-
ing these rarely occurring outcomes. Likewise data was sparse for
harmful events, such as infection (Analysis 1.4.1 (5 studies, 1819
participants): RR 1.02, 95% CI 0.84 to 1.22; I2 = 30%), CMV
infection (Analysis 1.4.2 (RR 1.04, 95% CI 0.80 to 1.36; partic-
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ipants = 1758; studies = 5; I2 = 0%), and malignancy (Analysis
1.4.3 (3 studies, 756 participants): RR 0.77, 95%CI 0.41 to 1.46;
I2 = 0%) and a difference in these outcomes could not be demon-
strated up to five years after transplantation. There was also no
evidence of difference in kidney function as determined by mea-
surement of serum creatinine and creatinine clearance up to one
as well as up to five years after transplantation (Analysis 1.5) (See
also Summary of findings for the main comparison).
Sensitivity and subgroup analyses for steroid withdrawal
versus steroid maintenance studies
Results of the sensitivity and subgroup analyses are summarised in
Table 1.
We have performed sensitivity analysis to assess the impact of pub-
lication status and use of intention-to-treat-analysis on primary
endpoints (mortality, death censored graft loss, acute rejection and
biopsy-proven acute rejection) using data from studies reporting
these outcomes at any time point within the first year after trans-
plantation. There was no evidence to suggest a difference in effect
estimates of mortality, graft loss and biopsy-proven acute rejection
for studies depending on whether they have performed intention-
to-treat analysis or whether the study was published in a peer-
reviewed journal. The significant increase in risk for acute rejec-
tion in patients withdrawn from steroids compared versus those
maintained on steroids was further increased in studies published
in a peer-reviewed journal (8 studies, 1741 participants: RR 2.02,
95% CI 1.26 to 3.23) and in studies that applied intention-to-
treat analysis (6 studies, 1199 participants: RR 2.07, 95% CI 1.10
to 3.91), but was lost in studies published as abstract-only and
in studies where intention-to-treat analysis was either not used or
unclear.
Weperformed subgroup analysis stratified by calcineurin-inhibitor
type, type of antimetabolite and induction treatment on primary
endpoints (mortality, death censored graft loss, acute rejection and
biopsy-proven acute rejection) using data from studies reporting
these outcomes at any time point within the first year after trans-
plantation. There was no difference in mortality and graft loss
in any of the subgroups. The risk of acute rejection after steroid
withdrawal was further increased in patients treated with CsA (9
studies, 1357 participants: RR 2.08, 95% 1.29 to 3.35), especially
among those who did not receive an additional antimetabolite (2
studies, 150 participants: RR 5.80, 95% CI 2.16 to 15.57) and in
patients who did not receive induction treatment (8 studies, 1765
participants: RR 1.93, 95% CI 1.26 to 2.94), but was decreased
in patients who received either MMF or enteric-coated mycophe-
nolate sodium (6 studies, 1612 participants: RR 1.41, 95% CI
1.02 to 1.94) or any type of antimetabolite (8 studies, 1763 par-
ticipants: RR 1.46, 95% CI 1.07 to 1.98).
Steroid avoidance versus steroid maintenance
Results are summarised in Summary of findings 2.
Steroid avoidance did not show a significant effect on patient mor-
tality at either one year (Analysis 2.1.1 (10 studies, 1462 partic-
ipants): RR 0.96, 95% CI 0.52 to 1.80; I2 = 0%) or one to five
years post transplantation (Analysis 2.1.2 (7 studies, 1201 par-
ticipants): RR 0.57, 95% CI 0.32 to 1.01; I2 = 0%). Likewise
steroid avoidance did not show any significant effects on graft loss
excluding death at either one year (Analysis 2.1.5 (7 studies, 1211
participants): RR 1.09, 95% CI 0.64 to 1.86; I2 = 0%) or one
to five years post transplantation (Analysis 2.1.6 (7 studies, 1245
participants): RR 0.98, 95% CI 0.66 to 1.45; I2 = 0%).
Steroid avoidance significantly increased the risk of acute rejec-
tion within the first year after transplantation by 58% compared
versus patients maintained on steroids (Analysis 2.2.1 (7 studies,
835 participants): RR 1.58, 95% CI 1.08 to 2.30; I2 = 63%).
This effect of steroid avoidance was also demonstrated for biopsy-
proven acute rejection with a risk increase of 94% within the first
year after transplantation (Analysis 2.2.2 (6 studies, 1073 partici-
pants): RR 1.94, 95% CI 1.26 to 2.98; I2 = 45%).
There was no evidence of difference in the occurrence of NODAT,
cardiovascular events, infection, CMV infection and malignancy
between groups up to five years after transplantation (Analysis 2.3;
Analysis 2.4). Kidney function determined as serum creatinine
and creatinine clearance up to one year as well as up to five years
after transplantation was not different for patients treated with
steroids for less than 14 days compared versus patients maintained
on steroids (Analysis 2.5).
Sensitivity and subgroup analysis for steroid avoidance
versus steroid maintenance - studies
We performed sensitivity analysis to assess the impact of use of
intention-to-treat-analysis on primary endpoints (mortality, death
censored graft loss, acute rejection and biopsy-proven acute re-
jection) using data from studies reporting these outcomes at any
time point within the first year after transplantation. There was
no study investigating steroid avoidance compared versus steroid
maintenance that was published as abstract only, consequently the
influence of publication status on the effect estimates could not be
tested. There was no evidence to suggest a difference in effect esti-
mates of mortality and graft loss for studies depending on whether
they have performed intention-to-treat analysis. The increased risk
for acute rejection and biopsy-proven acute rejection in patients
treated with steroids for less than 14 days after kidney transplan-
tation compared versus those maintained on steroids was further
increased in studies that applied intention-to-treat analysis (acute
rejection: 4 studies, 655 participants: RR 1.92, 95% CI 1.18 to
3.14; biopsy-proven acute rejection: 4 studies, 918 participants:
RR 2.31, 95% CI 1.47 to 3.63), but lost significance in studies
where intention-to-treat analysis was either not used or unclear.
We have performed subgroup analysis stratified by type of cal-
cineurin inhibitor, type of antimetabolite and induction treatment
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on primary endpoints (mortality, death censored graft loss, acute
rejection and biopsy-proven acute rejection) using data from stud-
ies reporting these outcomes at any time point within the first year
after transplantation. Stratified analysis did not reveal any differ-
ence in patient mortality and graft loss. The significant increase in
risk for biopsy-proven acute rejection persisted in patients treated
with CsA (3 studies, 615 participants: RR 1.89, 95% CI 1.29 to
2.79), while patients treated with TAC did not have an increased
risk for biopsy-proven acute rejection (See Table 2).
Steroid avoidance versus steroid withdrawal
Only three studies investigating the effect of steroid avoidance
compared versus steroid withdrawal were identified, wherefore
data is specifically sparse for this comparison. There is no evidence
to suggest a difference in any outcome (death: Analysis 3.1; rejec-
tion: Analysis 3.2; NODAT, infection, malignancy: Analysis 3.3;
kidney function: Analysis 3.4). Sensitivity and subgroup analysis
could not be performed due to the small number of studies iden-
tified.
Studies in children with kidney transplant recipients
Steroid withdrawal versus steroid maintenance
We identified only two studies that investigated the effect of steroid
withdrawal compared versus steroid maintenance in children (
Benfield 2005; Höcker 2009). Death and graft loss at five years
were significantly lower for children withdrawn from steroids, but
these results were drawn from Benfield 2005 only, since neither
death nor graft loss were observed inHöcker 2009 (Analysis 4.1.2:
RR 0.16, 95% CI 0.02 to 1.35). The effect of steroid withdrawal
on acute rejection is unclear due to the small number of studies
and wide confidence intervals (Analysis 4.2). Kidney function was
reported in Höcker 2009 only and was not significantly different
between groups (Analysis 4.3).
Benfield 2005 was terminated early due to an unanticipated high
incidence of post-transplant lymphoproliferative disease. Of the
274 enrolled participants, 19 developed post-transplant lympho-
proliferative disease, 10 before randomisation. Sensitivity and sub-
group analysis could not be performed due to the small number
of studies identified.
Steroid avoidance versus steroid maintenance
Only Mericq 2013 investigated the effect of steroid avoidance
compared versus steroid maintenance in children. Neither death
nor graft loss was observed in this study, and due to sparse data, a
difference in biopsy-proven acute rejection could not be demon-
strated. Kidney function was not reported. Sensitivity and sub-
group analysis could not be performed on a single study.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Steroid avoidance versus steroid maintenance for kidney transplant recipients
Patient or population: kidney transplant recipients
Intervention: steroid avoidance
Comparison: steroid maintenance
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Steroid avoidance ver-
sus steroid mainte-
nance
M ortality
Follow-up: 1 year
31 per 1000 30 per 1000
(16 to 56)
RR 0.96
(0.52 to 1.8)
1462 (10) ⊕⊕©©
low1,2
Graft loss (excluding
death)
Follow-up: 1 year
42 per 1000 46 per 1000
(27 to 79)
RR 1.09
(0.64 to 1.86)
1211 (7) ⊕⊕©©
low2,3
Acute rejection
Follow-up: 1 year
204 per 1000 323 per 1000
(221 to 470)
RR 1.58
(1.08 to 2.3)
835 (7) ⊕⊕⊕©
moderate4
NODAT
Follow-up: 5 years
107 per 1000 80 per 1000
(54 to 117)
RR 0.75
(0.51 to 1.1)
1618 (9) ⊕⊕©©
low2,5
CM V Infection
Follow-up: 5 years
106 per 1000 101 per 1000
(74 to 138)
RR 0.96
(0.7 to 1.31)
1454 (6) ⊕⊕©©
low2,6
* The assumed risk is the baseline risk in the control group treated with steroid maintenance. The corresponding risk (and its 95% conf idence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io; NODAT: new-onset diabetes af ter transplantat ion; CMV - cytomegalovirus
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate
1 All studies were unblinded. Six studies were industry sponsored. In six studies random sequence generat ion or allocat ion
concealment or both was unclear. In two studies ITT was either not performed or unclear. One study had select ive outcome
report ing
2 Total number of events was fewer than 300
3 All studies were unblinded. Five studies were industry sponsored. In four studies random sequence generat ion or allocat ion
concealment or both was unclear. ITT was unclear in one study. One study had select ive outcome report ing
4 All studies were unblinded. Five studies were industry sponsored. In four studies random sequence generat ion or allocat ion
concealment or both was unclear. In three studies ITT was either not performed or unclear. One study had select ive outcome
report ing
5 Most studies were unblinded (8 studies). Five studies were industry sponsored. In four studies random sequence generat ion
or allocat ion concealment or both was unclear. One study had select ive outcome report ing
6 Most studies were unblinded (5 studies). Four studies were industry sponsored. One study had unclear ITT
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D I S C U S S I O N
Summary of main results
The aim of this review was to provide updated evidence address-
ing the benefits and harms of steroid avoidance and withdrawal
in kidney transplant recipients. All identified studies concerned
one of the three comparisons defined for this review. The major-
ity of studies compared steroid withdrawal versus steroid main-
tenance (24 adult studies, 2 studies in children). Steroid avoid-
ance was compared versus steroid maintenance in 19 studies, one
of which was conducted in child kidney transplantation. Of the
three studies that compared steroid avoidance versus steroid with-
drawal, none involved children. In adult kidney transplantation
meta-analysis could be carried out for all three comparisons, but
data was particularly scarce for the comparison of steroid avoid-
ance with steroid withdrawal. The low number of studies with
child kidney transplant recipients did not enable data synthesis
through meta-analysis.
We were unable to demonstrate clear beneficial effects, such as a
reduction in mortality or NODAT within five years after trans-
plantation for steroids withdrawal or avoidance in adult kidney
transplant recipients. Both steroid withdrawal and steroid avoid-
ance showed little or no effect on mortality, graft loss, and CMV
infection. The risk of acute rejection did significantly increase by
77% after steroid withdrawal and by 58% after steroid avoidance
compared to steroid maintenance (see Summary of findings for
the main comparison, Summary of findings 2).
The effect of steroid withdrawal in children is uncertain. The
available data allowed only one meta-analysis for acute rejection in
children, which found no significant difference. Death and graft
loss had not been observed in one of the two studies in children and
outcomes such as biopsy-proven acute rejection and malignancy
were only reported in one of the two studies which further reduced
the quantity of the available data. Only one study investigated the
effect of steroid avoidance compared versus steroid maintenance
in children, thus a meta-analysis was not possible.
Overall completeness and applicability of
evidence
An extensive literature review was performed to identify studies
that assessed the benefits and harms of steroidwithdrawal or avoid-
ance in kidney transplant recipients. In general, two parameters
are particularly relevant for assessing benefits and harms of steroid
withdrawal in kidney transplant recipients: firstly, the time-point
of steroid withdrawal after kidney transplantation and secondly,
the duration of follow-up to observe outcome events in kidney
transplant patients.
Steroids are withdrawn at various time points after kidney trans-
plantation in clinical practice and this fact was reflected by the
variety of time points used to investigate the effects of steroid
withdrawal in clinical studies. We used a cut-off of 14 days after
transplantation to discriminate between steroid withdrawal and
steroid avoidance. With this approach we were able to combine
different time points for steroid withdrawal within these clinically
relevant time frames. The majority of steroid avoidance studies
used steroids for seven days or less, and the majority of the steroid
withdrawal studies withdrew steroids between three to six months
after transplantation. Thus, our findings may not be applicable
for patients who are withdrawn from steroids at other time-points
after transplantation.
Most studies had between one and three years of follow-up after
either steroid avoidance or withdrawal which constitutes a major
limitation for conclusions regarding long-term consequences for
patient and graft survival. Acute rejection is a major risk factor
for reduced long-term graft survival and typically occurs within
the first year after transplantation. The impact of acute rejection
on long-term graft outcomes depends on the severity, recurrence
and treatment of the acute rejection.While particularly severe and
recurrent rejections increase the risk of graft loss, a single early
acute rejection with complete functional recovery after treatment
appears to be less harmful for long-term graft outcomes. Most
of the acute rejections reported in the included studies occurred
early after transplantation and were mild and easily controlled
with steroids which could be an argument to conclude that an
increased risk of long-term graft loss after steroid withdrawal is
unlikely. However, recognizing that potential harms arising from
steroid withdrawal may remain hidden for up to five years after
steroid withdrawal (Gulanikar 1991); follow-up periods of the in-
cluded studies were too short to determine long-term graft sur-
vival. Furthermore, it is important to stress that only half of the
studies reported acute rejection. Consequently, potential harmful
effects of steroid withdrawal on long-term graft survival cannot be
ruled out with this review with sufficient confidence.
Reporting of harmful events was especially limited and inconsis-
tent. More than half of the studies did not report adverse events
such as infection and CMV infection and less than a third of
the studies reported malignancy and cardiovascular events. Even
though we did not find evidence to suggest a difference in harmful
events, it is important to point out that the absence of evidence
does not mean there is evidence for absence of effect. It is unclear
which outcomes occurred in the studies that provided no data.
Although we believe this is themost comprehensive evidence sum-
mary on this topic, interpretation of our findings must consider
the limitations of available data from this cohort. The value of
increasing available evidence of potential harms associated with
interventions has been widely recognised and is also not a prob-
lem peculiar to this review, but is common to many randomised
studies and systematic reviews (Cuervo 2003; Tunis 2003).
Only one study investigating steroid avoidance included an
mTOR-inhibitor as baseline immunosuppression. Consequently,
we cannot extrapolate the safety of steroid avoidance or withdrawal
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to protocols including mTOR-inhibitors.
The inclusion and exclusion criteria for participation in the in-
cluded studies may mean that our findings are not generalizable
to all kidney transplant recipients. Eight studies did not specify
any exclusion criteria, of which four did not specify any inclusion
criteria. In three studies only recipients of a living kidney trans-
plant were included and 11 studies included solely recipients of
a cadaveric kidney transplant. Seventeen studies limited partici-
pation for patients who received their first kidney transplant and
16 studies excluded kidney transplant recipients who had experi-
enced previous acute rejection. Kidney transplant recipients with
a PRA > 50% were excluded in 13 studies. It is unclear whether
the findings of this review apply to kidney transplant recipients
with a higher immunologic transplant risk.
Although almost all studies included participants of a wide range
of adult ages, none of the studies reported results for different age
groups. Therefore we were unable to determine whether there is
any difference in results depending on age. Due to the low number
of studies in child kidney transplantation, our findings need to
be interpreted with great caution in the light of a clear lack of
evidence in children.
Quality of the evidence
The quality of the included studies was rather variable. The main
limitations in the quality of the studies were allocation conceal-
ment, incomplete outcome data, blinding of participants and per-
sonnel and disclosure of funding. Of the 48 included studies only
five studies blinded participants and personnel. This was consid-
ered a high risk of bias because clinical decision making could be
influenced by knowledge of the treatment, such as for example that
patients withdrawn from steroids were more closely monitored
for signs of acute rejection. Adequate allocation concealment was
reported in 14 studies and 19 studies demonstrated adequate se-
quence generation. The lack of adequate sequence generation and
allocation concealment can lead to biased estimates of treatment
effects in the original study and thus in a systematic review (Hollis
1999; Juni 1999; Moher 1998; Schulz 1995). All hard clinical
outcomes (mortality, graft loss, acute rejection) were reported in
37 studies, but incomplete reporting of relevant data for a meta-
analysis in many studies hampered use of the provided data in our
analysis. Comparison of kidney function was only possible in a
limited number of studies because frequently either the number of
participants in whom kidney function was measured or a measure
of variability of the effect estimate were not provided. It might
be more informative to compare the number of patients at risk
of graft loss with a low creatinine clearance rather than assessing
mean data. However, these data were not provided in any of the
studies. Similarly dichotomous outcomes, especially infection and
acute rejection were frequently reported as rates or episodes which
complicated the use of such data for meta-analysis. For disclosure
of funding sources, 16 studies reported receiving of funding from
pharmaceutical companies and 28 studies did not disclose their
sponsor. We found that blinding of outcome assessors was ade-
quate in 43 studies where the primary outcome were hard-clinical
endpoints (mortality, graft loss, acute rejection) and considered
unlikely to be influenced by lack of blinding.
Potential biases in the review process
We searched multiple databases without language restriction in
attempt to reduce publication bias. The Cochrane Kidney and
Transplant’s Specialised Register contains handsearched reports of
studies presented at conferences and meetings, but there is a possi-
bility that wemissed unpublished data presented at smaller confer-
ences or studies published in foreign language journals and low im-
pact journals. Studies may have been added since our last search of
the register. Not all included studies reported all outcomes which
may have affected the results of the meta-analysis.
Agreements and disagreements with other
studies or reviews
Several previous systematic reviews have addressed steroid avoid-
ance and withdrawal after kidney transplantation. The first re-
view included three steroid withdrawal and four steroid avoidance
studies in patients on CsA with or without AZA and showed a
significant increase in acute rejection with an incidence of acute
rejection of 48% in those withdrawn from steroids versus 30% in
those maintained on steroids (P = 0.012) (Hricik 1993). The re-
view published seven years later (Kasiske 2000) included 10 stud-
ies and showed an increased proportion of patients with acute
rejection by 0.14 (95% CI 0.10 to 0.17; P < 0.001) and an in-
crease in graft failure after steroid withdrawal by 40% (RR 1.40,
95% CI 1.09 to 1.70; P = 0.012). Most studies included in this
meta-analysis used CsA-based immunosuppression with either no
anti-metabolite added or in combination with AZA. Only two
studies with MMF were included and subgroup analysis showed
similar results for these studies compared versus those that did
not include MMF. A review of six studies of steroid withdrawal
in kidney transplant recipients on triple therapy with calcineurin
inhibitors and MMF showed an increase in acute rejection and
no difference in graft failure (Pascual 2004). Due to the relative
short follow-up in these six studies long-term consequences for
graft survival given the observed increase in acute rejection after
steroid withdrawal is unclear. A meta-analysis published in 2012
by Knight 2010 found an increased risk of acute rejection and a
reduced cardiovascular risk after steroid withdrawal or avoidance,
but these findings resulted from a combined analysis of all steroid
withdrawal or avoidance time points and were based on surrogate
outcomes such as hypercholesterolaemia, hypertension and NO-
DAT. Another review (Pascual 2012) with nine studies comparing
steroid avoidance to steroid maintenance in kidney transplant re-
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cipients who received an immunosuppressive regimen consisting
of antibody induction, either CsA or TAC and MMF reported
that the increased risk of acute rejection in steroid avoidance was
lost when patients received TAC-based immunosuppression.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Steroid avoidance and steroid withdrawal after kidney transplan-
tation significantly increased the risk of acute rejection. We found
no evidence to suggest a difference in patient and graft survival
up to five years after transplantation, but the data to support the
absence of harm is limited due to the low number of events ob-
served in rather small studies. Follow-up periods were too short to
draw any conclusions on long-term outcomes in kidney transplant
recipients after steroid withdrawal or avoidance. In child kidney
transplant recipients data is very limited and does not allow any
conclusions about steroid withdrawal, but caution is warranted
with induction treatment that may increase the risk of post-trans-
plant lymphoproliferative disease in children.
Implications for research
Proving that steroid avoidance or withdrawal after kidney trans-
plantation is safe and beneficial requires demonstration of benefi-
cial effects, such as a reduction in patient mortality or cardiovascu-
lar events while at the same time graft survival is not reduced in the
long-term. Until now, only short-term data exist that demonstrate
an increased risk of acute rejection and the absence of evidence of
harm, but there is no long-termdata to drawany conclusions about
the harms and benefits of steroid avoidance or withdrawal beyond
five years after transplantation. Long-term RCTs are needed to
determine whether steroid withdrawal and avoidance after kidney
transplantation are safe and beneficial. Child kidney transplant
recipients constitute a target population in a clear need of well-
conducted steroid withdrawal studies.
A C K N OW L E D G E M E N T S
The authors would like to acknowledge GailHiggins, Information
Specialist for Cochrane Kidney and Transplant, for performing
the literature searches.
R E F E R E N C E S
References to studies included in this review
Ahsan 1999 {published data only}
∗ Ahsan N, Hricik D, Matas A, Rose S, Tomlanovich
S, Wilkinson A, et al. Prednisone withdrawal in kidney
transplant recipients on cyclosporine and mycophenolate
mofetil - a prospective randomized study. Steroid
Withdrawal Study Group. Transplantation 1999;68(12):
1865–74. [MEDLINE: 10628766]
Matas A, Ewell M, Cooperative Clinical Trials in Adult
Transplantation Group. Prednisone withdrawal in kidney
transplant recipients on CSA/MMF - a prospective
randomized study [abstract no: 4]. Transplantation 1999;
67(9):S543. [CENTRAL: CN–00765998; ]
Albert 1985 {published data only}
Albert FW, Schmidt U. Cyclosporin A (Cy A) therapy with
or without steroids in cadaveric kidney transplantation.
A prospective randomized one-center study [abstract].
Kidney International 1985;28(4):708. [CENTRAL:
CN–00550573; ]
Albert FW, Schmidt U. Cyclosporine therapy with or
without steroids in cadaveric kidney transplantation - A
prospective randomized one-center study. Transplantation
Proceedings 1985;17(6):2669–70. [EMBASE: 1986055112]
Aswad 1998 {published data only}
Aswad S, Zapanta R, Wu L, Bogaard T, Asai P, Khetan U, et
al. Steroid withdrawal in living related kidney transplant
patients receiving FK506 [abstract]. 35th Congress.
European Renal Association. European Dialysis and
Transplantation Association; 1998 Jun 6-9; Rimini, Italy.
1998:394. [CENTRAL: CN–00483058; ]
ATLAS Study 2005 {published data only}
Klinger M, Vitko S, Salmela K, Wlodarczyk Z, Tyden
G, ATLAS Study Group. Large, prospective study
evaluating steroid-free immunosuppression with tacrolimus/
basiliximab and tacrolimus/MMF compared with
tacrolimus/MMF/steroids in renal transplantation [abstract
no: W748]. Nephrology Dialysis Transplantation 2003;18
(Suppl 4):788–9. [CENTRAL: CN–00446121; ]
Kramer BK, Klinger M, Salmela K, Wlodarczyk Z,
Tyden G, Vitko S. Two steroid-free immunosuppressive
regimens (basiliximab/tacrolimus and tacrolimus/MMF)
in comparison to tacrolimus/MMF/steroid therapy after
renal transplantation [abstract no: F-FC039]. Journal
of the American Society of Nephrology 2003;14(Nov):9A.
[CENTRAL: CN–00583329; ]
Kramer BK, Klinger M, Vitko S, Glyda M, Midtvedt K,
Stefoni S, et al. Tacrolimus-based, steroid-free regimens
in renal transplantation: 3-year follow-up of the ATLAS
trial. Transplantation 2012;94(5):492–8. [MEDLINE:
22858806]
Kramer BK, Klinger M, Wlodarczyk Z, Ostrowski M,
Midvedt K, Stefoni S, et al. Tacrolimus combined with
two different corticosteroid-free regimens compared with a
standard triple regimen in renal transplantation: one year
observational results. Clinical Transplantation 2010;24(1):
24Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
E1–9. [MEDLINE: 19925464]
Kramer BK, Kruger B, Hoffmann U, Wlodarcyzk Z, Tyden
G, Senatorski G, et al. 1-year-follow-up of two steroid-
free immunosuppressive regimens - basiliximab/tacrolimus
and tacrolimus/MMF - in comparison to tacrolimus/
MMF/steroids after renal transplantation [abstract no: F-
PO1026]. Journal of the American Society of Nephrology
2004;15(Oct):289A. [CENTRAL: CN–00688822; ]
Kramer BK, Kruger B, Mack M, Obed A, Banas B,
Paczek L, et al. Steroid withdrawal or steroid avoidance
in renal transplant recipients: focus on tacrolimus-based
immunosuppressive regimens. Transplantation Proceedings
2005;37(4):1789–91. [MEDLINE: 15919467]
Kramer BK, Margreiter R, Hoffmann U, Wlodarcyzk Z,
Tyden G, Senatorski G, et al. 1-year-follow-up of two
steroid-free immunosuppressive regimens - basiliximab/
tacrolimus and tacrolimus/MMF - compared to tacrolimus/
MMF/steroids after renal transplantation [abstract no:
216]. 3rd International Congress on Immunosuppression;
2004 Dec 8-11; San Diego (CA). 2004.
∗ Vitko S, Klinger M, Salmela K, Wlodarczyk Z, Tyden
G, Senatorski G, et al. Two corticosteroid-free regimens-
tacrolimus monotherapy after basiliximab administration
and tacrolimus/mycophenolate mofetil-in comparison with
a standard triple regimen in renal transplantation: results
of the Atlas study. Transplantation 2005;80(12):1734–41.
[MEDLINE: 16378069]
Vitko S, Klinger M, Salmela KW, Tyden G, ATLAS
Study Group. Comparison of two steroid-free regimens
- basiliximab/tacrolimus and tacrolimus/MMF - with
tacrolimus/MMF/steroid therapy after renal transplantation
[abstract]. American Journal of Transplantation 2003;3
(Suppl 5):312. [CENTRAL: CN–00433656; ]
Benfield 2005 {published data only}
Benfield MR, Bartosh S, Ikle D, Warshaw B, Bridges N,
Morrison Y, et al. A randomized double-blind, placebo
controlled trial of steroid withdrawal after pediatric renal
transplantation. American Journal of Transplantation 2010;
10(1):81–8. [MEDLINE: 19663893]
Benfield MR, Munoz R, Warshaw BL, Bartosh SM,
Stablein DM, McIntosh MJ, et al. A randomized controlled
double-blind trial of steroid withdrawal in pediatric renal
transplantation: a study of the Cooperative Clinical trials
in pediatric transplantation (CCTPT) [abstract no: 966].
American Journal of Transplantation 2005;5(Suppl 11):402.
[CENTRAL: CN–00676069; ]
McDonald RA, McIntosh M, Stablein D, Grimm P,
Wyatt R, Lirenman D, et al. Increased incidence of
PTLD in pediatric renal transplant recipients enrolled in a
randomized controlled trial of steroid withdrawal: a study
of the CCTPT [abstract no: 1028]. American Journal of
Transplantation 2005;5(Suppl 11):418.
McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D,
Grimm P, et al. Incidence of PTLD in pediatric renal
transplant recipients receiving basiliximab, calcineurin
inhibitor, sirolimus and steroids. American Journal of
Transplantation 2008;8(5):984–9. [MEDLINE: 18416737]
Boletis 2001 {published data only}
∗ Boletis JN, Konstadinidou I, Chelioti H, Theodoropoulou
H, Avdikou K, Kostakis A, et al. Successful withdrawal
of steroid after renal transplantation. Transplantation
Proceedings 2001;33(1-2):1231–3. [MEDLINE: 11267272]
Boletis JN, Konstadinidou I, Chelioti H, Theodoropoulou
H, Avdikou K, Kostakis A, et al. Successful withdrawal
of steroids after renal transplantation [abstract]. XVIII
International Congress of the Transplantation Society;
2000 Aug 27-Sep 1; Rome, Italy. 2000. [CENTRAL:
CN–00444474; ]
Boletis JN, Konstadinidou I, Darema M, Psimenou E,
Chiras T, Kostakis A, et al. Steroids withdrawal in renal
transplant recipients: a randomized controlled study
[abstract no: T447]. Nephrology Dialysis Transplantation
2002;17(Suppl 1):312. [CENTRAL: CN–00509095; ]
Boots 2002 {published data only}
Boots JM, Christaiaans MH, van Duijnhoven EM, Van
Suylen RJ, van Hooff JP. Early steroid withdrawal in renal
transplant recipients with tacrolimus dual therapy [abstract].
XIXth International Congress of the Transplantation
Society; 2002 Aug 25-30; Miami (FL). 2002. [CENTRAL:
CN–00415308; ]
∗ Boots JM, Christiaans MH, Van Duijnhoven EM, Van
Suylen RJ, Van Hooff JP. Early steroid withdrawal in
renal transplantation with tacrolimus dual therapy: a pilot
study. Transplantation 2002;74(12):1703–9. [MEDLINE:
12499885]
Boots JM, Christiaans MH, van Duijnhoven EM, van
Suylen R, van Hooff JP. Early steroid withdrawal in renal
transplant recipients with tacrolimus double therapy
immunosuppression [abstract]. Journal of the American
Society of Nephrology 2001;12(Program & Abstracts):878A.
[CENTRAL: CN–00550471; ]
Boots JM, Christiaans MH, van Duijnhoven EM, van
Suylen RJ, van Hooff JP. Early steroid withdrawal in renal
transplantation with tacrolimus dual therapy: a pilot
study. Transplantation Proceedings 2002;34(5):1698–9.
[MEDLINE: 12176542]
Bouma 1996 {published data only}
Bouma GJ, Hollander DA, van der Meer-Prins EM, van
Bree SP, van Rood JJ, van der Woude FJ, et al. In vitro
sensitivity to prednisolone may predict kidney rejection
after steroid withdrawal. Transplantation 1996;62(10):
1422–9. [MEDLINE: 8958267]
Bouma GJ, Hollander DJ, Doxiadis IN, van der Meer-
Prins EM, Van Bree SP, van Rood JJ, et al. In vitro
study: prediction of graft rejection after withdrawal
of steroids [In vitro–untersuchungen zur voraussage
von transplantatabstossungen nach steroid–sbsetzung:
eine pilot–studie]. Transplantationsmedizin: Organ Der
Deutschen Transplantationsgesellschaft 1996;8(2):79–83.
[EMBASE: 1996240201]
∗ Hollander AA, Hene RJ, Hermans J, van Es LA, van der
Woude FJ. Late prednisone withdrawal in cyclosporine-
treated kidney transplant patients: a randomized study.
25Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Journal of the American Society of Nephrology 1997;8(2):
294–301. [MEDLINE: 9048349]
Hollander AA, Hene RJ, van Es LA, van der Woude FJ. Late
prednisone withdrawal in renal transplant patients [abstract
no: A3323]. Journal of the American Society of Nephrology
1996;7(9):1911.
Hollander AA, Hene RJ, van Es LA, van der Woude FJ.
Late prednisone withdrawal in renal transplant patients
[abstract]. Nephrology Dialysis Transplantation 1996;11(6):
A276. [CENTRAL: CN–00261334; ]
Burke 2000 {published data only}
Burke J, Francos BB, Francos GC. Double-blind, placebo-
controlled trial of steroid withdrawal in kidney transplant
recipients with a cyclosporine/mycophenolate regimen-
three year follow up [abstract]. American Journal of
Transplantation 2001;1(Suppl 1):296. [CENTRAL:
CN–00764555; ]
Burke JF, Francos GC, Francos BB, Michael B, Gaughan
WJ. A double-blind, placebo-controlled, three-year study of
steroid withdrawal using a neoral-based immunosuppressive
regimen in primary renal transplant recipients: an interim
report [abstract no: 426]. Transplantation 2000;69(8
Suppl):S224. [CENTRAL: CN–00444589; ]
∗ Francos GC, Frankel CJ, Dunn SR, Francos BB, Burke JF.
Double-blind, placebo-controlled, 3 year study of steroid
withdrawal using a neoral and mycophenolate mofetil
(MMF)-based immunosuppressive regimen in primary renal
transplant recipients [abstract no: 137]. American Journal
of Transplantation 2002;2(Suppl 3):172. [CENTRAL:
CN–00415671; ]
del Castillo 2005 {published data only}
∗ Del Castillo D, Franco A, Tabernero JM, Errasti P, Valdes
F, García C, et al. Prospective, multicenter, randomized,
open-label study of myfortic with steroid withdrawal vs
myfortic with standard steroid regimen to prevent acute
rejection in de novo kidney transplantation [abstract no:
136]. American Journal of Transplantation 2005;5(Suppl
11):191. [CENTRAL: CN–00644130; ]
De Vecchi 1986 {published data only}
De Vecchi A, Tarantino A, Montagnino G, Aroldi A,
Aniasi A, Vegeto A, et al. Ciclosporin alone or combined
with steroid in the treatment of cadaveric renal transplant
recipients. Clinical Transplantation 1987;1:198–202.
[CENTRAL: CN–00764108; ]
∗ De Vecchi A, Tarantino A, Rivolta E, Egidi F, Montagnino
G, Berardinelli L, et al. Ciclosporin alone or associated
with steroid for immunosuppression of cadaveric renal
transplants?. Contributions to Nephrology 1986;51:88–90.
[MEDLINE: 3552426]
De Vecchi A, Tarantino A, Rivoltan E, Egidi F, Ponticelli C.
Need for steroid in cyclosporine (Cy) treated cadaveric renal
transplant recipients (pts) [abstract]. Kidney International
1985;28(2):394. [CENTRAL: CN–00550392; ]
DOMINOS Study 2012 {published data only}
∗ Thierry A, Mourad G, Buchler M, Kamar N, Villemain
F, Heng AE, et al. Steroid avoidance with early intensified
dosing of enteric-coated mycophenolate sodium: a
randomized multicentre trial in kidney transplant recipients.
Nephrology Dialysis Transplantation 2012;27(9):3651–9.
[MEDLINE: 22645323]
Touchard G, Mourad G, Lebranchu Y, Rostaing L,
Villemain F. Multicenter, randomized, comparative, open-
label study to evaluate efficacy and safety a combination of
anti-IL2R, intensified dose of enteric-coated mycophenolate
sodium (EC-MPS) for 6 weeks, ciclosporine micro-
emulsion (CsA-ME), with or without steroids, in adult
kidney de novo transplant recipients (TxR) [abstract no:
1679]. American Journal of Transplantation 2010;10(Suppl
4):515.
Touchard G,MouradG, Lebranchu Y, Rostaing L, Villemain
F, Heng AE, et al. Intensified dose of enteric-coated
mycophenolate sodium (EC-MPS) for steroids avoidance, in
combination with ciclosporine micro-emulsion (CsA-ME):
multicenter, randomized, open label, comparative study in
de novo kidney transplantation (DOMINOS) [abstract no:
P-557]. Transplant International 2009;22(Suppl 2):232–3.
EVIDENCE Study 2014 {published data only}
Carmellini M, Todeschini P, Manzia TM, Valerio F, Messina
M, Sghirlanzoni MC, et al. Twelve-month outcomes
from EVIDENCE trial (everolimus once-a-day regimen
with cyclosporine versus corticosteroid elimination) in
adult kidney transplant recipients [abstract no: O193].
Transplant International 2013;26(Suppl 2):100. [EMBASE:
71359334]
∗ Ponticelli C, Carmellini M, Tisone G, Sandrini S, Segoloni
G, Rigotti P, et al. A randomized trial of everolimus and
low-dose cyclosporine in renal transplantation: with or
without steroids?. Transplantation Proceedings 2014;46(10):
3375–82. [MEDLINE: 25498055]
Farmer 2006 {published data only}
Farmer C, Abbs I, Hilton R, et al. What is the value of short
synacthen tests in predicting the ease of steroid withdrawal
in renal transplant recipients? A randomised controlled
trial [abstract]. American Journal of Transplantation 2001;1
(Suppl 1):190. [CENTRAL: CN–00767027; ]
∗ Farmer CK, Hampson G, Abbs IC, Hilton RM, Koffman
CG, Fogelman I, et al. Late low-dose steroid withdrawal
in renal transplant recipients increases bone formation and
bone mineral density. American Journal of Transplantation
2006;6(12):2929–36. [MEDLINE: 17061994]
FRANCIA Study 2007 {published data only}
Albano L, Cantarovich D, Rostaing L, Kamar N, Ducloux
D, Mourad G, et al. Corticosteroid avoidance in adult
kidney transplant recipients receiving ATG Fresenius
induction: 5 years results of a prospective and randomized
study [abstract no: P497]. Transplant International 2013;26
(Suppl 2):285. [EMBASE: 71360109]
Cantarovich D. Steroid avoidance in adult kidney transplant
recipients: 5-year results of a prospective and randomized
multicenter study [abstract no: 234]. American Journal of
Transplantation 2013;13(Suppl S5):101–2. [EMBASE:
71056810]
Cantarovich D, FRANCIA French Study Group. ATG-
Fresenius induction and immunosuppression without
26Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
steroids following renal transplantation: a prospective
and randomized study [abstract no: P189]. Transplant
International 2007;20(Suppl 2):141. [CENTRAL:
CN–00740578; ]
Cantarovich D, FRANCIA Study Group. Acute renal
rejections are increased in the absence of corticosteroids
but are not detrimental at one year in the context of
ATG induction [abstract no: 515]. American Journal
of Transplantation 2010;10(Suppl 4):191. [EMBASE:
70463876]
Cantarovich D, Rostaing L, Kamar N, Ducloux D, Saint-
Hillier Y, Mourad G, et al. Early corticosteroid avoidance
in kidney transplant recipients receiving ATG-F induction:
5-year actual results of a prospective and randomized study.
American Journal of Transplantation 2014;14(11):2556–64.
[MEDLINE: 25243534]
∗ Cantarovich D, Rostaing L, Kamar N, Saint-Hillier Y,
Ducloux D, Mourad G, et al. Corticosteroid avoidance
in adult kidney transplant recipients under rabbit anti-T-
lymphocyte globulin, mycophenolate mofetil and delayed
cyclosporine microemulsion introduction. Transplant
International 2010;23(3):313–24. [MEDLINE: 19843296]
Cantarovich D, Rostaing L, Mourad G. Steroid avoidance
after renal transplantation: results of a prospective and
randomized trial using Fresenius ATG [abstract no: 711].
Transplantation 2008;86(2 Suppl):249. [CENTRAL:
CN–00740579; ]
Louis S, Audrain M, Cantarovich D, Schaffrath B,
Hofmann K, Janssen U, et al. Long-term cell monitoring
of kidney recipients after an antilymphocyte globulin
induction with and without steroids. Transplantation 2007;
83(6):712–21. [MEDLINE: 17414703]
FREEDOM Study 2008 {published data only}
Chadban S, Walker R, Russ G, Kanellis J. Renal functions
and rejection incidence in de novo renal transplant patients
randomised to steroid avoidance, steroid withdrawal or
standard steroids [abstract]. Immunology & Cell Biology
2007;85(4):A24.
Schena FP, Vincenti F, Paraskevas S, Hauser I, FREEDOM
Study Group. Renal function and rejection incidence in
de novo renal transplant patients randomized to steroid
avoidance, steroid withdrawal or standard steroids [abstract
no: F-FC153]. Journal of the American Society of Nephrology
2006;17(Abstracts):69A. [CENTRAL: CN–00601969; ]
∗ Schena FP, Vincenti F, Paraskevas S, Hauser I, Grinyo
J, FREEDOM Study Group. 12-month results of
a prospective, randomized trial of steroid avoidance,
steroid withdrawal or standard steroids in de novo
renal transplant patients receiving cyclosporine, enteric-
coated mycophenolate sodium (EC-MPS, myfortic®)
and basiliximab [abstract no: 54]. American Journal of
Transplantation 2006;6(Suppl 2):84–5. [CENTRAL:
CN–00644263; ]
Vincenti F, Schena F, Walker R, Pescovitz M, Shoker A. 3
months interim results of a 12-month study with enteric-
coated mycophenolate sodium (EC-MPS, Myfortic®),
basiliximab, and neoral C-2 comparing different steroid
protocols in de novo kidney recipients [abstract no: TH-
PO544]. Journal of the American Society of Nephrology 2005;
16(Oct):236A. [CENTRAL: CN–00583476; ]
Vincenti F, Schena FP, Paraskevas S, Hauser I, FREEDOM
Study Group. Comparison of metabolic parameters in
renal transplant patients randomized to steroid avoidance,
steroid withdrawal or standard steroids with a 12-month,
randomized, multicenter trial [abstract no: F-PO1076].
Journal of the American Society of Nephrology 2006;17
(Abstracts):562A. [CENTRAL: CN–00602097; ]
Vincenti F, Schena FP, Paraskevas S, Hauser I, Grinyo
J. Metabolic effects of steroid avoidance or early steroid
withdrawal: 12-month results of a randomized trial in
de novo renal transplant patients receiving cyclosporine,
enteric-coated mycophenolate sodium (EC-MPS) and
basiliximab [abstract no: 1232]. American Journal of
Transplantation 2006;6(Suppl 2):483. [CENTRAL:
CN–00765654; ]
Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG,
Grinyo J, et al. A randomized, multicenter study of steroid
avoidance, early steroid withdrawal or standard steroid
therapy in kidney transplant recipients.[Erratum appears
in Am J Transplant.2008 May;8(5):1080]. American
Journal of Transplantation 2008;8(2):307–16. [MEDLINE:
18211506]
Vincenti F, Schena FP, Walker R, Pescovitz MD,
Shoker A, Grinyo J, et al. Preliminary 3-month results
comparing immunosuppressive regimens of enteric-coated
mycophenolate sodium (EC-MPS) without steroids vs
short-term use of steroids vs standard steroid treatment
including basiliximab, and neoral C-2 in de novo kidney
recipients [abstract no: 1542]. American Journal of
Transplantation 2005;5(Suppl 11):548. [CENTRAL:
CN–00644288; ]
Walker R, Campbell S, Chadban S, Kanellis J, Pilmore
H, Russ G. Preliminary results of a 12-month study
with enteric-coated mycophenolate sodium (EC-MPS),
basiliximab, and neoral C-2 comparing a regimen without
steroids or short-term use of steroids with standard steroid
treatment in de novo kidney recipients [abstract no: 34].
Transplantation Society of Australia & New Zealand
(TSANZ). 24th Annual Scientific Meeting; 2006 Mar
29-31; Canberra, Australia. 2006:52. [CENTRAL:
CN–00583481; ]
Walker R, Chadban S, Russ G, et al. Comparison
of metabolic parameters in renal transplant patients
randomised to steroid avoidance, steroid withdrawal
or standard steroids within a 12 month randomised
multicentre trial [abstract]. Transplantation Society of
Australia & New Zealand (TSANZ). 25th Annual Scientific
Meeting; 2007 Mar 28-30; Canberra (ACT). 2007:32.
[CENTRAL: CN–00764330; ]
Walker R, Vincenti F, Schena FP, Pescovitz MD, Shoker A,
Grinyo J, et al. Preliminary results of a 12-month study
with enteric-coated mycophenolate sodium (EC-MPS),
basiliximab, and neoral C-2 comparing two investigational
steroid regimens (without steroids or short-term use of
27Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
steroids) with standard steroid treatment in de novo kidney
recipients [abstract no: T-PO50027]. Nephrology 2005;10
(Suppl):A214. [CENTRAL: CN–00583480; ]
Gulanikar 1991 {published data only}
Gulanikar AC, Belitsky P, MacDonald AS, Cohen A, Bitter-
Suermann H. Randomized controlled trial of steroids
versus no steroids in stable cyclosporine-treated renal graft
recipients. Transplantation Proceedings 1991;23(1 Pt 2):
990–1. [MEDLINE: 1989355]
∗ Sinclair NR. Low-dose steroid therapy in cyclosporine-
treated renal transplant recipients with well-functioning
grafts. The Canadian Multicentre Transplant Study Group.
CMAJ Canadian Medical Association Journal 1992;147(5):
645–57. [MEDLINE: 1521210]
Höcker 2009 {published data only}
Hoecker B, Weber LT, Feneberg R, Drube J, John U,
Fehrenbach H, et al. Prospective randomized trial on late
steroid withdrawal in pediatric renal transplant recipients
under CsA and MMF: 2-year data [abstract no: 605].
American Journal of Transplantation 2009;9(Suppl 2):366.
[EMBASE: 70010478]
Höcker B, Weber LT, Feneberg R, Drube J, John U,
Fehrenbach H, et al. Improved growth and cardiovascular
risk after late steroid withdrawal: 2-year results of
a prospective, randomised trial in paediatric renal
transplantation. Nephrology Dialysis Transplantation 2010;
25(2):617–24. [MEDLINE: 19793929]
∗ Höcker B, Weber LT, Feneberg R, Drube J, John U,
Fehrenbach H, et al. Prospective, randomized trial on late
steroid withdrawal in pediatric renal transplant recipients
under cyclosporine microemulsion and mycophenolate
mofetil. Transplantation 2009;87(6):934–41. [MEDLINE:
19300199]
Tönshoff B, Weber L, Höcker B. Prospective randomized
multicenter trial on withdrawal of steroids in pediatric
renal transplant recipients with stable graft function on
cyclosporin A (CsA) and mycophenolate mofetil (MMF)
[abstract no: 240 (SY)]. Pediatric Nephrology 2007;22(9):
1429.
Weber LT, Hoecker B, Feneberg R, Drube J, John U,
Fehrenbach H, et al. Late steroid withdrawal in pediatric
renal transplant recipients under cyclosporin microemulsion
and mycophenolate mofetil [abstract no: SA-PO2535].
Journal of the American Society of Nephrology 2008;19
(Abstracts Issue):679A.
Weber LT, Hoecker B, Feneberg R, Drube J, John U,
Fehrenbach H, et al. Prospective randomized trial on late
steroid withdrawal in pediatric renal transplant recipients
under CSA and MMF: 2-year data [abstract no: SAT-M-
124]. Pediatric Nephrology 2009;24(7):1876.
INFINITY Study 2013 {published data only}
Thierry A, Mourad G, Buchler M, Kamar N, Villemain
F, Heng A, et al. Three-year safety and efficacy outcomes
in kidney transplant patients randomized to steroid
avoidance or maintenance steroids with early intensified
dosing of enteric-coated mycophenolate sodium: The
INFINITY Study [abstract no: B1099]. American Journal
of Transplantation 2013;13(Suppl S5):358. [EMBASE:
71057675]
Isoniemi 1990 {published data only}
Isoniemi H. Renal allograft immunosuppression V: Glucose
intolerance occurring in different immunosuppressive
treatments. Clinical Transplantation 1991;5(3):268–72.
[EMBASE: 1991187379]
Isoniemi H. Renal allograft immunosuppression. III. Triple
therapy versus three different combinations of double drug
treatment: two year results in kidney transplant patients.
Transplant International 1991;4(1):31–7. [MEDLINE:
2059298]
∗ Isoniemi H, Ahonen J, Eklund B, Hockerstedt K,
Salmela K, von Willebrand E, et al. Renal allograft
immunosuppression. II. A randomized trial of withdrawal
of one drug in triple drug immunosuppression. Transplant
International 1990;3(3):121–7. [MEDLINE: 2271083]
Isoniemi H, Ahonen J, Krogerus L, Eklund B, Hockerstedt
K, Salmela K, et al. Chronic rejection of renal allografts
with four immunosuppressive regimens. Transplantation
Proceedings 1992;24(6):2716–7. [MEDLINE: 1465912]
Isoniemi H, Eklund B, Hockerstedt K, Korsback C, Salmela
K, von Willebrand E, et al. Discontinuation of one drug
in triple drug treatment of renal allograft patients: 1-year
results. Transplantation Proceedings 1990;22(4):1365–6.
[MEDLINE: 2202111]
Isoniemi H, Krogerus L, von Willebrand E, Taskinen
E, Gronhagen-Riska C, Ahonen J, et al. Renal
allograft immunosuppression. VI. Triple drug therapy
versus immunosuppressive double drug combinations:
histopathological findings in renal allografts. Transplant
International 1991;4(3):151–6. [MEDLINE: 1958279]
Isoniemi H, Tikkanen M, Hayry P, Eklund B, Hockerstedt
K, Salmela K, et al. Lipid profiles with triple drug
immunosuppressive therapy and with double drug
combinations after renal transplantation and stable graft
function. Transplantation Proceedings 1991;23(1 Pt 2):
1029–31. [MEDLINE: 1989148]
Isoniemi H, Tikkanen MJ, Ahonen J, Hayry P. Renal
allograft immunosuppression. IV. Comparison of lipid
and lipoprotein profiles in blood using double and triple
immunosuppressive drug combinations. Transplant
International 1991;4(3):130–5. [MEDLINE: 1958276]
Isoniemi H, von Willebrand E, Ahonen J, Eklund B,
Hockerstedt K, Krogerus L, et al. Late histopathological
findings in renal allografts with four immunosuppressive
regimens. Transplant International 1992;5 Suppl 1:S6–7.
[MEDLINE: 14621718]
Isoniemi HM, Ahonen J, Tikkanen MJ, von Willebrand
EO, Krogerus L, Eklund BH, et al. Long-term consequences
of different immunosuppressive regimens for renal
allografts.[Erratum appears in Transplantation 1998
Sep 15;66(5):678]. Transplantation 1993;55(3):494–9.
[MEDLINE: 8456467]
Isoniemi HM, Krogerus L, von Willebrand E, Taskinen
E, Ahonen J, Hayry P. Histopathological findings in well-
functioning, long-term renal allografts. Kidney International
28Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1992;41(1):155–60. [MEDLINE: 1593852]
Jankowska-Gan 2009 {published data only}
Jankowska-Gan E, Sollinger HW, Pirsch JD, Cai J,
Pascual J, Haynes LD, et al. Successful reduction of
immunosuppression in older renal transplant recipients who
exhibit donor-specific regulation. Transplantation 2009;88
(4):533–41. [MEDLINE: 19696637]
Johnson 1989a {published data only}
Johnson RW, Mallick NP, Bakran A, Pearson RC, Scott
PD, Dyer P, et al. Cadaver renal transplantation without
maintenance steroids. Transplantation Proceedings 1989;21
(1 Pt 2):1581–2. [MEDLINE: 2652513]
∗ Johnson RW, Mallick NP, Scott PD, Riad H, Pearson
RC, Dyer P, et al. Prospective trials with cyclosporine
monotherapy in cadaver renal transplantation. Journal
of Nephrology 1990;3(4 Suppl 1):47–9. [EMBASE:
1992097616]
Kacar 2004 {published data only}
Kacar S, Gurkan A, Karaoglan M, Akman F, Varilsuha
C, Karaca C, et al. Steroid withdrawal protocol in renal
transplantation [abstract]. 41st Congress. European
Renal Association. European Dialysis and Transplantation
Association; 2004 May 15-18; Lisbon, Portugal. 2004:401.
[CENTRAL: CN–00509258; ]
Kim 2002 {published data only}
Kim EH, Gohh R, Morrissey P, Simpson M, Monaco A,
Yango A. Rapid steroid withdrawal versus standard steroid
treatment in patients treated with basiliximab, cyclosporine,
and mycophenolate mofetil for the prevention of acute
rejection in kidney transplantation: a 2-year follow-up
[abstract no: 1029]. American Journal of Transplantation
2002;2(Suppl 3):397. [CENTRAL: CN–00416017; ]
Kumar 2005 {published data only}
Fa K, Kode RK, Lu Q, Kumar MS, Laftavi MR, Pankewycz
OG. Value of one month protocol biopsies combined with
a molecular analysis in predicting efficacy of rapid steroid
withdrawal after renal transplantation [abstract no: 132].
American Journal of Transplantation 2002;2(Suppl 3):171.
[CENTRAL: CN–00415620; ]
Fa K, Laftavi MR, Ferry E, Kumar AM, Fyfe B, Pankewycz
OG. The predictive value of subclinical rejection in a steroid
free immunosuppressive regimen [abstract no: 1282].
American Journal of Transplantation 2003;3(Suppl 5):480.
[CENTRAL: CN–00445267; ]
Kumar MS, Hahn J, Adams C, Fa K, Fyfe B, Damask A, et
al. Steroid avoidance (SA) in kidney transplant recipients
treated with simulect (BMAB), neoral (CSA) and cellcept
(MMF) - a randomized prospective controlled clinical trial
[abstract]. American Journal of Transplantation 2002;2
(Suppl 3):393.
Kumar MS, Hahn J, Adams C, Fa K, Fyfe B, Damask A, et
al. Steroid avoidance (SA) in kidney transplant recipients
treated with simulect (BMAB), neoral (CSA) and cellcept
(MMF)-a randomized prospective controlled clinical trial
[abstract no: 2440]. XIXth International Congress of the
Transplantation Society; 2002 Aug 25-30; Miami (FL).
2002. [CENTRAL: CN–00416079; ]
Kumar MS, Heifets M, Moritz MJ, Parikh MH, Saeed
MI, Lingaraju R, et al. Basiliximab induction in African
American recipients (AA) of cadaver kidneys (CAD)
facilitates steroid avoidance, reduces acute rejection (AR)
and prolongs survival [abstract no: 1627]. American Journal
of Transplantation 2005;5(Suppl 11):570. [CENTRAL:
CN–00644172; ]
Kumar MS, Heifets M, Moritz MJ, Saeed MI, Khan SM,
Fyfe B, et al. Safety and efficacy of steroid withdrawal two
days after kidney transplantation: analysis of results at three
years. Transplantation 2006;81(6):832–9. [MEDLINE:
16570004]
∗ Kumar MS, Xiao SG, Fyfe B, Sierka D, Heifets
M, Moritz MJ, et al. Steroid avoidance in renal
transplantation using basiliximab induction, cyclosporine-
based immunosuppression and protocol biopsies. Clinical
Transplantation 2005;19(1):61–9. [MEDLINE: 15659136]
Laftavi 2005 {published data only}
Laftavi M, Stefanick B, Stephan R, Kohli R, Min I,
Sridhar N, et al. The significance of protocol biopsy in
immunominimization protocol: a prospective study of
steroid withdrawal [abstract no: O229]. Transplantation
2004;78(2 Suppl):89. [CENTRAL: CN–00509305; ]
Laftavi MR, Leca N, Dagher F, Kilmer L, Stephanick B,
Kohli R, et al. Steroid withdrawal is associated with more
chronic allograft nephropathy (CAN) following kidney
transplantation [abstract no: 518]. American Journal of
Transplantation 2005;5(Suppl 11):288.
∗ Laftavi MR, Stephan R, Stefanick B, Kohli R, Dagher
F, Applegate M, et al. Randomized prospective trial of
early steroid withdrawal compared with low-dose steroids
in renal transplant recipients using serial protocol biopsies
to assess efficacy and safety. Surgery 2005;137(3):364–71.
[MEDLINE: 15746793]
Pankewycz OG, Stephan R, Stefanick B, Dagher F,
Applegate M, Kohli R, et al. The clinical benefits of
early steroid withdrawal (7 days) and utility of protocol
biopsies at 1, 6 and 12 months in guiding steroid-free
immunosuppressive therapy after renal transplantation
[abstract no: 1534]. American Journal of Transplantation
2004;4(Suppl 8):579. [CENTRAL: CN–00509401; ]
Pankewyez O, Stephan R, Stefanick B, Rubino A, Kohli
R, Min I, et al. Induction immunosuppression for
renal transplantation using thymoglobulin, FK506 and
mycophenolate mofetil allows for safe steroid withdrawal
and eliminates the need for early protocol biopsies [abstract
no: 1271]. American Journal of Transplantation 2003;3
(Suppl 5):478. [CENTRAL: CN–00447092; ]
Lebranchu 1999 {published data only}
Hene RJ, M55002 Study Group. A randomized, double-
blind, multi-center trial comparing two corticosteroid
regimens in combination with mycophenolate mofetil
(MMF) and cyslosporine (CYA) in renal transplant
recipients [abstract no: 420]. Transplantation 1998;65(12):
29Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S107. [CENTRAL: CN–00763818; ]
Lebranchu Y. Comparison of two corticosteroid regimens
in combination with CellCept and cyclosporine A for
prevention of acute allograft rejection: 12 month results of
a double-blind, randomized, multi-center study. M 55002
Study Group. Transplantation Proceedings 1999;31(1-2):
249–50. [MEDLINE: 10083095]
Lebranchu Y, Aubert P, Bayle F, Bedrossian J, Berthoux
F, Bourbigot B, et al. Could steroids be withdrawn in
renal transplant patients sequentially treated with ATG,
cyclosporine, and cellcept? One-year results of a double-
blind, randomized, multicenter study comparing normal
dose versus low-dose and withdrawal of steroids. M 55002
French Study Group. Transplantation Proceedings 2000;32
(2):396–7. [MEDLINE: 10715452]
Lebranchu Y, M55002 Study Group. A comparison of two
corticosteroid regimens in kidney transplanted patients
treated with ATG/OKT3 induction, mycophenolate
mofetil (MMF) and cyclosporine A (CyA) for prevention
of acute allograft rejection. 12 months results of a double-
blind, randomized, multi-center study [abstract no:
932]. Transplantation 1999;67(7):S239. [CENTRAL:
CN–00763351; ]
Nowacka-Cieciura E, Durlik M, Cieciura T, Kukula K,
Lewandowska D, Baczkowska T, et al. Elevated serum
immunoglobulins after steroid withdrawal in renal allograft
recipients. Transplantation Proceedings 2002;34(2):564–6.
[MEDLINE: 12009625]
Nowacka-Cieciura E, Durlik M, Cieciura T, Lewandowska
D, Baczkowska T, Kukula K, et al. Steroid withdrawal after
renal transplantation--risks and benefits. Transplantation
Proceedings 2002;34(2):560–3. [MEDLINE: 12009624]
Nowacka-Cieciura E, Durlik M, Cieciura T, Talalaj M,
Kukula K, Lewadowska D, et al. Positive effect of steroid
withdrawal on bone mineral density in renal allograft
recipients [abstract no: P0568W]. XVIII International
Congress of the Transplantation Society; 2000 Aug 27-Sept
1; Rome, Italy. 2000. [CENTRAL: CN–00446978; ]
Nowacka-Cieciura E, Durlik M, Cieciura T, Talalaj M,
Kukula K, Lewandowska D, et al. Positive effect of steroid
withdrawal on bone mineral density in renal allograft
recipients. Transplantation Proceedings 2001;33(1-2):
1273–7. [MEDLINE: 11267289]
Nowacka-Cieciura E, Soluch L, Cieciura T, Lewandowska
D, Durlik M, Shaibani B, et al. Effect of glucocorticoid-
free immunosuppressive protocol on serum lipids in renal
transplant patients. Transplantation Proceedings 2000;32(6):
1339–43. [MEDLINE: 10995973]
Puig i Mari JM. Induction treatment with mycophenolate
mofetil, cyclosporine, and low-dose steroids with subsequent
early withdrawal in renal transplant patients: results of
the Spanish Group. Spanish Group of the CellCept
Study. Transplantation Proceedings 1999;31(6):2256–8.
[MEDLINE: 10500566]
∗ Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F,
Ekberg H. Double-blind comparison of two corticosteroid
regimens plus mycophenolate mofetil and cyclosporine for
prevention of acute renal allograft rejection. Transplantation
2000;70(9):1352–9. [MEDLINE: 11087152]
Maiorca 1988 {published data only}
Cristinelli L, Brunori G, Manganoni AM, Manganoni A,
Setti G, Maiorca R. Controlled study of steroid withdrawal
after 6 months in renal transplant patients treated with
ciclosporin. Contributions to Nephrology 1986;51:91–5.
[MEDLINE: 3552427]
Cristinelli L, Brunori G, Setti G, Manganoni A, Manganoni
AM, Scolari F, et al. Withdrawal of methylprednisolone at
the sixth month in renal transplant recipients treated with
cyclosporine. Transplantation Proceedings 1987;19(1 Pt 3):
2021–3. [MEDLINE: 3079069]
Cristinelli L, Brunori G, Setti G, Scolari F, Scaini P,
Manganoni S, et al. Controlled randomised trial of
methylprednisolone withdrawal at the sixth month in renal
transplant recipients treated with cyclosporin [abstract].
Nephrology Dialysis Transplantation 1986;1(2):139.
[CENTRAL: CN–00260301; ]
∗ Maiorca R, Cristinelli L, Brunori G, Setti G, Salerni B,
De Nobili U, et al. Prospective controlled trial of steroid
withdrawal after six months in renal transplant patients
treated with cyclosporine. Transplantation Proceedings 1988;
20(3 Suppl 3):121–5. [MEDLINE: 3291224]
Matl 2000 {published data only}
Matl I, Lacha J, Lodererova A, Simova M, Teplan V,
Lanska V, et al. Withdrawal of prednisone from a triple
combination of immunosuppressive agents after kidney
transplantation [Vysazení prednisonu z trojkombinace
imunosupresiv u nemocných po transplantaci ledviny].
Casopis Lekaru Ceskych 2000;139(4):115–9. [MEDLINE:
10838741]
∗ Matl I, Lacha J, Lodererova A, Simova M, Teplan V,
Lanska V, et al. Withdrawal of steroids from triple-
drug therapy in kidney transplant patients. Nephrology
Dialysis Transplantation 2000;15(7):1041–5. [MEDLINE:
10862645]
Matl I, Lacha J, Lodererova A, Simova M, Vitko S.
Withdrawal of steroids from triple drug therapy in renal
transplant patients [abstract]. 35th Congress. European
Renal Association. European Dialysis and Transplantation
Association; 1998 Jun 6-9; Rimini, Italy. 1998:351.
[CENTRAL: CN–00485004; ]
Mericq 2013 {published data only}
Mericq V, Salas P, Pinto V, Cano F, Reyes L, Brown K, et
al. Steroid withdrawal in pediatric kidney transplant allows
better growth, lipids and body composition: a randomized
controlled trial. Hormone Research in Pædiatrics 2013;79(2):
88–96. [MEDLINE: 23429258]
Montagnino 2005 {published data only}
∗ Montagnino G, Sandrini S, Casciani C, Schena FP,
Carmellini M, Civati G, et al. A randomized trial of
steroid avoidance in renal transplant patients treated with
everolimus and cyclosporine. Transplantation Proceedings
2005;37(2):788–90. [MEDLINE: 15848532]
Montagnino G, Sandrini S, Iorio B, Schena FP, Carmellini
M, Rigotti P, et al. A randomized exploratory trial of
30Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
steroid avoidance in renal transplant patients treated
with everolimus and low-dose cyclosporine. Nephrology
Dialysis Transplantation 2008;23(2):707–14. [MEDLINE:
17890244]
Ponticelli C, Sandrini S, Casciani C, Schena FP, STAR
Group. A randomized trial of steroid avoidance in
renal transplant patients treated with everolimus and
cyclosporine. [abstract no: O432]. Transplantation 2004;
78(2 Suppl):170. [CENTRAL: CN–00509422; ]
Nagib 2015 {published data only}
Nagib AM, Abbas MH, Abu-Elmagd MM, Denewar AA,
Neamatalla AH, Refaie AF, et al. Long-term study of steroid
avoidance in renal transplant patients: a single-center
experience. Transplant Proceedings 2015;47(4):1099–104.
[MEDLINE: 26036529]
Nagib AM, Neamatalla AH, Bakr MA, Refaie AF,
Abo-Elmagd MM, Wafa IW. Long term study of
steroid avoidance in renal transplant patients: A single
center experience [abstract]. Experimental & Clinical
Transplantation 2014;12:100. [EMBASE: 71976229]
Nematalla 2007 {published data only}
Gheith OA, Nematalla AH, Bakr MA, Refaie A, Shokeir
AA, Ghoneim MA. Cost-benefit of steroid avoidance in
renal transplant patients: a prospective randomized study.
Scandinavian Journal of Urology & Nephrology 2010;44(3):
175–82. [MEDLINE: 20230185]
Gheith OA, Nematalla AH, Bakr MA, Refaie A, Shokeir
AA, Ghoneim MA. Steroid avoidance reduce the cost
of morbidities after live-donor renal allotransplants: a
prospective, randomized, controlled study. Experimental
& Clinical Transplantation: Official Journal of the Middle
East Society for Organ Transplantation 2011;9(2):121–7.
[MEDLINE: 21453230]
Neamatalla A, Bakr A, El Agroudy A, El Shehawy E,
Shokier A, Ghoneim M. Improving quality of life after
steroid avoidance immunosuppression regimen in live
donor renal allotransplant recipients - a prospective
randomized controlled study single center experience (two
year follow up) [abstract no: FP222]. Nephrology Dialysis
Transplantation 2007;22(Suppl 6):vi93.
Neamatalla AH, Bakr MA, El Agroudy AE, El Shehawy
EL, Shokier AA. Improving quality of life after steroid
avoidance immunosuppression regimen in live donor
renal allotransplant recipients - a prospective randomized
controlled study single center experience (two year follow
up) [abstract no: P163]. Transplant International 2007;20
(Suppl 2):134. [CENTRAL: CN–00653762; ]
Nematalla AH, Bakr MA, El Agroudy A, El Shehawy
E, Abdel Rahman ME. Steroid free immunosuppression
regimen in live donor renal allotransplant recipients - a
prospective randomized study (single center experience)
[abstract no: PO-466]. Transplant International 2005;18
(Suppl 1):157.
Nematalla AH, Bakr MA, El Agroudy AE, El
Shehawy E, Salim M, Shokier AA. Steroid avoidance
immunosuppression regimen in live donor renal
allotransplant recipients - a prospective randomized
controlled study single center experience (one year
follow up) [abstract no: SP734]. Nephrology Dialysis
Transplantation 2006;21(Suppl 4):iv263. [CENTRAL:
CN–00653763; ]
Nematalla AH, Bakr MA, Gheith OA, Akl A, EL
Agroudy AE, EL Shahawy M, et al. Steroid avoidance
immunosuppression: long term evaluation in live donor
renal allotransplant recipients [abstract no: P66]. British
Transplantation Society (BTS).11th Annual Congress;
2008 Apr 16-18; Glasgow, UK. 2008. [CENTRAL:
CN–00766492; ]
Nematalla AH, Bakr MA, Gheith OA, Akl AE. Steroid
avoidance immunosuppressive protocol: long term
evaluation of prospective randomized study after live
donor renal allotransplant [abstract: O-323]. Transplant
International 2009;22(Suppl 2):86–7.
∗ Nematalla AH, Bakr MA, Gheith OA, El Agroudy
AE, El Shahawy, Aghoneim M. Steroid-avoidance
immunosuppression regimen in live-donor renal
allotransplant recipients: a prospective, randomized,
controlled study. Experimental & Clinical Transplantation:
Official Journal of the Middle East Society for Organ
Transplantation 2007;5(2):673–9. [MEDLINE: 18194120]
Nott 1985 {published data only}
∗ Griffin PJ, Da Costa CA, Salaman JR. A controlled trial of
steroids in cyclosporine-treated renal transplant recipients.
Transplantation 1987;43(4):505–8. [MEDLINE: 3554643]
Griffin PJ, Gomes da Costa CA, Salaman JR. Renal
transplantation without steroids: a controlled clinical trial.
Transplantation Proceedings 1986;18(4):797–8. [EMBASE:
1986223826]
Nott D, Griffin PJ, Salaman JR. Low-dose steroids do not
augment cyclosporine immunosuppression but do diminish
cyclosporine nephrotoxicity. Transplantation Proceedings
1985;17(1 II):1289–90. [EMBASE: 1985078719]
Salaman JR, Gomes Da Costa CA, Griffin PJ. Renal
transplantation without steroids. Journal of Pediatrics 1987;
111(6 Pt 2):1026–8. [MEDLINE: 3316575]
Park 1994 {published data only}
∗ Kim HC, Chang KJ, Kwon JK, Park SB, Cho WH, Park
CH. Long-term results of cyclosporine monotherapy in
renal transplantation. Transplantation Proceedings 1998;30
(7):3539–40. [MEDLINE: 9838550]
Park K, Kim ST, Lee SR, Koh YB, Kim HC. A 1-year
prospective randomized study in Korean living donor
kidney transplant recipients: comparing cyclosporine
monotherapy and cyclosporine/prednisolone during the
maintenance phase of immunosuppression. Transplantation
Proceedings 1994;26(4):1985–6. [MEDLINE: 8066642]
Pelletier 2006 {published data only}
Akin B, Ferguson RM, Pelletier RP. Five year follow-up
after steroid withdrawal demonstrates no evidence of
worsening renal function [abstract]. American Journal
of Transplantation 2004;4(Suppl 8):298. [CENTRAL:
CN–00509047; ]
Ing SW, Sinnott LT, Davies EA, Pelletier RP. Bone mineral
density changes in a prospective, randomized trial of steroid
31Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
withdrawal in kidney transplant recipients [abstract no:
621]. American Journal of Transplantation 2007;7(Suppl 2):
310. [CENTRAL: CN–00764017; ]
Ing SW, Sinnott LT, Donepudi S, Davies EA, Pelletier RP,
Lane NE. Change in bone mineral density at one year
following glucocorticoid withdrawal in kidney transplant
recipients. Clinical Transplantation 2011;25(2):E113–23.
[MEDLINE: 20961333]
∗ Pelletier RP, Akin B, Ferguson RM. Prospective,
randomized trial of steroid withdrawal in kidney recipients
treated with mycophenolate mofetil and cyclosporine.
Clinical Transplantation 2006;20(1):10–8. [MEDLINE:
16556147]
Pelletier RP, Davies EA, Elkhammas EA, Bumgardner GL,
Henry ML, Ferguson RM. Randomized, prospective trial of
prednisone withdrawal in stable renal transplant recipients
[abstract]. Transplantation 2000; Vol. 69, issue 8 Suppl:
S260. [CENTRAL: CN–00447152; ]
Pisani 2001 {published data only}
Coppelli A, Buonomo O, Iaria G, Pisani F, Pollicita S,
Rizzello A. Preliminary results of a prospective randomized
study of basiliximab and steroid withdrawal in kidney
transplantation [abstract no: 1617]. 2001 A Transplant
Odyssey; 2001 Aug 20-23; Istanbul, Turkey. 2001.
[CENTRAL: CN–00400600; ]
∗ Pisani F, Buonomo O, Iaria G, Tisone G, Mazzarella
V, Pollicita S, et al. Preliminary results of a prospective
randomized study of basiliximab in kidney transplantation.
Transplantation Proceedings 2001;33(1-2):2032–3.
[MEDLINE: 11267613]
Ponticelli 1997 {published data only}
Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci
C, Ponticelli C. Effects of three immunosuppressive
regimens on vertebral bone density in renal transplant
recipients: a prospective study. Transplantation 1997;63(3):
380–6. [MEDLINE: 9039927]
Montagnino G, Tarantino A, Maccario M, Elli A, Cesana
B, Ponticelli C. Long-term results with cyclosporine
monotherapy in renal transplant patients: a multivariate
analysis of risk factors. American Journal of Kidney Diseases
2000;35(6):1135–43. [MEDLINE: 10845828]
∗ Montagnino G, Tarantino A, Segoloni GP, Cambi V,
Rizzo G, Altieri P, et al. Long-term results of a randomized
study comparing three immunosuppressive schedules with
cyclosporine in cadaveric kidney transplantation. Journal
of the American Society of Nephrology 2001;12(10):2163–9.
[MEDLINE: 11562416]
Ponticelli C. Steroid withdrawal in organ transplant
recipients [abstract no: 0351]. XVIII International
Congress of the Transplantation Society; 2000 Aug 27-Sept
1; Rome, Italy. 2000. [CENTRAL: CN–00583616; ]
Ponticelli C, Aroldi A. Osteoporosis after organ
transplantation. Lancet 2001;357(9268):1623.
[MEDLINE: 11386321]
Ponticelli C, Tarantino A, Montagnino G. Steroid
withdrawal in renal transplant recipients. Transplantation
Proceedings 2001;33(1-2):987–8. [MEDLINE: 11267158]
Ponticelli C, Tarantino A, Segoloni GP, Cambi V, Rizzo G,
Altieri P, et al. A randomized study comparing cyclosporine
alone vs double and triple therapy in renal transplants. The
Italian Multicentre Study Group for Renal Transplantation
(SIMTRe). Transplantation Proceedings 1997;29(1-2):
290–1. [MEDLINE: 9123000]
Ponticelli C, Tarantino A, Segoloni GP, Cambi V, Rizzo
G, Altieri P, et al. A randomized study comparing
three cyclosporine-based regimens in cadaveric renal
transplantation. Italian Multicentre Study Group for Renal
Transplantation (SIMTRe). Journal of the American Society
of Nephrology 1997;8(4):638–46. [MEDLINE: 10495794]
Tarantino A, Italian Multicentre Study Group for
Renal Transplantation (SIMTRe). Is cylosporine
(CsA, Sandimmun) monotherapy an effective and
safe immunosuppressant in renal transplant recipients?
[abstract]. 16th Annual Meeting. American Society of
Transplant Physicians (ASTP); 1997 May 10-14; Chicago
(ILL). 1997:128. [CENTRAL: CN–00509501; ]
Tarantino A, Segoloni GP, Cambi V, Rizzo G, Altieri P,
Mastrangelo F, et al. A randomized study comparing
three cyclosporine-based regimens in cadaveric renal
transplantation: results at 7 years. Transplantation
Proceedings 1998;30(5):1729–31. [MEDLINE: 9723258]
Tarantino A, per il Gruppo SIMTRE. Long-term results of
a randomized trial of 3 cyclosporine (CSA) regimens in
cadaveric kidney allografts (TXC) [abstract]. Nephrology
Dialysis Transplantation 2000;15(9):A250. [CENTRAL:
CN–00461836; ]
Ratcliffe 1993 {published data only}
Dudley CR, Ratcliffe PJ, et al. Effect of steroid withdrawal
on graft function in renal transplant recipients [abstract].
Nephrology Dialysis Transplantation 1994;9(11):1672.
[CENTRAL: CN–00261076; ]
∗ Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith
B, Morris PJ. Randomised controlled trial of steroid
withdrawal in renal transplant recipients receiving triple
immunosuppression. Lancet 1996;348(9028):643–8.
[MEDLINE: 8782754]
Ratcliffe PJ, Firth JD, Higgins RM, Smith B, Gray DW,
Morris PJ. Randomized controlled trial of complete steroid
withdrawal in renal transplant patients receiving triple
immunosuppression. Transplantation Proceedings 1993;25
(1 Pt 1):590. [MEDLINE: 8438427]
Sandrini 2009 {published data only}
∗ Sandrini S, Setti G, Bossini N, Chiappini R, Valerio F,
Mazzola G, et al. Early (fifth day) vs. late (sixth month)
steroid withdrawal in renal transplant recipients treated with
Neoral plus Rapamune: four-yr results of a randomized
monocenter study. Clinical Transplantation 2010;24(5):
669–77. [MEDLINE: 20030684]
Sandrini S, Setti G, Bossini N, Maffei C, Iovinella L,
Tognazzi N, et al. Steroid withdrawal five days after
renal transplantation allows for the prevention of wound-
healing complications associated with sirolimus therapy.
32Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Clinical Transplantation 2009;23(1):16–22. [MEDLINE:
18727661]
Schulak 1989 {published data only}
Hricik DE, Mayes JT, Schulak JA. Independent effects
of cyclosporine and prednisone on posttransplant
hypercholesterolemia. American Journal of Kidney Diseases
1991;18(3):353–8. [MEDLINE: 1882828]
Hricik DE, Moritz C, Mayes JT, Schulak JA. Association of
the absence of steroid therapy with increased cyclosporine
blood levels in renal transplant recipients. Transplantation
1990;49(1):221–3. [MEDLINE: 2301016]
Hricik DE, Whalen CC, Lautman J, Bartucci MR,
Moir EJ, Mayes JT, et al. Withdrawal of steroids after
renal transplantation--clinical predictors of outcome.
Transplantation 1992;53(1):41–5. [MEDLINE: 1733083]
∗ Schulak JA, Mayes JT, Moritz CE, Hricik DE. A
prospective randomized trial of prednisone versus no
prednisone maintenance therapy in cyclosporine-treated
and azathioprine-treated renal transplant patients.
Transplantation 1990;49(2):327–32. [MEDLINE:
2407003]
Schulak JA, Moritz CE, Hricik DE. Renal transplantation
without prednisolone: effects of bone marrow tolerance
azathioprine. Transplantation Proceedings 1989;21(1 Pt 2):
1709–11. [MEDLINE: 2652560]
Smak Gregoor 1999 {published data only}
Roodnat J, Hilbrands LB, Hene RJ, De Sevaux RG,
Gregoor PJ, Van Gestel JA, et al. 15 year follow-up of
a multicentre, randomised, calcineurin inhibitor (CNI)
withdrawal study in kidney transplantation [abstract no:
BO156]. Transplant International 2013;26(Suppl 2):83–4.
[EMBASE: 71359271]
Roodnat JI, Hilbrands LB, Hene RJ, de Sevaux RG, Smak
Gregoor PJ, Kal-van Gestel JA, et al. 15-year follow-up of a
multicenter, randomized, calcineurin inhibitor withdrawal
study in kidney transplantation. Transplantation 2014;98
(1):47–53. [MEDLINE: 24521775]
Smak Gregoor PJ, De Sevaux RG, Ligtenberg G, et al. A
prospective randomised study of withdrawal of cyclosporine
or prednisone in renal transplant recipients treated with
mycophenolate mofetil, cyclosporine, and prednisone:
18 months follow-up data [abstract]. American Journal
of Transplantation 2001;1(Suppl 1):246. [CENTRAL:
CN–00763745; ]
Smak Gregoor PJ, de Sevaux RG, Hene RJ, Hesse CJ,
Hilbrands LB, Vos P, et al. Effect of cyclosporine on
mycophenolic acid trough levels in kidney transplant
recipients. Transplantation 1999;68(10):1603–6.
[MEDLINE: 10589962]
∗ Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, Hoitsma
AJ, Hene RJ, Weimar W, et al. Withdrawal of cyclosporine
or prednisone six months after kidney transplantation in
patients on triple drug therapy: a randomized, prospective,
multicenter study. Journal of the American Society of
Nephrology 2002;13(5):1365–73. [MEDLINE: 11961025]
Smak Gregoor PJ, van Gelder T, IJzermans JN, Weimar
W. Long-term results of a randomized, prospective study
after withdrawal of cyclosporine or prednisone in renal
transplant recipients treated with mycophenolate mofetil,
cyclosporine, and prednisone [abstract]. American Journal
of Transplantation 2003;3(Suppl 5):217. [CENTRAL:
CN–00447777; ]
Van Gelder T, De Sevaux R, Hene R, Weimar W, Hoitsma
A, Ligtenberg G, et al. Discontinuation of cyclosporine
or prednisone 6 months after kidney transplantation:
a randomized trial [abstract]. Journal of the American
Society of Nephrology 2001;12(Program & Abstracts):920A.
[CENTRAL: CN–00583812; ]
de Sevaux RGL, Gregoor P, Smak JH, Hene RJ, Weimar
W, Hoitsma AJ, et al. Withdrawal of cyclosporine or
prednisone in renal transplant recipients treated with
mycophenolate mofetil, cyclosporine, and prednisone: a
randomized study [abstract no: 935]. Transplantation 1999;
67(7):S240. [CENTRAL: CN–00767038; ]
Sola 2002 {published data only}
Sola E, Alférez MJ, Cabello M, Burgos D, González MM.
Low-dose and rapid steroid withdrawal in renal transplant
patients treated with tacrolimus and mycophenolate
mofetil. Transplantation Proceedings 2002;34(5):1689–90.
[MEDLINE: 12176537]
Stiller 1983 {published data only}
Canadian Transplant Study Group. The requirements
for maintenance steroids in cyclosporine-treated renal
transplant recipients [abstract]. Kidney International 1984;
25(6):998.
∗ MacDonald AS, Daloze P, Dandavino R, Jindal S, Bear
L, Dossetor JB, et al. A randomized study of cyclosporine
with and without prednisone in renal allograft recipients.
Canadian Transplant Group. Transplantation Proceedings
1987;19(1 Pt 3):1865–6. [MEDLINE: 3079054]
Stiller C. The requirements for maintenance steroids
in cyclosporine-treated renal transplant recipients.
Transplantation Proceedings 1983;15(4 Suppl 1-2):2490–4.
[EMBASE: 1984089082]
THOMAS Study 2002 {published data only}
Boots JM, van den Ham EC, Christiaans MH, van Hooff
JP. Risk of adrenal insufficiency with steroid maintenance
therapy in renal transplantation. Transplantation Proceedings
2002;34(5):1696–7. [MEDLINE: 12176541]
Budde K, Salmela K, Pascual J, Rigotti P, THOMAS
Follow-up Study Group. Steroid-withdrawal in tacrolimus-
treated renal transplant recipients: results of a 3-year
follow-up study [abstract]. 3rd International Congress on
Immunosuppression; 2004 Dec 8-11; San Diego (CA).
2004. [CENTRAL: CN–00550470; ]
Jindal RM, Salmela K, Vanrentergheim Y, van Hooff
JP, Squifflet JP. Reduction of high cholesterol levels by
early withdrawal of steroids from a tacrolimus-based
triple regimen [abstract no: 206]. American Journal
of Transplantation 2002;2(Suppl 3):190. [CENTRAL:
CN–00520347; ]
Pascual J, Van Hooff JP, Salmela K, Lang P, Rigotti
P, Budde K. Three-year observational follow-up of a
multicenter, randomized trial on tacrolimus-based therapy
33Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
with withdrawal of steroids or mycophenolate mofetil
after renal transplant. Transplantation 2006;82(1):55–61.
[MEDLINE: 16861942]
Pascual J, Vanrenterghem Y, van Hooff JP, Squifflet JP,
Salmela K, Rigotti P. Safe withdrawal of MMF or steroids
following 3-months of tacrolimus triple therapy: results of
a large, prospective, multicentre study [abstract]. XIXth
International Congress of the Transplantation Society;
2002 Aug 25-30; Miami (FL). 2002. [CENTRAL:
CN–00416426; ]
Pascual J, van Hooff JP, Salmela K, Budde K, Rigotti P,
Lang P. Long-term efficacy and safety of steroid-withdrawal
in tacrolimus treated renal transplant recipients: results of
a 3 year follow-up [abstract no: 1524]. American Journal
of Transplantation 2004;4(Suppl 8):576–7. [CENTRAL:
CN–00615852; ]
Rigotti P, European Tacrolimus/MMF Transplantation
Study Group. Patients with high cholesterol levels
benefit most from early withdrawal of corticosteroids.
Transplantation Proceedings 2002;34(5):1797–8.
[MEDLINE: 12176581]
Squifflet JP, Vanrenterghem Y, van Hooff JP, Salmela K,
Rigotti P, European Tacrolimus/MMF Transplantation
Study Group. Safe withdrawal of corticosteroids or
mycophenolate mofetil: results of a large, prospective,
multicenter, randomized study. Transplantation Proceedings
2002;34(5):1584–6. [MEDLINE: 12176495]
∗ Vanrenterghem Y, van Hooff JP, Squifflet JP, Salmela
K, Rigotti P, Jindal RM, et al. Minimization of
immunosuppressive therapy after renal transplantation:
results of a randomized controlled trial. American Journal of
Transplantation 2005;5(1):87–95. [MEDLINE: 15636615]
van Hooff JP, European Tacrolimus/MMF Transplantation
Study Group. Effect of controlled steroid withdrawal on
glucose levels in a tacrolimus-based immunosuppression
regimen [abstract]. 3rd International Congress on
Immunosuppression; 2004 Dec 8-11; San Diego (CA).
2004. [CENTRAL: CN–00550420; ]
van Hooff JP, Salmela K, Budde K, Pascual J, Rigotti P,
Lang P, et al. Long-term efficacy and safety of steroid-
withdrawal in tacrolimus-treated patients: results of a long-
term follow-up study in renal transplant recipients [abstract
no: 99]. 11th Congress of the European Society for
Transplantation (ESOT); 2003 Sept 20-24; Venice, Italy.
2003. [CENTRAL: CN–00653800; ]
van Hooff JP, Vanrenterghem Y, Squifflet JP, Salmela K,
Ancona E, European Tacrolimus/MMF Transplantation
Study Group. First, large, prospective study of a controlled
withdrawal of steroids or MMF following three months
of tacrolimus/MMF/steroid therapy [abstract]. Journal of
the American Society of Nephrology 2001;12(Program &
Abstracts):920A–1A. [CENTRAL: CN–00550422; ]
van den Ham EC, Kooman JP, Christiaans MH, van Hooff
JP. The influence of early steroid withdrawal on body
composition in renal transplant patients [abstract]. Journal
of the American Society of Nephrology 2000;11(Sept):711A.
[CENTRAL: CN–00550623; ]
van den Ham EC, Kooman JP, Christiaans MH, van Hooff
JP. The influence of early steroid withdrawal on bone
mineral density in renal transplant patients [abstract].
Journal of the American Society of Nephrology 2000;11(Sept):
711A. [CENTRAL: CN–00550623; ]
van den Ham EC, Kooman JP, Christiaans ML, van
Hooff JP. The influence of early steroid withdrawal on
body composition and bone mineral density in renal
transplantation patients. Transplant International 2003;16
(2):82–7. [MEDLINE: 12595969]
Vincenti 2003a {published data only}
Painter PL, Topp KS, Krasnoff JB, Adey D, Strasner A,
Tomlanovich S, et al. Health-related fitness and quality
of life following steroid withdrawal in renal transplant
recipients. Kidney International 2003;63(6):2309–16.
[MEDLINE: 12753323]
Topp KS, Painter PL, Walcott S, Krasnoff JB, Adey
D, Sakkas GK, et al. Alterations in skeletal muscle
structure are minimized with steroid withdrawal after
renal transplantation. Transplantation 2003;76(4):667–73.
[MEDLINE: 12973106]
Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Neylan
J, Roza A, et al. A multicenter randomized trial of
rapid steroid withdrawal vs standard steroid treatment in
patients treated with Simulect, Neoral and Cellcept for
the prevention of acute rejection in renal transplantation
[abstract no: 583]. Transplantation 1999;67(7):S152.
[CENTRAL: CN–00403005; ]
Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Neylan
J, Roza A, et al. Rapid steroid withdrawal versus standard
steroid therapy in patients treated with basiliximab,
cyclosporine, and mycophenolate mofetil for the prevention
of acute rejection in renal transplantation. Transplantation
Proceedings 2001;33(1-2):1011–2. [MEDLINE: 11267168]
∗ Vincenti F, Monaco A, Grinyo J, Kinkhabwala M,
Roza A. Multicenter randomized prospective trial
of steroid withdrawal in renal transplant recipients
receiving basiliximab, cyclosporine microemulsion and
mycophenolate mofetil. American Journal of Transplantation
2003;3(3):306–11. [MEDLINE: 12614286]
Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A,
Neylan J, et al. Rapid steroid withdrawal versus standard
steroid treatment in patients treated with simulect, neoral,
and cellcept for the prevention of acute rejection in renal
transplantation: a multicenter, randomized trial [abstract].
Transplantation 2000;69(8 Suppl):S133. [CENTRAL:
CN–00448209; ]
Woodle 2005 {published data only}
Alloway R, Woodle ES, Gaber AO, Pirsch J, Shihab F, Van
Veldhuisen P, et al. Multivariate analysis of risk factors for
acute rejection with early (7 day) corticosteroid withdrawal:
results from a randomized, double blind, placebo-controlled
trial [abstract no: 567]. American Journal of Transplantation
2006;6(Suppl 2):257.
Gaber AO, Moore LW, Alloway RR, Woodle ES, Pirsch
J, Shihab F, et al. Acute rejection characteristics from a
34Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
prospective, randomized, double-blind, placebo-controlled
multicenter trial of early corticosteroid withdrawal.
Transplantation 2013;95(4):573–9. [MEDLINE:
23423269]
Gaber AO, Moore LW, Pirsch J, Shihab F, Woodle ES,
Astellas Steroid Withdrawal Study Group. Characteristics
of rejection in renal allografts following early corticosteroid
withdrawal in a randomized controlled clinical trial: results
of 3 year followup [abstract no: 330]. American Journal
of Transplantation 2006;6(Suppl 2):178. [CENTRAL:
CN–00764094; ]
Lin S, Henning AK, Akhlaghi F, Reisfield R, Vergara-
Silva A, First MR. Interleukin-2 receptor antagonist
therapy leads to increased tacrolimus levels after kidney
transplantation. Therapeutic Drug Monitoring 2015;37(2):
206–13. [MEDLINE: 25162212]
Pirsch J, Woodle ES, Shihab F, Gaber AO, Van Veldhuisen
P, Gao J, et al. Effect of steroid withdrawal on new onset
diabetes after transplant: results of a randomized double-
blind placebo controlled trial [abstract no: 856]. American
Journal of Transplantation 2006;6(Suppl 2):355.
Pirsch JD, Henning AK, First MR, Fitzsimmons W,
Gaber AO, Reisfield R, et al. New-onset diabetes
after transplantation: results from a double-blind early
corticosteroid withdrawal trial. American Journal of
Transplantation 2015;15(7):1982–90. [MEDLINE:
25881802]
Shihab F, Woodle ES, Gaber AO, Pirsch J, Gao J, Van
Veldhuisen P, et al. Effect of corticosteroid withdrawal on
tacrolimus blood trough levels and dosing: results from a
randomized double-blind placebo controlled trial [abstract
no: 336]. American Journal of Transplantation 2006;6(Suppl
2):180.
Shihab F, Woodle ES, Gaber AO, Pirsch J, Van Veldhuisen
P, Gao J, et al. Leukopenia limits mycophenolic mofetil
dosing following early corticosteroid withdrawal: results
from a randomized double-blinded placebo controlled trial
[abstract no: 747]. American Journal of Transplantation
2006;6(Suppl 2):318.
Shihab FS, Lee ST, Smith LD, Woodle ES, Pirsch JD, Gaber
AO, et al. Effect of corticosteroid withdrawal on tacrolimus
and mycophenolate mofetil exposure in a randomized
multicenter study. American Journal of Transplantation
2013;13(2):474–84. [MEDLINE: 23167508]
Woodle ES. A multicenter, randomized, double blind,
placebo-controlled trial of early corticosteroid cessation:
final five year report [abstract no: 863]. Transplantation
2008;86(2 Suppl):301.
Woodle ES, Astellas Steroid Withdrawal Study Group.
A randomized double blind, placebo-controlled trial of
early corticosteroid cessation versus chronic corticosteroids:
five year results [abstract no: 453]. American Journal
of Transplantation 2008;8(Suppl 2):300. [CENTRAL:
CN–00644265; ]
Woodle ES, Astellas Steroid Withdrawal Study Group. A
randomized double blind, placebo-controlled trial of early
corticosteroid cessation versus chronic corticosteroids: four
year results [abstract no: 1704]. American Transplant
Congress; 2007 May 5-9; San Francisco (CA). 2007.
[CENTRAL: CN–00671799; ]
∗ Woodle ES, Astellas Steroid Withdrawal Study Group.
A randomized, double-blind placebo controlled trial of
early corticosteroid cessation versus chronic corticosteroids:
three year results [abstract no: 326]. American Journal
of Transplantation 2006;6(Suppl 2):177. [CENTRAL:
CN–00644264; ]
Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van
Veldhuisen P, et al. A prospective, randomized, double-
blind, placebo-controlled multicenter trial comparing early
(7 day) corticosteroid cessation versus long-term, low-dose
corticosteroid therapy. Annals of Surgery 2008;248(4):
564–77. [MEDLINE: 18936569]
Woodle ES, Fujisawa Corticosteroid Withdrawal Study
Group. A prospective, randomized, multicenter, double-
blind study of early corticosteroid cessation versus long-
term maintenance of corticosteroid therapy with tacrolimus
and mycophenolate mofetil in primary renal transplant
recipients: one year report. Transplantation Proceedings
2005;37(2):804–8. [MEDLINE: 15848538]
Woodle ES, Fujisawa Steroid Withdrawal Study Group. A
prospective, randomized, double blind multicenter study of
early (7 day) corticosteroid cessation vs. long term low dose
corticosteroid therapy under tacrolimus and mycophenolate
mofetil therapy with antibody induction in renal transplant
recipients [abstract no: P732]. Transplantation 2004;78(2
Suppl):457.
Woodle ES, Fujisawa Steroid Withdrawal Study Group. A
prospective, randomized, double blind multicenter study of
early (7 day) corticosteroid cessation vs. long term low dose
corticosteroid therapy under tacrolimus and mycophenolate
mofetil therapy with antibody induction in renal transplant
recipients [abstract]. American Journal of Transplantation
2004;4(Suppl 8):578. [CENTRAL: CN–00509566; ]
Woodle ES, Fujisawa Steroid Withdrawal Study Group. A
prospective, randomized, double blind, multicenter trial of
early (7 day) corticosteroid cessation vs long term low dose
corticosteroid therapy under tacrolimus and mycophenolate
mofetil therapy with antibody induction [abstract no: 183].
American Journal of Transplantation 2003;3(Suppl 5):198.
[CENTRAL: CN–00448416; ]
Woodle ES, Fujisawa Steroid Withdrawal Study Group. A
prospective, randomized, double blind, placebo controlled
multicenter study of early (7 day) corticosteroid cessation vs.
long term low dose corticosteroid therapy under tacrolimus
and mycophenolate mofetil therapy with antibody induction
in renal transplant recipients [abstract]. 3rd International
Congress on Immunosuppression; 2004 Dec 8-11; San
Diego (CA). 2004. [CENTRAL: CN–00550702; ]
Woodle ES, Fujisawa Steroid Withdrawal Study Group. A
randomized, double blinded, placebo controlled trial of
early corticosteroid cessation versus chronic corticosteroid
maintenance therapy [abstract no: 1511]. American Journal
of Transplantation 2005;5(Suppl 11):540.
Woodle ES, Gaber AO, Shihab F, Pirsch J, First MR,
35Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fitzsimmons W, et al. Comparison of T cell depleting
and non-T cell depleting antibody induction therapy for
early corticosteroid withdrawal regimens [abstract no: 849].
American Journal of Transplantation 2006;6(Suppl 2):353.
[CENTRAL: CN–00764352; ]
Woodle ES, Pirsch J, Alloway R, Shihab F, Gaber AO,
Van Veldhuisen P, et al. Long term effects of early
corticosteroid withdrawal and chronic corticosteroid
therapy on posttransplant weight gain [abstract no: 287].
American Journal of Transplantation 2006;6(Suppl 2):163.
Woodle ES, Pirsch J, Gaber AO, Shihab F, Alloway R, First
MR, et al. African Americans experience different risks and
benefits from early corticosteroid withdrawal than non-
African Americans: results from a three year, double blind,
randomized, placebo controlled trial [abstract no: 325].
American Journal of Transplantation 2006;6(Suppl 2):176.
Zhu 2008a {published data only}
Zhu QG, Zhao YK, Liu W, Luo H, Qiu Y, Gao ZZ. Two-
year observation of a randomized trial on tacrolimus-based
therapy with withdrawal of steroids or mycophenolate
mofetil after renal transplantation. Chinese Medical Sciences
Journal 2008;23(4):244–8. [MEDLINE: 19180887]
References to studies excluded from this review
Alexander 2006 {published data only}
Alexander JW, Goodman HR, Cardi M, Austin J,
Goel S, Safdar S, et al. Simultaneous corticosteroid
avoidance and calcineurin inhibitor minimization in renal
transplantation. Transplant International 2006;19(4):
295–302. [MEDLINE: 16573545]
Anil Kumar 2005 {published data only}
Anil Kumar MS, Fyfe B, Sierka D, Heifets M, Saeed
MI, Parikh MH. Comparison of efficacy and safety of
sirolimus (SLR) and mycophenolate mofetil (MMF) as
adjunct to calcineurin inhibitor (CNIi) based steroid free
immunosuppression in kidney transplantation [abstract].
American Journal of Transplantation 2004;4(Suppl 8):578.
[CENTRAL: CN–00509056; ]
Anil Kumar MS, Heifets M, Fyfe B, Saaed MI, Moritz
MJ, Parikh MH, et al. Comparison of steroid avoidance
in tacrolimus/mycophenolate mofetil and tacrolimus/
sirolimus combination in kidney transplantation monitored
by surveillance biopsy. Transplantation 2005;80(6):807–14.
[MEDLINE: 16210969]
Anil Kumar MS, Heifets M, Fyfe B, Sierka D, Saeed
MI, Parekh M, et al. A prospective randomized study
to compare the efficacy and safety of sirolimus (SLR)
and mycophenolate mofetil (MMF) monitored by
protocol biopsies in tacrolimus (TAC) based steroid
free immunosuppression [abstract]. American Journal
of Transplantation 2004;4(Suppl 8):216. [CENTRAL:
CN–00509296; ]
Kumar A, Lee D, Xiao SG, Moritz MJ, Fyfe B, Heifets M,
et al. Comparison of tacrolimus (FK506) and sirolimus
(SRL) combination with FK506 and mycophenolate
mofetil (MMF) in kidney transplant recipients with steroid
avoidance [abstract]. American Journal of Transplantation
2003;3(Suppl 5):350. [CENTRAL: CN–00446223; ]
Axelrod 2005 {published data only}
Axelrod D, Leventhal JR, Gallon LG, Parker MA,
Kaufman DB. Reduction of CMV disease with steroid-
free immunosuppression in simultaneous pancreas-kidney
transplant recipients. American Journal of Transplantation
2005;5(6):1423–9. [MEDLINE: 15888050]
Berney 2004 {published data only}
Berney T, Bucher P, Mathe Z, Andres A, Bosco D, Mage
R, et al. Islet of langerhans allogeneic transplantation
at the University of Geneva in the steroid free era
in islet after kidney and simultaneous islet-kidney
transplantations. Transplantation Proceedings 2004;36(4):
1121–2. [MEDLINE: 15194390]
Birkeland 1998b {published data only}
Birkeland SA, Larsen KE, Rohr N. Pediatric renal
transplantation without steroids. Pediatric Nephrology 1998;
12(2):87–92. [MEDLINE: 9543361]
Birkeland 2002 {published data only}
Birkeland SA, Beck-Nielsen H, Rohr N, Bertuzzi F, Secchi
A, Shapiro J, et al. Steroid-free immunosuppression
in kidney-islet transplantation: a long-term follow-up.
Transplantation 2002;73(9):1527. [MEDLINE: 12023637]
Budde 2001 {published data only}
Budde K, Diekmann F, Fritsche L, Geissler S, Hallebach G,
Neumayer H. Steroid withdrawal in long-term cyclosporine
treated patients using mycophenolate mofetil: a prospective
randomized pilot study [abstract no: 1233]. A Transplant
Odyssey; 2001 Aug 20-23; Istanbul, Turkey. 2001.
[CENTRAL: CN–00644340; ]
Budde K, Fritsche L, Geissler S, Hallebach G, Diekmann F,
Mai I, et al. Steroid withdrawal in long-term cyclosporine A
treated patients using mycophenolate mofetil: a prospective
randomized pilot study. Transplantation Proceedings 2001;
33(7-8):3250–2. [MEDLINE: 11750392]
Budde K, Geissler S, Hallebach G, Fritsche L, Waiser
J, Neumayer H. Prospective randomized trial of steroid
withdrawal in mycophenolate mofetil (MMF) and
cyclosporine (CYA) treated patients (PTS) [abstract].
Journal of the American Society of Nephrology 1998;9
(Program & Abstracts):668A. [CENTRAL: CN–00444574;
]
Budde K, Geissler S, Hallebach G, Waiser J, Fritsche
L, Bohler T, et al. Prospective randomized pilot study
of steroid withdrawal with mycophenolate mofetil in
long-term cyclosporine-treated patients: 4-year follow-
up. Transplantation Proceedings 2002;34(5):1703–5.
[MEDLINE: 12176544]
CAMPASIA Study 2005 {published data only}
Munoz AS, Cabanayan-Casasola CB, Danguilan RA, Padua
FB, Ona ET. Campath-1H (alemtuzumab) as an induction
agent for the prevention of graft rejection and preservation
of renal function in kidney transplant patients: Philippine
36Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3-year follow-up. Transplantation Proceedings 2008;40(7):
2230–3. [MEDLINE: 18790200]
Vathsala A, CAMPASIA Study Group. Safety and efficacy
of campath-1h (mabcampath®) with low dose cyclosporine
monotherapy in patients receiving kidney transplants - 6
month analysis of the pilot randomised controlled [abstract].
Transplantation 2004;78(2 Suppl):56. [CENTRAL:
CN–00509538; ]
Vathsala A, Campasia Study Group. One year results of
a pilot randomised controlled trial of the effectiveness of
alemtuzumab as an induction agent for prevention of graft
rejection and preservation of renal function in patients
receiving kidney transplants [abstract no: T-PO50029].
Nephrology 2005;10(Suppl):A215. [CENTRAL:
CN–00583367; ]
Vathsala A, Ona ET, Tan S, Suresh S, Chan Y, Lou H,
et al. CAMPASIA: a pilot randomised controlled trial
of the effectiveness of campath-1h (mabcampath®) as
an induction agent for prevention of graft rejection and
preservation of renal function in patients receiving kidney
transplants [abstract]. American Journal of Transplantation
2004;4(Suppl 8):406. [CENTRAL: CN–00509539; ]
Vathsala A, Ona ET, Tan SY, Suresh S, Lou HX, Cabanayan
Casasola CB, et al. Lymphocyte recovery after depletion
by alemtuzumab in renal transplant recipients: impact
on outcome [abstract no: 1015]. American Journal of
Transplantation 2005;5(Suppl 11):415. [CENTRAL:
CN–00644284; ]
Vathsala A, Ona ET, Tan SY, Suresh S, Lou HX, Casasola
CB, et al. Induction therapy with alemtuzumab together
with low dose cyclosporine monotherapy permits steroid-
free immunosuppression, mitigates drug-related, non-
immune toxicities and improves quality of life [abstract no:
TH-PO550]. Journal of the American Society of Nephrology
2006;17(Abstracts):224A. [CENTRAL: CN–00644285; ]
Vathsala A, Ona ET, Tan SY, Suresh S, Lou HX, Casasola
CB, et al. Randomized trial of Alemtuzumab for prevention
of graft rejection and preservation of renal function after
kidney transplantation. Transplantation 2005;80(6):
765–74. [MEDLINE: 16210963]
CARMEN Study 2005 {published data only}
Budde K, Neumayer HH, Rostaing L, Catarovich D,
Mourad G, Rigotti P, et al. Steroid-free immunosuppression
with daclizumab, tacrolimus and MMF is efficacious and
improves cholesterol, glucose and bone mineral density -
the CARMEN study [abstract]. Transplantation 2004;78(2
Suppl):168. [CENTRAL: CN–00509111; ]
Cantarovich D, Rostaing L, Mourad G, Neumayer HH,
Rigotti P, Tacrolimus Steroid Withdrawal Study Group. The
combination of Daclizumab, Tacrolimus, and MMF is an
effective and safe steroid-free immunosuppressive regimen
after renal transplantation. Results of a large multicentre
trial [abstract]. Nephrology Dialysis Transplantation 2003;18
(Suppl 4):788. [CENTRAL: CN–00444672; ]
Kramer BK, Kruger B, Mack M, Obed A, Banas B,
Paczek L, et al. Steroid withdrawal or steroid avoidance
in renal transplant recipients: focus on tacrolimus-based
immunosuppressive regimens. Transplantation Proceedings
2005;37(4):1789–91. [MEDLINE: 15919467]
Mourad G, Rostaing L, Cantarovich D, Neumayer H,
Rigotti P, Tacrolimus Steroid Withdrawal Study Group.
Immunosuppression without steroids: daclizumab/
tacrolimus/MMF vs. tacrolimus/MMF/steroids in renal
transplantation [abstract no: 12]. 11th Congress of the
European Society for Transplantation (ESOT); 2003 Sept
20-24; Venice, Italy. 2003. [CENTRAL: CN–00653705; ]
Pascual J, Rigotti P, Vialtel P, Sanchez-Fructuoso A, Escuin
F, Bone Mineral Density Study Group. Immunosuppression
without steroids: a daclizumab, tacrolimus and MMF
regimen prevents loss of bone mass following renal
transplantation [abstract no: 369]. 11th Congress of the
European Society for Transplantation (ESOT); 2003 Sept
20-24; Venice, Italy. 2003. [CENTRAL: CN–00653764; ]
Rigotti P, Vialtel P, Pascual J, Sanchez-Fructuoso A, Escuin
F, Bone Mineral Density Study Group. Immunosuppression
without maintenance steroids prevents decline of bone
mineral density following renal transplantation [abstract].
American Journal of Transplantation 2003;3(Suppl 5):199.
[CENTRAL: CN–00447406; ]
Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti
P, Mariat C, et al. Corticosteroid-free immunosuppression
with tacrolimus, mycophenolate mofetil, and daclizumab
induction in renal transplantation. Transplantation 2005;79
(7):807–14. [MEDLINE: 15818323]
Rostaing L, Catarovich D, Mourad G, Neumayer
HH, Rigotti P, CARMEN Study Group. Steroid-free
immunosuppression with a combination of Daclizumab,
Tacrolimus and MMF is efficacious and safe: results of a
large multicenter trial in renal transplantation [abstract].
American Journal of Transplantation 2003;3(Suppl 5):312.
[CENTRAL: CN–00447473; ]
Zaoui P, Vialtel P, Rigotti P, Pascual J, Sanchez-Fructuoso A,
Escuin F, et al. A steroid-free immunosuppressive regimen
of Daclizumab, Tacrolimus and MMF prevents loss of bone
mass following renal transplantation [abstract no: T670].
Nephrology Dialysis Transplantation 2003;18(Suppl 4):495.
[CENTRAL: CN–00448519; ]
Citterio 2002 {published data only}
Citterio F, Baldan N, Tondolo E, Marchini F, Castagneto
M, Rigotti P. Medium term results of steroid withdrawal in
tacrolimus treated renal transplant recipients [abstract]. 3rd
International Congress on Immunosuppression; 2004 Dec
8-11; San Diego (CA). 2004. [CENTRAL: CN–00550659;
]
Citterio F, Baldan N, Tondolo V, Marchini F, Romagnoli
J, Furian L, et al. Five years prospective study of steroid
withdrawal in renal transplant recipients [abstract no: 340].
American Journal of Transplantation 2005;5(Suppl 11):242.
[CENTRAL: CN–00644339; ]
Citterio F, Rigotti P, Scata MC, Baldan N, Marchini F,
Castagneto M. Steroid withdrawal in renal transplant
patients immunosuppressed with tacrolimus [abstract no:
135]. American Journal of Transplantation 2002;2(Suppl 3):
37Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
172. [CENTRAL: CN–00415437; ]
Citterio F, Rigotti P, Scata MC, Romagnoli J, Baldan N,
Marchini F, et al. Steroid withdrawal from tacrolimus-
based therapy in renal transplant patients. Transplantation
Proceedings 2002;34(5):1707–8. [MEDLINE: 12176545]
CORRETA Study 2008 {published data only}
Garcia VD, Carvalho DB, Goncalves RT, Cavalcanti
RL, Campos HH, Abbud-Filho M, et al. CORRETA
trial (corticosteroid reduction with tacrolimus):
prospective Brazilian multicenter, randomized trial of
early corticosteroid reduction vs regular corticosteroid
dosage maintenance on a tacrolimus (Prograf®) and
mycophenolate mofetil (Cellcept®) immunosuppression
regimen in kidney transplant recipients - interim analysis
[abstract no: P146]. Transplant International 2007;20
(Suppl 2):130–1. [CENTRAL: CN–00724889; ]
Garcia VD, Carvalho DB, Goncalves RT, Cavalcanti
RL, Campos HH, Abbud-Filho M, et al. Corticosteroid
reduction with tacrolimus (CORRETA) TRIAL: a
prospective Brazilian multicenter, randomized trial of early
corticosteroid reduction versus regular corticosteroid dosage
maintenance on a tacrolimus (Prograf ) and mycophenolate
mofetil (Cellcept) immunosuppression regimen in kidney
transplant recipients: interim analysis. Transplantation
Proceedings 2008;40(3):689–92. [MEDLINE: 18454988]
Garcia VD, Carvalho DB, Goncalves RT, Cavalcanti RL,
Campos HH, Abbud-Filho M, et al. Randomized trial of
early corticosteroid reduction vs. regular-dose corticosteroid
maintenance in combination with tacrolimus and
mycophenolate mofetil in living donor kidney transplant
recipients: the Brazilian CORRETA trial. Clinical
Transplantation 2010;24(4):E109–15. [MEDLINE:
20047610]
Curtis 1982 {published data only}
Curtis JJ, Galla JH, Woodford SY, Lucas BA, Luke RG.
Effect of alternate-day prednisone on plasma lipids in renal
transplant recipients. Kidney International 1982;22(1):
42–7. [MEDLINE: 6750206]
Daniel 1985 {published data only}
Daniel V,Opelz G,Dreikorn K. Lymphocyte subpopulations
in kidney transplant patients with different types of
immunosuppression. Transplantation Proceedings 1985;17
(6):2254–7. [EMBASE: 1986058424]
Dreikorn K, Horsch R, Rohl L. A randomized trial
with different immunosuppressive regimens after renal
transplantation. Transplantation Proceedings 1985;17(6):
2663–5. [EMBASE: 1986055110]
De Backer 1992 {published data only}
De Backer D, Abramowicz D, Goldman M, De Pauw
L, Viseur P, Vanherweghem JL, et al. High or low dose
steroid therapy for acute renal transplant rejection after
prophylactic OKT3 treatment: a prospective randomized
study. Transplant International 1992;5 Suppl 1:S437–9.
[MEDLINE: 14621839]
Delucchi 2006 {published data only}
Delucchi B A, Valenzuela A M, Ferrario B M, Lillo D
AM, Guerrero G JL, Rodriguez S E, et al. Early steroid
withdrawal in pediatric renal transplantation [Retiro
precoz de esteroides en la inmunosupresion del trasplante
renal pediatrico]. Revista Medica de Chile 2006;134(11):
1393–401. [MEDLINE: 17277852]
de Sandes Freitas 2011 {published data only}
de Sandes Freitas TV, Harada KM, Felipe CR, Galante
NZ, Sampaio EL, Ikehara E, et al. Steroid or tacrolimus
withdrawal in renal transplant recipients using sirolimus.
International Urology & Nephrology 2011;43(4):1221–8.
[MEDLINE: 21761129]
ECSEL Study 2008 {published data only}
Smith MP, Newstead CG, Ahmad N, Lewington AJ, Tibble
S, Lodge JP, et al. Poor tolerance of sirolimus in a steroid
avoidance regimen for renal transplantation. Transplantation
2008;85(4):636–9. [MEDLINE: 18347544]
Welberry-Smith MP, Gone K, Tibble S, Littler D, Newstead
CG, et al. Poor tolerance of sirolimus in a steroid avoidance
regime [abstract no: P37]. British Transplantation Society
(BTS). 9th Annual Congress; 2006 Mar 29-31; Edinburgh,
UK. 2006.
Hibbs 2010 {published data only}
Hibbs J, Hamdallah O, Cannon R, Ravindra K, Ouseph
R, Gleason J, et al. Alemtuzumab induction with rapid
corticosteroid elimination is associated with comparable
outcomes in high immunologic risk and non high risk renal
transplant recipients [abstract no: 976]. American Journal
of Transplantation 2010;10(Suppl 4):322. [EMBASE:
70464352]
Hilbrands 1993 {published data only}
Hilbrands LB, Demacker PN, Hoitsma AJ. Cyclosporin
and serum lipids in renal transplant recipients. Lancet 1993;
341(8847):765–6. [MEDLINE: 8095674]
Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF,
Koene RA. The effects of cyclosporine and prednisone on
serum lipid and (APO)lipoprotein levels in renal transplant
recipients. Journal of the American Society of Nephrology
1995;5(12):2073–81. [MEDLINE: 7579056]
Hilbrands LB, Hoitsma AJ, Koene KA. Randomized,
prospective trial of cyclosporine monotherapy versus
azathioprine-prednisone from three months after renal
transplantation. Transplantation 1996;61(7):1038–46.
[MEDLINE: 8623182]
Hilbrands LB, Hoitsma AJ, Koene RA. Costs of drugs used
after renal transplantation. Transplant International 1996;9
Suppl 1:S399–402. [MEDLINE: 8959872]
Hilbrands LB, Hoitsma AJ, Koene RA. Effect of
immunosuppressive therapy on quality of life after renal
transplantation [abstract]. Journal of the American Society of
Nephrology 1994;5(3):1011. [CENTRAL: CN–00615875;
]
Hilbrands LB, Hoitsma AJ, Koene RA. Medication
compliance after renal transplantation. Transplantation
1995;60(9):914–20. [MEDLINE: 7491693]
Hilbrands LB, Hoitsma AJ, Koene RA. The effect of
immunosuppressive drugs on quality of life after renal
transplantation. Transplantation 1995;59(9):1263–70.
[MEDLINE: 7762059]
38Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hodson 1989 {published data only}
Hodson EM, Knight JF, Sheil AG, Roy LP. Cyclosporin A
as sole immunosuppressive agent for renal transplantation
in children: effect on catch-up growth. Transplantation
Proceedings 1989;21(1 Pt 2):1687–92. [MEDLINE:
2652553]
Hricik 1993a {published data only}
Hricik DE, Schulak JA. Metabolic effects of steroid
withdrawal in adult renal transplant recipients. Kidney
International - Supplement 1993;43:S26–9. [MEDLINE:
8246365]
Hricik 1993b {published data only}
Hricik DE, O’Toole MA, Schulak JA, Herson J. Steroid-free
immunosuppression in cyclosporine-treated renal transplant
recipients: a meta-analysis. Journal of the American Society of
Nephrology 1993;4(6):1300–5. [MEDLINE: 8130356]
John 2005 {published data only}
John E, Lumpaopang A, Oberholzer J, Testa G, Sankary
H, Benedetti E. Superior outcomes in growth and renal
function with early steroid discontinuation in pediatric
kidney transplantation: 1 1/2 years follow-up [abstract no:
1329]. American Journal of Transplantation 2005;5(Suppl
11):494.
Juarez 2006 {published data only}
Juarez FJ, Barrios Y, Cano L, Lopez E, Martinez J,
Limones M, et al. A randomized trial comparing two
corticosteroid regimens combined with mycophenolate
mofetil and cyclosporine for prevention of acute renal
allograft rejection. Transplantation Proceedings 2006;38(9):
2866–8. [MEDLINE: 17112851]
Kim 2004 {published data only}
Kim B, Huh W, Baek HJ, Lim YH, Yeo HM, Kim JA,
et al. Randomized trial of tacrolimus versus cyclosporine
in steroid withdrawal in living donor renal transplant
recipients [abstract no: SU-PO523]. Journal of the American
Society of Nephrology 2003;14(Nov):648A. [CENTRAL:
CN–00626065; ]
Kim B, Huh W, Kim MO, Yeo HM, Kim HJ, Kim JA,
et al. Randomized trial of tacrolimus versus cyclosporine
in steroid withdrawal in living donor renal transplant
recipients. Korean Journal of Nephrology 2004;23(5):
785–92. [CENTRAL: CN–01044957; ]
Kim SJ, Lee KW, Lee DS, Lee HH, Lee SK, Kim B, et
al. Randomized trial of tacrolimus versus cyclosporine
in steroid withdrawal in living donor renal transplant
recipients. Transplantation Proceedings 2004;36(7):
2098–100. [MEDLINE: 15518759]
Kim 2005 {published data only}
Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Matti
Vehaskari V. Effect of age, ethnicity, and glucocorticoid
use on tacrolimus pharmacokinetics in pediatric renal
transplant patients. Pediatric Transplantation 2005;9(2):
162–9. [MEDLINE: 15787787]
Lehmann 2004 {published data only}
Lehmann R, Weber M, Berthold P, Zullig R, Pfammatter
T, Moritz W, et al. Successful simultaneous islet-kidney
transplantation using a steroid-free immunosuppression:
two-year follow-up. American Journal of Transplantation
2004;4(7):1117–23. [MEDLINE: 15196070]
Li 2011a {published data only}
Li S, Wang W, Hu X, Ren L, Yin H, Yang X, et al.
The effects of early rapid corticosteroid reduction on
cell-mediated immunity in kidney transplant recipients.
Transplant Immunology 2011;24(2):127–30. [MEDLINE:
20888912]
Li SH, Wang W, Hu XP, Yin H, Ren L, Yang XY, et al.
Monitoring immune function after rapid corticosteroid
reduction in kidney transplant recipients. Chinese Medical
Journal 2011;124(5):679–82. [MEDLINE: 21518557]
Morris 1982 {published data only}
Morris PJ, Chan L, French ME, Ting A. Low dose oral
prednisolone in renal transplantation. Lancet 1982;1
(8271):525–7. [MEDLINE: 6120389]
MYSS Study 2004 {published data only}
Gotti E, Perico N, Gaspari F, Cattaneo D, Lesti MD,
Ruggenenti P, et al. Blood cyclosporine level soon
after kidney transplantation is a major determinant of
rejection: insights from the Mycophenolate Steroid-Sparing
Trial. Transplantation Proceedings 2005;37(5):2037–40.
[MEDLINE: 15964332]
Perico N, Ruggenenti P, Gotti E, Gaspari F, Cattaneo
D, Valente U, et al. In renal transplantation blood
cyclosporine levels soon after surgery act as a major
determinant of rejection: insights from the MY.S.S. trial.
Kidney International 2004;65(3):1084–90. [MEDLINE:
14871429]
Perico N, Ruggenenti P, Gotti E, Gaspari F, Cattaneo
D, Valente U, et al. In renal transplantation low blood
cyclosporine levels soon after surgery is a determinant of
rejection: insights from the MY.S.S. trial [abstract]. Journal
of the American Society of Nephrology 2003;14(Nov):11A.
[CENTRAL: CN–00601980; ]
Remuzzi G, Cravedi P, Costantini M, Lesti M, Ganeva
M, Gherardi G, et al. Mycophenolate mofetil versus
azathioprine for prevention of chronic allograft dysfunction
in renal transplantation: the MYSS follow-up randomized,
controlled clinical trial. Journal of the American Society of
Nephrology 2007;18(6):1973–85. [MEDLINE: 17460145]
Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov BD,
Ene-Iordache B, et al. Mycophenolate mofetil versus
azathioprine for prevention of acute rejection in renal
transplantation (MYSS): a randomised trial. Lancet 2004;
364(9433):503–12. [MEDLINE: 15302193]
NCT00089947 {published data only}
NCT00089947. Randomized, prospective, phase 2 study
comparing thymoglobulin in a rapid discontinuation
of corticosteroids protocol with standard corticosteroid
therapy in living donor renal transplantation using
mycophenolate mofetil and tacrolimus maintenance
therapy. www.clinicaltrials.gov/ct2/show/NCT00089947
(accessed 15 February 2016).
39Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nori 2008 {published data only}
Nori US, Pesavento TE, Davies EA, Von Visger J, Miller
BS, Ferguson RM. Randomized, prospective prednisone
(P) withdrawal trial in kidney transplant patients treated
with sirolimus (S) vs microemulsified cyclosporine (CsA)
based regimens [abstract no: 458]. American Journal
of Transplantation 2008;8(Suppl 2):301. [CENTRAL:
CN–00725014; ]
Paczek 2003a {published data only}
Paczek L, Wlodarczyk Z, Perner F, Vitko S, Ostrowski M,
Bachleda P, et al. Absence of rejection and stable serum
creatinine are excellent criteria for steroid-withdrawal in
kidney transplant patients receiving tacrolimus treatment
[abstract]. Nephrology Dialysis Transplantation 2003;18
(Suppl 4):787–8. [CENTRAL: CN–00447076; ]
Papadakis 1982 {published data only}
Papadakis J, Brown CB, Cameron JS, Adu D, Bewick M,
Donaghey R, et al. High versus “low” dose corticosteroids
in recipients of cadaveric kidneys: prospective controlled
trial. British Medical Journal Clinical Research Ed 1983;286
(6371):1097–100. [MEDLINE: 6404341]
Papadakis JT, Bewick M, Cameron JS, Rudge C, Ogg CS,
Brown CB, et al. Low dose steroids in renal transplantation.
Lancet 1982;1(8277):916–7. [MEDLINE: 6122138]
Reed 1991 {published data only}
Reed A, Pirsch JD, Armbrust MJ, Burlingham WJ,
Knechtle SJ, D’Alessandro AM, et al. A comparison of
donor-specific and random transfusions in living-related
renal transplantation and their effect on steroid withdrawal.
Transplantation Proceedings 1991 Feb;23(1 Pt 2):1321–2.
[MEDLINE: 1989226]
Remport 2001 {published data only}
Remport A, Sasvari I, Borka P, Toronyi E, Sarvary E,
Weszelits W, et al. Comparative analysis of mycophenolate-
mofetil-cyclosporin immunosuppression of kidney
transplantation recipients with two different corticosteroid
doses and conventional cyclosporin-corticosteroid
therapy [abstract]. XVIII International Congress of the
Transplantation Society; 2000 Aug 27-Sept 1; Rome, Italy.
2000. [CENTRAL: CN–00447378; ]
Remport A, Sasvari I, Borka P, Toronyi E, Sarvary
E, Weszelits W, et al. Evaluation of the effect of
different corticosteroid doses in combination with
mycophenolate-mofetil-cyclosporin immunosuppression
in kidney transplanted recipients [abstract]. Nephrology
Dialysis Transplantation 2000;15(9):A256. [CENTRAL:
CN–00461586; ]
Remport A, Sasvari I, Toronyi E, Borka P, Lazar N, Jaray J, et
al. Mycofenolate mofetil-cyclosporine immunosuppression
of kidney transplantation recipients with two different
corticosteroid doses. Transplantation Proceedings 2001;33
(3):2302–3. [MEDLINE: 11377537]
Robertson 1980 {published data only}
Robertson AJ, Gibbs J, Potts R, Brown RA, Browning MC,
Beck JS. Renal transplant rejection after gradual withdrawal
of prednisolone. British Medical Journal 1980;281(6235):
305–6. [MEDLINE: 7000255]
Sarwal 2012 {published data only}
Chaudhuri A, Ozawa M, Everly MJ, Ettenger R,
Dharnidharka V, Benfield M, et al. The clinical impact
of humoral immunity in pediatric renal transplantation.
Journal of the American Society of Nephrology 2013;24(4):
655–64. [MEDLINE: 23449533]
Kambham N, NaesensM, Sigdel T,Waskerwitz J, Salvatierra
O, Sarwal M. A protocol biopsy analysis from an NIH
multicenter pediatric renal transplant trial reveals no adverse
effect of steroid avoidance on the histological evolution of
chronic graft injury [abstract no: LB01]. American Journal
of Transplantation 2008;8(Suppl 2):334.
Naesens M, KambhamN, Sigdel T,Waskerwitz J, Salvatierra
O, Sarwal M. A protocol biopsy analysis from an NIH
multicenter pediatric renal transplant trial revels no adverse
effect of steroid avoidance on the histological evolution of
chronic graft injury [abstract no: 54]. Transplantation 2008;
86(2S):18.
Naesens M, Salvatierra O, Benfield M, Ettenger
RB, Dharnidharka V, Harmon W, et al. Subclinical
inflammation and chronic renal allograft injury in a
randomized trial on steroid avoidance in pediatric kidney
transplantation. American Journal of Transplantation 2012;
12(10):2730–43. [MEDLINE: 22694733]
Sarwal M, Benfield M, Ettenger R, Dharnidharka V,
Mathias R, McDonald R, et al. One year results of a
prospective, randomized, multicenter trial of steroid
avoidance in pediatric renal transplantation [abstract no:
52]. American Journal of Transplantation 2008;8(Suppl 2):
192.
Sarwal M, Chadhuri A, Ozawa M, Everly M, Ettenger R,
Dharnidharka V, et al. The clinical impact and evolution
of humoral immunity in a randomized multicenter trial of
steroid avoidance in pediatric renal transplantation [abstract
no: D1767]. American Journal of Transplantation 2013;13
(Suppl S5):552. [EMBASE: 71058343]
Sarwal MM, Ettenger RB, Dharnidharka V, Benfield M,
Mathias R, Portale A, et al. Complete steroid avoidance
is effective and safe in children with renal transplants: a
multicenter randomized trial with three-year follow-up.
American Journal of Transplantation 2012;12(10):2719–29.
[MEDLINE: 22694755]
SENIOR Study 2009 {published data only}
Andres A, Budde K, Clavien PA, Becker T, Kessler M,
Pisarski P, et al. A randomized trial comparing renal function
in older kidney transplant patients following delayed versus
immediate tacrolimus administration. Transplantation
2009;88(9):1101–8. [MEDLINE: 19898206]
Shapiro 1993 {published data only}
Shapiro R, Jordan M, Scantlebury V, Vivas C, Fung J,
McCauley J, et al. A prospective, randomized trial of FK-
506 in renal transplantation--a comparison between double-
and triple-drug therapy. Clinical Transplantation 1994;8(6):
508–15. [MEDLINE: 7532475]
Shapiro R, Jordan ML, Scantlebury VP, Fung JJ, Jensen C,
Vivas C, et al. Randomized trial of FK 506/prednisone vs
FK 506/azathioprine/prednisone after renal transplantation:
40Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
preliminary report. Transplantation Proceedings 1993;25(1
Pt 1):669–72. [MEDLINE: 7679836]
Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Fung JJ,
McCauley J, et al. A prospective randomized trial of FK506-
based immunosuppression after renal transplantation.
Transplantation 1995;59(4):485–90. [MEDLINE:
7533343]
Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Fung JJ,
McCauley J, et al. A prospective, randomized trial of FK
506/prednisone vs FK 506/azathioprine/prednisone in renal
transplant patients. Transplantation Proceedings 1995;27(1):
814–7. [MEDLINE: 7533432]
Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Gitsch HA,
McCauley J, et al. The outcome after steroid withdrawal
in renal transplant patients receiving tacrolimus-based
immunosuppression [abstract no: 188]. 16th Annual
Meeting. American Society of Transplant Physicians
(ASTP); 1997 May 10-14; Chicago (ILL). 1997:131.
[CENTRAL: CN–00509473; ]
Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Gritsch
HA, McCauley J, et al. Outcome after steroid withdrawal
in renal transplant patients receiving tacrolimus-based
immunosuppression. Transplantation Proceedings 1998;30
(4):1375–7. [MEDLINE: 9636557]
Shapiro R, Jordan ML, Scantlebury VP, Vivas C,
Gritsch HA, McCauley J, et al. Tacrolimus in renal
transplantation. Transplantation Proceedings 1996;28(4):
2117–8. [MEDLINE: 8769173]
Silverstein 2005 {published data only}
Silverstein DM, Aviles DH, LeBlanc PM, Jung FF,
Vehaskari VM. Results of one-year follow-up of steroid-free
immunosuppression in pediatric renal transplant patients.
Pediatric Transplantation 2005;9(5):589–97. [MEDLINE:
16176415]
SOCRATES Study 2014 {published data only}
Chadban SJ, Eris JM, Kanellis J, Pilmore H, Lee PC, Lim
SK, et al. A randomized, controlled trial of everolimus-
based dual immunosuppression versus standard of care in de
novo kidney transplant recipients. Transplant International
2014;27(3):302–11. [MEDLINE: 24279685]
Russ G, Eris J, Kanellis J, Hutchison B, Hibberd A, Pilmore
H, et al. Multicentre RCT of early switch to everolimus
plus steroids or everolimus plus CSA versus CSA, MPA
and steroids in de novo kidney transplant recipients: 12
month analysis [abstract no: 93]. Transplantation Society of
Australia & New Zealand (TSANZ). 30th Annual Scientific
Meeting; 2012 Jun 27-29; Canberra (ACT). 2012:103.
Tarantino 1991 {published data only}
Tarantino A, Aroldi A, Stucchi L, Montagnino G,
Mascaretti L, Vegeto A, et al. A randomized prospective
trial comparing cyclosporine monotherapy with triple-drug
therapy in renal transplantation. Transplantation 1991;52
(1):53–7. [MEDLINE: 1858154]
Teplan 2003 {published data only}
Teplan V, Schuck O, Stollova M, Vitko S. Obesity and
hyperhomocysteinaemia after kidney transplantation.
Nephrology Dialysis Transplantation 2003;18 Suppl 5:
v71–3. [MEDLINE: 12817077]
ter Meulen 2002 {published data only}
Hendrikx TK, Klepper M, Ijzermans J, Weimar W, Baan
CC. Clinical rejection and persistent immune regulation in
kidney transplant patients. Transplant Immunology 2009;21
(3):129–35. [MEDLINE: 19398001]
Hesselink DA, Ngyuen H, Wabbijn M, Gregoor PJ,
Steyerberg EW, van Riemsdijk IC, et al. Tacrolimus dose
requirement in renal transplant recipients is significantly
higher when used in combination with corticosteroids.
British Journal of Clinical Pharmacology 2003;56(3):327–30.
[MEDLINE: 12919182]
Hesselink DA, Ngyuen H, Wabbijn M, Smak Gregoor PJH,
Steyerberg EW, van Riemsdijk IC, et al. Tacrolimus dose
requirement in renal transplant recipients is significantly
higher when used in combination with corticosteroids
[abstract]. American Journal of Transplantation 2003;3
(Suppl 5):482.
ter Meulen CG, Goertz JH, Klasen IS, Verweij CM,
Hilbrands LB, Wetzels JF, et al. Decreased renal excretion
of soluble interleukin-2 receptor alpha after treatment with
daclizumab. Kidney International 2003;64(2):697–703.
[MEDLINE: 12846768]
ter Meulen CG, Hilbrands LB, van den Bergh JP, Hermus
AR, Hoitsma AJ. The influence of corticosteroids on
quantitative ultrasound parameters of the calcaneus in
the 1st year after renal transplantation. Osteoporosis
International 2005;16(3):255–62. [MEDLINE: 15232677]
ter Meulen CG, van Riemsdijk I, Hene RJ, Christiaans
MH, Borm GF, Corstens FH, et al. No important influence
of limited steroid exposure on bone mass during the first
year after renal transplantation: a prospective, randomized,
multicenter study. Transplantation 2004;78(1):101–6.
[MEDLINE: 15257046]
ter Meulen CG, van Riemsdijk I, Hene RJ, Christiaans
MH, Borm GF, van Gelder T, et al. Steroid-withdrawal at
3 days after renal transplantation with anti-IL-2 receptor
alpha therapy: a prospective, randomized, multicenter
study. American Journal of Transplantation 2004;4(5):
803–10. [MEDLINE: 15084178]
ter Meulen CG, van Riemsdijk IC, Hene RJ,
Christiaans MH, van Gelder T, Hilbrands LB, et al.
A prospective randomized trial comparing steroid-free
immunosuppression with limited steroid exposure on bone
mineral density in the first year after renal transplantation
[abstract no: 0344]. XIXth International Congress of the
Transplantation Society; 2002 Aug 25-30; Miami (FL).
2002. [CENTRAL: CN–00402832; ]
van Gelder T, ter Meulen CG, Hene RJ, Christiaans MH,
Borm GF, van Riemsdijk IC, et al. Steroid withdrawal
at three days after renal transplantation with anti IL-2
receptor therapy: a prospective randomized multicenter
trial [abstract]. American Journal of Transplantation 2004;4
(Suppl 8):578. [CENTRAL: CN–00509529; ]
van Riemsdijk IC, Termeulen RG, Christiaans MH, Hene
RJ, Hoitsma AJ, van Hooff JP, et al. Anti-CD25 prophylaxis
41Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
allows steroid-free renal transplantation in tacrolimus-based
immunosuppression [abstract no: 133]. American Journal
of Transplantation 2002;2(Suppl 3):171. [CENTRAL:
CN–00402963; ]
TRIMS Study 2010 {published data only}
Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S,
Kuo PC, TRIMS Study Investigators. A prospective,
randomized, multicenter study evaluating early
corticosteroid withdrawal with Thymoglobulin in living-
donor kidney transplantation. Clinical Transplantation
2010;24(1):73–83. [MEDLINE: 19930408]
Woodle ES, TRIMS Study Group. A randomized,
prospective, multicenter comparative study evaluating a
thymoglobulin-based early corticosteroid cessation regime in
renal transplantation [abstract no: 673]. American Journal
of Transplantation 2006;6(Suppl 2):294. [CENTRAL:
CN–00716028; ]
Woodle ES, TRIMS Study Group. A randomized,
prospective, multicenter study of thymoglobulin in
renal transplantation for induction and minimization of
steroids (TRIMS) [abstract no: 1632]. American Journal
of Transplantation 2005;5(Suppl 11):571. [CENTRAL:
CN–00716027; ]
TWIST Study 2010 {published data only}
Billing H, Hoecker B, Fichtner A, Van Damme-Lombaerts
R, Friman S, Jaray J, et al. Single nucleotide polymorphism
of CYP3A5 influences the exposure to tacrolimus in
pediatric renal transplant recipients: A pharmacogenetic
substudy of the TWIST trial [abstract]. Transplantation
2014;98(Suppl 1):147. [EMBASE: 71543993]
Billing H, Sander A, Susal C, Ovens J, Feneberg R, Hocker
B, et al. Soluble CD30 and ELISA-detected human
leukocyte antigen antibodies for the prediction of acute
rejection in pediatric renal transplant recipients. Transplant
International 2013 Mar;26(3):331–8. [MEDLINE:
23279372]
Feneberg R. Single nucleotide polymorphisms of CYP3A5,
but not of other genes, influence the exposure to tacrolimus
in paediatric renal transplant recipients: a pharmacognetic
substudy of the Twist Study [abstract no: SAT-M-130].
Transplantation Society of Australia & New Zealand
(TSANZ). 27th Annual Meeting; 2009 Jun 17-19;
Canberra (ACT). 2009:121.
Grenda R, Watson A, Trompeter R, Tonshoff B, Jaray
J, Fitzpatrick M, et al. A randomized trial to assess the
impact of early steroid withdrawal on growth in pediatric
renal transplantation: the TWIST study. American Journal
of Transplantation 2010;10(4):828–36. [MEDLINE:
20420639]
Trompeter RS, Grenda R, Watson A. Improved growth in
pediatric kidney recipients after early steroid withdrawal:
daclizumab, tacrolimus (TAC) and mycophenolate mofetil
(MMF) versus TAC, MMF and steroids (TWIST Study)
[abstract no: 604]. American Journal of Transplantation
2009;9(Suppl 2):365. [EMBASE: 70010477]
Watson AR, Grenda R, Trompeter RS. Reduced
complications after early steroid withdrawal in paediatric
kidney recipients: daclizumab (DAC), tacrolimus (TAC)
and mycophenolate mofetil (MMF) versus TAC, MMF
and steroids (Twist Study) [abstract no: OC053]. Pediatric
Nephrology 2009;24(9):1799.
Webb N, Douglas S, Rajai A, Roberts S, Grenda R, Marks
SD, et al. Corticosteroid free immunosuppression is
associated with continuing improved growth in young
children following kidney transplantation: long term
follow-up results from the TWIST randomised controlled
trial [abstract no: O76]. Pediatric Nephrology 2014;29(9):
1683. [EMBASE: 71662390]
Webb NJ, Douglas SE, Rajai A, Roberts SA, Grenda R,
Marks SD, et al. Corticosteroid-free kidney transplantation
improves growth: 2-year follow-up of the TWIST
randomized controlled trial. Transplantation 2015;99(6):
1178–85. [MEDLINE: 25539467]
Weimert 2008 {published data only}
Weimert N, Alloway R, Vinks A, Rike A, Young S, Cardi
M, et al. A 12-month, prospective, randomized, single
center, open label pilot study to evaluate the safety and
efficacy of Myfortic® in combination with tacrolimus
and thymoglobulin® in early corticosteroid withdrawal
[abstract no: 102]. Transplantation 2008;86(2 Suppl):36.
References to studies awaiting assessment
Newstead 1989 {published data only}
Newstead C, Moore R, et al. Renal transplant function
after steroid withdrawal from triple immunosuppression
[abstract]. Nephrology Dialysis Transplantation 1989;4:518.
[CENTRAL: CN–00260463; ]
Additional references
ANZDATA 2012
Clayton P, Campbell S, Chadban S, McDonald S, Hurst K.
ANZDATA Registry Report 2012. Adelaide, South Australia:
Australia and New Zealand Dialysis and Transplant Registry,
2012.
Basadonna 1993
Basadonna GP, Matas AJ, Gillingham KJ, Payne WD,
Dunn DL, Sutherland DE, et al. Early versus late acute
renal allograft rejection: Impact on chronic rejection.
Transplantation 1993;55(5):993–5. [MEDLINE: 8497913]
Coutinho 2011
Coutinho AE, Chapman KE. The anti-inflammatory
and immunosuppressive effects of glucocorticoids, recent
developments and mechanistic insights. Molecular &
Cellular Endocrinology 2011;335(1):2–13. [MEDLINE:
20398732]
Cuervo 2003
Cuervo LG, Clarke M. Balancing benefits and harms in
health care. BMJ 2003;327(7406):65–6. [MEDLINE:
12855496]
Czock 2005
Czock D, Keller F, Rasche FM, Haussler U.
Pharmacokinetics and pharmacodynamics of systemically
42Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
administered glucocorticoids. Clinical Pharmacokinetics
2005;44(1):61–98. [MEDLINE: 15634032]
Da Silva 2006
Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês
LB, et al. Safety of low dose glucocorticoid treatment in
rheumatoid arthritis: published evidence and prospective
trial data. Annals of the Rheumatic Diseases 2006;65(3):
285–93. [MEDLINE: 16107513]
Deeks 2001
Deeks JJ, Altman DG, Bradburn MJ. Statistical methods
for examining heterogeneity and combining results from
several studies in meta-analysis. In: Egger M, Davey Smith
G, Altman DG editor(s). Systematic reviews in health care:
meta-analysis in context. 2nd Edition. London: BMJ
Publishing Group, 2001:285-312.
ERA-EDTA 2013
ERA-EDTA Registry. ERA-EDTA Registry Annual Report
2011. Amsterdam: Academic Medical Center, Department
of Medical Informatics, 2013.
Higgins 2003
Higgins JP, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327
(7414):557–60. [MEDLINE: 12958120]
Higgins 2011
Higgins JP, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.
Hollis 1999
Hollis S, Campbell F. What is meant by intention to treat
analysis? Survey of published randomised controlled trials.
BMJ 1999;319(7221):670–4. [MEDLINE: 10480822]
Hricik 1993
Hricik DE, O’Toole MA, Schulak JA, Herson J. Steroid-free
immunosuppression in cyclosporine-treated renal transplant
recipients: a meta-analysis. Journal of the American Society of
Nephrology 1993;4(6):1300–5. [MEDLINE: 8130356]
Hricik 2002
Hricik DE. Steroid-free immunosuppression in kidney
transplantation: an editorial review. American Journal of
Transplantation 2002;2(1):19–24. [MEDLINE: 12095051]
Juni 1999
Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring
the quality of clinical trials for meta-analysis. JAMA 1999;
282(11):1054-60. [MEDLINE: 10493204]
Kasiske 2000
Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-
analysis of immunosuppression withdrawal trials in renal
transplantation. Journal of the American Society of Nephrology
2000;11(10):1910–7. [MEDLINE: 11004223]
Knight 2010
Knight SR, Morris PJ. Steroid avoidance or withdrawal
after renal transplantation increases the risk of acute
rejection but decreases cardiovascular risk. A meta-analysis.
Transplantation 2010;89(1):1–14. [MEDLINE: 20061913]
Massy 1996
Massy ZA, Guijarro C, Kasiske BL. Clinical predictors of
chronic renal allograft rejection. Kidney International -
Supplement 1996;52:S85–8. [MEDLINE: 8587291]
Matas 2005
Matas AJ, Kandaswamy R, Gillingham KJ, McHugh L,
Ibrahim H, Kasiske B, et al. Prednisone-free maintenance
immunosuppression-a 5-year experience. American Journal
of Transplantation 2005;5(10):2473–8. [MEDLINE:
16162197]
Moher 1998
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher
M. Does the quality of reports of randomised trials affect
estimates of intervention efficacy reported in meta-analyses?
. Lancet 1998;352(9128):609–13. [MEDLINE: 9746022]
Opelz 2005
Opelz G, Dohler B, Laux G, Collaborative Transplant
Study. Long-term prospective study of steroid withdrawal
in kidney and heart transplant recipients. American Journal
of Transplantation 2005;5(4 Pt 1):720–8. [MEDLINE:
15760395]
OPTN/SRTR 2014
Department of Health and Human Services, Health
Resources and Services Administration, Healthcare Systems
Bureau, Division of Transplantation, United Network for
Organ Sharing. 2012 Annual Report of the U.S. Organ
Procurement and Transplantation Network and the Scientific
Registry of Transplant Recipients: Transplant Data 1994-
2013. Ann Arbor, USA: HHS/HRSA/OSP/DOT and
UNOS, 2012.
Pascual 2002
Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N,
Cosimi AB. Strategies to improve long-term outcomes after
renal transplantation. New England Journal of Medicine
2002;346(8):580–90. [MEDLINE: 11856798]
Pascual 2004
Pascual J, Quereda C, Zamora J, Hernandez D. Steroid
withdrawal in renal transplant patients on triple therapy with
a calcineurin inhibitor and mycophenolate mofetil: a meta-
analysis of randomized controlled trials. Transplantation
2004;78(10):1548–56. [MEDLINE: 15599321]
Pascual 2012
Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very
early steroid withdrawal or complete avoidance for kidney
transplant recipients: a systematic review. Nephrology
Dialysis Transplantation 2012;27(2):825–32. [MEDLINE:
21785040]
Patel 2001
Patel S, Kwan JT, McCloskey E, McGee G, Thomas G,
Johnson D, et al. Prevalence and causes of low bone density
and fractures in kidney transplant patients. Journal of Bone
& Mineral Research 2001;16(10):1863–70. [MEDLINE:
11585351]
Prasad 2003
Prasad GV, Nash MM, McFarlane PA, Zaltzman JS. Renal
transplant recipient attitudes toward steroid use and steroid
43Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
withdrawal. Clinical Transplantation 2003;17(2):135–9.
[MEDLINE: 12709080]
Schulz 1995
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical
evidence of bias. Dimensions of methodological quality
associated with estimates of treatment effects in controlled
trials. JAMA 1995;273(5):408–12. [MEDLINE: 7823387]
Tunis 2003
Tunis SR, Stryer DB, Clancy CM. Practical clinical trials;
increasing the value of clinical research for decision making
in clinical and health policy. JAMA 2003;290(12):1624–32.
[MEDLINE: 14506122]
References to other published versions of this review
Pascual 2006
Pascual Santos J, Quereda C, Zamora J. Steroid avoidance
or withdrawal for kidney transplant recipients. Cochrane
Database of Systematic Reviews 2006, Issue 1. [DOI:
10.1002/14651858.CD005632]
Pascual 2009
Pascual J, Zamora J, Galeano C, Royuela A, Quereda
C. Steroid avoidance or withdrawal for kidney transplant
recipients. Cochrane Database of Systematic Reviews 2009,
Issue 1. [DOI: 10.1002/14651858.CD005632.pub2]
∗ Indicates the major publication for the study
44Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahsan 1999
Methods • Study design: parallel RCT
• Study duration: not reported
• Follow-up period: 1 year
• Primary endpoint: biopsy-proven or presumptive acute rejection episode or
treatment failure within 1 year post-transplant
Participants • Country: USA
• Setting: multicentre (21 centres)
• Health status: first cadaveric or living kidney transplant; > 18 years; SCr < 2.4
mg/dL or CrCl > 50 mL/min
• Number: withdrawal group (134); maintenance group (132)
• Median age, range (years): withdrawal group: (50, 20 to 71); maintenance group
(50, 18 to 74)
• Sex (female): withdrawal group (34%); maintenance group (45%)
• Donor source (living donor): withdrawal group (45%); maintenance group (41%)
• Exclusion criteria: acute rejection; proteinuria > 2 g/d; significant gastrointestinal
disorder; WCC < 2500/mm3 , Hb < 6.5 g/dL; immunosuppression other than CsA +
MMF + steroids
Interventions Withdrawal group
• Steroid withdrawal (prednisone) 3 months after transplantation
• Prednisone 10 to 15 mg/d before randomisation, after randomisation: days 1 to
21: 15 mg/d, days 22 to 28: 12.5 mg/d, days 29 to 35: 10 mg/d, days 36 to 42: 7.5
mg/d, days 43 to 49: 5 mg/d, days 50 to 56: 2.5 mg/day, then withdrawn
Maintenance group
• Steroid maintenance (prednisone)
• Prednisone: days 1 to 21: 15 mg/d; days 22 to 42: 12.5 mg/d; days 43 to 365: 10
mg/d
Baseline immunosuppression
• CsA: 5 to 15 mg/kg/d
• MMF: months 1 to 3: 2000 mg/d, adjusted to centre practice
Outcomes • Mortality
• Graft loss
• Acute rejection
• Biopsy-proven acute rejection
• Infection
• Kidney function measures: SCr (mg/dL), CrCl (mL/min)
Notes • Did not report number screened for eligibility
• The study was stopped on 22 July 1998 due to statistically significant difference
in the incidence of acute rejection
• Funding source: Roche Laboratories
• Contact with study authors for additional information: authors contacted 28
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Ahsan 1999 (Continued)
August 2013; response received 28 August 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomization was stratified by centre
and was done centrally to maintain a 1:1
ratio at each centre’
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind placebo controlled. Stated
’After randomisation, recipients received
blister packs containing tablets for their
’prednisone’ dose. Neither recipients nor
physicians knew whether a randomised pa-
tient was in the withdrawal group’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind placebo controlled. Stated
’After randomisation, recipients received
blister packs containing tablets for their
’prednisone’ dose. Neither recipients nor
physicians knew whether a randomised pa-
tient was in the withdrawal group’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind placebo controlled. Out-
comes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all participants
were followed for the primary endpoint un-
til study closure on 22 July 1998
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias High risk The study was supported by Roche Labo-
ratories
Albert 1985
Methods • Study design: parallel RCT
• Time frame: 1983 to 1984
• Follow-up period: 13 (2 to 23) months
• Primary endpoint: not reported
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Albert 1985 (Continued)
Participants • Country: Germany
• Setting: single centre
• Inclusion criteria: not reported
• Number analysed: avoidance group (25); withdrawal group (25)
• Mean age, range (years): avoidance group (38, 10 to 51); withdrawal group (36,
21 to 54)
• Sex (female): avoidance group (44%); withdrawal group (32%)
• Exclusion criteria: not reported
Interventions Avoidance group
• CsA monotherapy
Withdrawal group
• Steroid withdrawal 3 to 6 months after transplantation
Baseline immunosuppression
• CsA
◦ Started with 15 mg/kg, divided into two daily doses, adjusted to trough
levels 250 to 700 ng/mL
• Steroids
◦ Steroid avoidance group: no steroids
◦ Steroid withdrawal group: oral fluocortolone: 0.5 mg/kg, withdrawn 3 to 6
months after transplantation
Outcomes • Mortality
• Graft loss
Notes • Did not report the number screened for eligibility or randomised
• Number of patients discontinued treatment
◦ Switched from avoidance group to withdrawal group: 13
◦ Switched from withdrawal group to avoidance group: 1
◦ 4 patients in avoidance group and 5 patients in withdrawal group switched
to AZA and steroids
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided
Allocation concealment (selection bias) Unclear risk not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
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Albert 1985 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether ITT analysis performed,
total number of patients by group analysed
not reported, results presented as percent-
ages/rates
Selective reporting (reporting bias) High risk Acute rejection not reported
Other bias Unclear risk Funding sources not reported
Aswad 1998
Methods • Study design: parallel RCT
• Time frame: not reported
• Follow-up period: not reported
• Primary endpoint: not reported
Participants • Country: USA
• Setting: single centre
• Living kidney transplant, no further inclusion criteria provided
• Number analysed: withdrawal group (11); maintenance group (10)
• Mean age ± SD (years): not reported
• Sex: not reported
• Exclusion criteria: not reported
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• TAC: adjusted to trough levels month 1: 10 to 15 ng/mL; thereafter: 5 to 10 ng/
mL
• AZA: no further information provided
• Prednisone: no further information provided
Outcomes • Mortality
• Graft loss
• Acute rejection
• SCr
Notes • Did not report the number screened for eligibility or randomised
Risk of bias
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Aswad 1998 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Stated ’randomly assigned’ but no further
information provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of patients by group not reported
for outcomes; unclear if ITT analysis per-
formed
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Abstract-only publication
ATLAS Study 2005
Methods • Study design: parallel RCT
• Time frame: not reported, but before 2005
• Follow-up period: 3 years
• Primary endpoint: incidence of and time to first biopsy-proven acute rejection
within 6 months after transplantation
Participants • Country: 10 European countries
• Setting: multicentre (21 centres)
• First cadaveric or living kidney transplant; aged 18 to 65 years
• Number (randomised/analysed): withdrawal group (152/147); maintenance
group (151/151)
• Mean age ± SD (years): withdrawal group (44 ± 12); maintenance group (43 ± 13)
• Sex (female): withdrawal group (35%); maintenance group (40%)
• Donor source (living donor): withdrawal group (13%); maintenance group (12%)
• Exclusion criteria: PRA ≥ 50% in previous 6 months; previous organ transplant;
non-heart beating kidney donor; requiring any other immunosuppression; HIV
infection; uncontrolled infection; significant liver disease; malignancy; severe
diarrhoea; vomiting; active peptic ulcer
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ATLAS Study 2005 (Continued)
Interventions Treatment group
• Steroid withdrawal day 1 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• TAC: started within 12 hours before transplantation with 0.2 mg/kg divided in
two doses, adjusted to trough levels day 28: 10 to 20 ng/mL, thereafter: 5 to 15 ng/mL
• MMF: day 0: 1000 mg, day 1 to 14: 2000 mg, thereafter: 1000 mg
• Steroids
◦ IV methylprednisone: day 0: 500 mg or less
◦ Withdrawal group: no further steroids
◦ Maintenance group: IV methylprednisone day 1: 125 mg, or prednisone day
2 to 14: 20 mg; day 15 to 28: 15 mg; day 29 to 42: 10 mg; thereafter: 5 mg
Outcomes • Mortality
• Graft loss
• Biopsy-proven acute rejection
• NODAT
• Infection
• CMV infection
• Malignancy
• Cardiovascular events
• SCr (µM)
• CrCl (mL/min)
Notes • This study had a third arm with basiliximab induction followed by TAC
monotherapy (154 patients)
• Did not report number screened for eligibility
• Number of patients excluded from analysis
◦ Withdrawal group: 1 (either did not receive study drug or did not undergo
transplantation)
◦ Maintenance group: 4 (either did not receive study drug or did not undergo
transplantation)
• Number of patients discontinued study
◦ Withdrawal group: 8 (primarily because of protocol violation) within the
first year
◦ Maintenance group: 13 (primarily because of protocol violation) within the
first year
• 3-year follow-up: data of 278 patients available (139/139)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated ’Randomization was performed
with a 1:1 ratio stratified by centre. The
randomization list was generated by the
Data Operation Department of Fujisawa
50Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ATLAS Study 2005 (Continued)
GmbH. Each centre received a unique se-
quence of patient numbers and a set of
sealed envelopes.’
Allocation concealment (selection bias) Low risk Stated ’sealed envelopes’
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all patients fol-
lowed up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this reviewhave been
reported
Other bias High risk Sponsored by a grant fromFujisawaGmbH
The investigator-initiated 1-year follow-up
was supported by an unrestricted grant
from Astellas, Munich, Germany
Benfield 2005
Methods • Study design: parallel RCT
• Time frame: 2001 to 2004
• Follow-up period: 3 years
• Primary endpoint: change in standardised height z score
Participants • Country: Mexico, USA
• Setting: multicentre (17 centres)
• Age: 0 to 20 years
• First cadaveric or living kidney transplant; enrolment at transplantation;
randomisation 6 months after transplantation of participants without previous
rejection if clinical or histologic evidence of rejection in protocol biopsy absent
• Number: withdrawal group (73); maintenance group (59)
• Mean age ±SD (years): withdrawal group (11 ± 5); maintenance group (12 ± 6)
• Sex (female): withdrawal group (44%); maintenance group (37%)
• Donor source (living donors): withdrawal group (64%); maintenance group
(69%)
• Exclusion criteria: not reported
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Benfield 2005 (Continued)
Interventions Treatment group
• Steroid withdrawal 6 to 12 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: day 0 and 4
• CsA or TAC
◦ CsA trough level: weeks 1 to 2: 175 to 400 ng/mL; week 3 to month 3: 175
to 300 ng/mL; thereafter: 50 to 250 ng/mL;
◦ TAC trough level: weeks 1 to 4: 10 to 15 ng/mL; thereafter: 5 to 10 ng/mL
• SRL: starting on day 1 with 6 mg/m2/d adjusted to trough level: 10 to 20 ng/mL
• Steroids
◦ IV methylprednisone: day 0 and 1: 10 mg/kg
◦ Oral prednisone: starting on day 2 with 2 mg/kg/d, tapered to 0.15 mg/kg/d
by day 74
⋄ Withdrawal group: withdrawal by end of month 12 after
transplantation
⋄ Maintenance group: maintained on 0.15 mg/kg/d
Outcomes • Mortality
• Graft loss
• Acute rejection
• CrCl (mL/min)
• Malignancy (PTLD)
Notes • The study was terminated on 13 August 2004 due to an unanticipated high
incidence of post-transplant lymphoproliferative disease; 19 patients developed PTLD
(before randomisation: 10)
• Did not report number screened for eligibility
• 142/274 enrolled participants were not randomised (52% drop out before
randomisation), because of rejection (40), graft loss (9), death (2), had not yet reached
6 month protocol biopsy when study was stopped (35), adverse events (16). protocol
violation (4), lost to follow-up/withdrawal of consent (5), other reasons (31)
• Contact with study authors for additional information: authors contacted 8 July
2013; no response received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated ’centrally randomised’ but no fur-
ther information provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Stated ’in a placebo controlled double-
blinded fashion’ but no further informa-
tion provided
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Benfield 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated ’in a placebo controlled double-
blinded fashion’ but no further informa-
tion provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated ’in a placebo controlled double-
blinded fashion’ but no further informa-
tion provided.Outcomes are objective hard
endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk Total number of patients by group not
reported for outcomes; ITT analysis per-
formed
Selective reporting (reporting bias) Low risk Primary outcomes for this reviewhave been
reported
Other bias High risk High drop-out rate before randomisation
(52%)
Choice of calcineurin inhibitor was centre
specific (TAC or CsA)
Support provided byNIHUO1-A1-46135
and Wyeth Pharmaceuticals
The study was terminated early due to an
unanticipated high incidence of PTLD
Boletis 2001
Methods • Study design: parallel RCT
• Time frame: 1996 to 1998
• Follow-up period: 1 year
• Primary endpoint: not reported
Participants • Country: Greece
• Setting: single centre
• First cadaveric or living kidney transplant
◦ CsA ≥ 3 mg/kg with C0 levels of > 150 ng/mL and C2 levels > 600 ng/mL
without signs of nephrotoxicity
◦ MMF 2 g or 1.5 g if body weight < 50 kg
• Number randomised: withdrawal group (34); maintenance group (/32)
• Mean age ±SD (years): withdrawal group (43 ± 11); maintenance group (38 ± 11)
• Sex (female): withdrawal group (41%); maintenance group (19%)
• Donor source (living donors): withdrawal group (53%); maintenance group
(38%)
• Exclusion criteria: previous acute rejection; SCr > 2 mg/dL; proteinuria > 0.5 g/
24 h
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Boletis 2001 (Continued)
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation
Control group
• Steroid maintenance with alternate day steroid
Baseline immunosuppression
• CsA: no further information provided.
• MMF: no further information provided.
• Methylprednisone: no further information provided
Outcomes • Mortality
• Graft loss
• Acute rejection
• SCr (mg/dL)
Notes • Did not report number screened for eligibility
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomly assigned’ but no further
information provided
Allocation concealment (selection bias) Unclear risk not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of patients in whom the outcome
were measured is ambiguous (two reports
with different number of patients in each
group); 14% failed to comply with follow-
up protocol; unclear if ITT analysis per-
formed
Selective reporting (reporting bias) High risk Death and graft loss are only reported in
one of the two published reports, but num-
ber of participants in each group vary be-
tween reports
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Boletis 2001 (Continued)
Other bias Unclear risk Unclear whether informative censoring is
present, because the two published reports
are different in regard to number of partic-
ipants and time period of study
Funding source not reported
Boots 2002
Methods • Study design: parallel RCT
• Time frame: 1997 to 2000, excluding October 1998 to October 1999 (a different
multicentre study during that period)
• Follow-up period: 2.7 years (range 0.9 to 3.4) years
• Primary endpoints: patient survival, graft survival, incidence of first acute
rejection in first 6 months after transplantation
Participants • Country: The Netherlands
• Setting: multicentre (number of centres not reported)
• First and second cadaveric or living kidney transplant; Previous graft loss not
because of immunological causes; PRA < 50%; 18 to 65 years
• Number (randomised/analysed): avoidance group (28/28); withdrawal group (34/
34)
• Mean age ± SD (years): avoidance group (54 ±14); withdrawal group (48 ± 13)
• Sex (female): avoidance group (61%); withdrawal group (35%)
• Donor source (living donors): avoidance group (14%); withdrawal group (12%)
• Exclusion criteria: HLA identical living donor; mismatch on HLA-B or HLA-DR
locus
Interventions Avoidance group
• Steroid withdrawal 7 days after transplantation or after TAC levels > 15 ng/mL
Withdrawal group
• Steroid withdrawal 3 to 5 months after transplantation
Baseline immunosuppression
• TAC: started within 12 hours before transplantation with 0.1 to 0.15 mg/kg twice
daily adjusted to trough levels: week 1 to 2: 15 to 20 ng/mL; week 3 to 4: 10 to 15 ng/
mL; thereafter: reduced to 5 to 7 ng/mL 6 months after transplantation
• Steroids
◦ IV methylprednisone: day 0: 125 mg
◦ Avoidance group: oral prednisone: day 1 to 8: 10 mg, then stopped
◦ Withdrawal group: oral prednisone: month 1: 10 mg; month 2: 7.5 mg;
month 3: 5 mg; then withdrawn within 1 to 3 months
Outcomes • Mortality
• Graft loss
• Acute rejection
• Biopsy-proven acute rejection
• SCr (mg/dL)
• CrCl (mL/min)
• NODAT
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Boots 2002 (Continued)
• Infection
Notes • Number screened for eligibility: 76
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was performed by opening
a closed opaque numbered envelope
Allocation concealment (selection bias) Low risk Stated ’closed opaque envelopes’
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients followed up or accounted for;
ITT analysis performed (’Analyses were
made on an ITT basis.’
Selective reporting (reporting bias) Low risk Primary outcomes for this reviewhave been
reported
Other bias Unclear risk Funding source not reported
Bouma 1996
Methods • Study design: parallel RCT
• Time frame: 1993 to 1995
• Follow-up period: 1 year
• Primary endpoint: proportion of successful steroid withdrawal defined as lack of
prednisone reinstitution for any reason
Participants • Country: The Netherlands
• Setting: multicentre (2 centres)
• First and second cadaveric kidney transplant 1 year after transplantation on CsA +
steroids
• Number (analysed): withdrawal group (42); maintenance group (42)
• Mean age ± SD (years): withdrawal group (48 ± 13); maintenance group (54 ± 12)
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Bouma 1996 (Continued)
• Sex (female): withdrawal group (31%); maintenance group (31%)
• Exclusion criteria: CrCl < 40 mL/min; immunosuppression with AZA; steroid
requirement for other disease; PRA > 50%; previous graft loss within 3 months after
transplantation because of irreversible rejection; > 2 acute rejections of current
transplant
Interventions Treatment group
• Steroid withdrawal at least 1 year after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: twice daily, adjusted to whole blood level 80 to 150 µg/mL
• Steroids
◦ Oral prednisone: 10 mg/d
⋄ Withdrawal group: week 1 to 2: 7.5 mg/d; week 3 to 5: 5 mg/d; week 6
to 8: 2.5 mg/d; then withdrawn
⋄ Maintenance group: unchanged
Outcomes • Mortality
• Graft loss
• Acute rejection
• Biopsy-proven acute rejection
• NODAT
• Infection
• Malignancy
• Cardiovascular event
• CrCl (mL/min)
Notes • Did not report number screened for eligibility; 86 randomised; 84 analysed
• 28/42 patients in treatment group had successful steroid withdrawal
• Contact with study authors for additional information: authors contacted: 21
June 2013; response received: 4 July 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided
Allocation concealment (selection bias) Unclear risk not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
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Bouma 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all patients fol-
lowed up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias High risk This study was supported by a grant from
Sandoz, The Netherlands
Burke 2000
Methods • Study design: parallel RCT
• Time frame: not reported, but before 2000
• Follow-up period: 3 years
• Primary endpoint: not reported
Participants • Country: USA
• Setting: single centre
• First cadaveric or living kidney transplant; aged 18 to 65 years
• Number (randomised/analysed): withdrawal group (26/14); maintenance group
(25/15)
• Mean age (years): withdrawal group (46.5); maintenance group (47.1)
• Sex: not reported
• Donor source (living donors): withdrawal group (42%); maintenance group
(28%)
• Exclusion criteria: > 1 acute rejection during the first 3 months; previous graft loss
because of immunological causes; PRA > 50%
Interventions Treatment group
• Steroid withdrawal 3 months after transplantation (completed 6 months after
transplantation)
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: 8 to 10 mg/kg/d adjusted to blood levels 250 to 350 ng/mL
• MMF: 2 to 3 g/d
• Steroids
◦ Prednisone: day 0: 200 mg; day 1 to 5: tapered to 20 mg/d; day 6 to 90: 20
mg/d
◦ Withdrawal group: month 4 to 6: reduced by 5 mg/mo until complete
withdrawal at month 6
◦ Maintenance group: month 4 to 6: reduced to 10 mg/d at month 6; month
7 to 12: reduced to 15 mg every other day at month 12
Outcomes • SCr (mg/dL)
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Burke 2000 (Continued)
Notes • Did not report number screened for eligibility
• Number of patients discontinued study: 22 patients were withdrawn from the
study because of noncompliance (6), MMF intolerance (2), patient request for steroid
withdrawal (4), pulmonary disease requiring steroids (3), second acute rejection (2),
PTLD (1), hepatitis B (1), death (3)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’all patients were randomised’ but
no further information provided
Allocation concealment (selection bias) Unclear risk not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind placebo controlled, but par-
tially unblinded for interim analysis
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind placebo controlled, but par-
tially unblinded for interim analysis
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind placebo controlled, out-
comes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
High risk 43% of patients were withdrawn from the
study for various reasons; patients who
died/lost their graft were excluded from the
study; unclear if ITT analysis performed
Selective reporting (reporting bias) High risk Primary endpoints for this review not re-
ported, primarily surrogate outcomes re-
ported
Other bias Unclear risk Abstract data only available
Funding source not reported
De Vecchi 1986
Methods • Study design: parallel RCT
• Time frame: not reported but before 1986
• Follow-up period: 2 years
• Primary endpoint: not reported
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De Vecchi 1986 (Continued)
Participants • Country: Italy
• Setting: single centre
• Cadaveric kidney transplantation, no further inclusion criteria provided
• Number (randomised/analysed): withdrawal group (25/25); maintenance group
26/26)
• Mean age ± SD (years): withdrawal group (36 ± 12); maintenance group (36 ± 10)
• Sex (female): withdrawal group (48%); maintenance group (35%)
• Exclusion criteria: not reported
Interventions Treatment group
• Steroid withdrawal day 1 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: day 0 to 3: 5 mg/kg/d IV; from day 4: 15 mg/kg/d PO; tapered by 2 mg/kg
every 16 days until maintenance dose of 5 mg/kg/d at month 4, given as single
morning dose
• Steroids
◦ IV methylprednisone: 500 mg during transplantation
◦ Withdrawal group: no further steroids.
◦ Maintenance group: methylprednisone: day 1: 160 mg IV; day 2: 120 mg
IV; day 3: 16 mg; reduced by 4 mg every 2 months until maintenance dose of 8 mg/d
by the end of month 6
Outcomes • Mortality
• Graft loss
• Acute rejection
• SCr (mg/dL)
Notes • Did not report number screened for eligibility
• Number of patients discontinued treatment
◦ 18 patients in the withdrawal group had steroids added
◦ 6 patients in withdrawal group switched to AZA or triple
immunosuppression and were excluded
◦ 5 patients in maintenance group switched to AZA or triple
immunosuppression and were excluded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomly assigned’ but no further
information provided
Allocation concealment (selection bias) Low risk Stated ’assigned by sealed envelopes’
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De Vecchi 1986 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT analysis not performed; 6 patients in
treatment group and 5 patients in control
group excluded because of switch to differ-
ent immunosuppression
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Low risk Funded by grant of the Consiglio
Nazionale delle Richerche
del Castillo 2005
Methods • Study design: parallel RCT
• Time frame: 2002 to 2004
• Follow-up period: 1 year
• Primary endpoint: not reported
Participants • Country: Spain, Portugal
• Setting: multicentre (16 centres)
• First kidney transplant, no further inclusion criteria provided
• Number (randomised/analysed): withdrawal group (70/70); maintenance group
(72/72)
• Mean age ± SD (years): withdrawal group (47 ± 11); maintenance group (47 ± 11)
• Sex (female): withdrawal group (53%); maintenance group (26%)
• Exclusion criteria: not reported
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: not reported
• MMF: not reported
• Prednisone: not reported
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del Castillo 2005 (Continued)
Outcomes • Mortality
• Graft loss
• Acute rejection
• Biopsy-proven acute rejection
• SCr (mg/dL)
• CrCl (mL/min)
Notes • Did not report number screened for eligibility
• 4 patients were excluded post randomisation but pre-intervention because they
did not fulfil the inclusion criteria
• 2 control patients lost to follow-up during the 12 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all patients fol-
lowed-up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported; abstract data
only
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DOMINOS Study 2012
Methods • Study design: parallel RCT
• Time frame: 2007 to 2009
• Follow-up period: 6 months
• Primary endpoint: incidence of treatment failure month 6, defined as clinical
biopsy-proven acute rejection, graft loss, death or loss to follow-up
Participants • Country: France
• Setting: multicentre (14 centres)
• First or second cadaveric or living kidney transplant; PRA < 20%; 18 to 70 years
• Number (randomised/analysed): avoidance group (112/112); withdrawal group
(110/110)
• Mean age ± SD (years): avoidance group (51 ± 10); withdrawal group (51 ± 12)
• Sex (female): avoidance group (32%); withdrawal group (36%)
• Donor source (living donor): avoidance group (0%); withdrawal group (2%)
• Exclusion criteria: multi-organ transplant; previous non-kidney transplant; cold
ischaemia time > 36 hours; non-heart beating donor
Interventions Treatment group
• Avoidance group
◦ Steroid withdrawal day 1 after transplantation
Control group
• Withdrawal group
◦ Steroid withdrawal 4 to 6 months after transplantation
Baseline immunosuppression
• IL-2RA: according to centre protocol
• CsA: started within 24 hours of transplantation with 8mg/kg/d, divided into 2
single doses, adjusted to C2 levels: month 1: 1100 to 1300 ng/mL; month 2 to 3: 800
to 1000 ng/mL; month 4 to 6: 600 to 800 ng/mL
• EC-MPS: week 1 to 6: 2160 mg/d divided in two doses; after week 6: 1440 mg/d
divided in two doses
• Steroids
◦ IV methyl prednisone: day -1 and 0: 250 mg
◦ Avoidance group: no further steroids unless ’clinically mandated’
◦ Withdrawal group: prednisone: week 1: 1 mg/kg/d (max 80 mg/d); week 2:
0.5 mg/kg/d (max 40 mg/d); decreased by 5 mg/wk until dose 20 mg/d; decreased by
2.5 mg/wk until dose 10 mg/d; 10 mg/d maintained for 4 weeks and at least until
month 3, biopsy at month 3: with rejection continued at 10 mg/d, without rejection
decreased by 2.5 mg/15 days until stopped
Outcomes • Mortality
• Graft loss
• Biopsy-proven acute rejection
• SCr (µmol/L)
• CrCl (mL/min)
• eGFR (mL/min)
Notes • Did not report number screened for eligibility
• Number of patients discontinued study
◦ Avoidance group (20); adverse events (9); unsatisfactory therapeutic effect
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DOMINOS Study 2012 (Continued)
(11)
◦ Withdrawal group (20); adverse events (11); unsatisfactory therapeutic effect
(9)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Patients were randomised using a block
size of 4 with no stratification by the con-
tract research organizationusing a validated
automated system.’
Allocation concealment (selection bias) Low risk ’With sealed envelopes distributed to the
participating centers...opened after ran-
domization by the investigator.’
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed, all patients fol-
lowed up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias High risk The study was funded by Novartis Pharma
SAS, Rueil-Malmaison, France
The manuscript was prepared with edito-
rial support from a freelance medical writer
funded by Novartis Pharma SAS
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EVIDENCE Study 2014
Methods • Study design: parallel RCT
• Time frame: 2009 to 2012
• Follow-up period: 9 months
• Primary endpoint: treatment failure rate (mortality, graft loss, biopsy-proven
acute rejection, loss to follow-up) between randomisation (month 3) and month 12
after transplantation
Participants • Country: Italy
• Setting: multicentre (number of centres not reported)
• First or second kidney transplant from a donor aged > 14 years; aged > 18 years
• Number: withdrawal group (68); maintenance group (71)
• Mean age ± SD (years): withdrawal group (48 ± 12); maintenance group (49 ± 13)
• Sex (female): withdrawal group (32%); maintenance group (28%)
• Donor source (living donor): withdrawal group (4%); maintenance group (1%)
• Exclusion criteria: > 25% PRA, severe thrombocytopenia; leucopenia or anaemia;
history of malignancy within 5 years; viral hepatitis; pregnancy; severe adverse events
including active infections requiring hospitalisation
• Enrolled patients were not randomised if CrCl < 40 mL/min, proteinuria > 0.8 g/
24 h; severe adverse events or infections; poor adherence; withdrawal of consent;
development of anti-HLA antibodies
Interventions Treatment group
• Steroid withdrawal 3 months after transplantation, tapered by 1 mg/wk until
stopped within 5 to 6 weeks
• CsA: dose adjusted to C2 levels 300 to 500 ng/mL
• EVL: dose adjusted to C0 levels 6 to 10 ng/mL
Control group
• Steroid maintenance with oral prednisone 5 mg/d
• CsA: dose adjusted to C2 levels 200 to 450 ng/mL
• EVL: dose adjusted to C0 levels 6 to 10 ng/mL
Baseline immunosuppression
• Basiliximab: day 0 and 4
• CsA: within 48 hours of graft reperfusion at 4mg/kg/d twice daily; dose adjusted
to C2 levels: until day 30: 500 to 700 ng/mL; day 30 to 90: 300 to 500 ng/mL
• EVL: within 48 hours of graft reperfusion at 1.5 mg/d twice daily; dose adjusted
to C0 levels: day 3 to 7: 3 to 8 ng/mL; after day 7: 8 to 12 ng/mL
• Steroids
◦ IV methyl prednisone: day 0: 500 mg; day 1: 40 mg
◦ Oral prednisone: day 2 to 7: 20 mg; day 8 to 15: 15 mg; day 16 to 22: 12.5
mg; day 23 to 30: 10 mg; day 30 to 45: 7.5 mg; day 46 to 90: 5 mg
Outcomes • Treatment failure rate (mortality, graft loss, biopsy-proven acute rejection, loss to
follow-up)
• Mortality
• Graft loss
• Biopsy-proven acute rejection
• Change in CrCl (mL/min)
• Change in eGFR (mL/min)
• NODAT
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EVIDENCE Study 2014 (Continued)
Notes • Screened for eligibility (332), randomised (184), analysed in ITT population
(184); PP population (135)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’...eligible patients were randomised 1:1 to
1 of the treatment arms. Randomization
was stratified according to centre, recipient
age at transplantation (<60 and 60 years)
and creatinine clearance at month 3 (55
and >55 mL/min), according to a biased
coin design.’
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ITT analysis for primary analysis, but total
number of patients by group for outcomes
not reported
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias High risk Difference in CsA levels between groups
(higher levels in treatment group)
The study was sponsored by Novartis ac-
cording to ClinicalTrials.gov. ’Editorial as-
sistance was provided by Mary Hines,
SpringerHealthcareCommunications, and
funded by Novartis Farma, Italy.’
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Farmer 2006
Methods • Study design: parallel RCT
• Time frame: not reported but before 2006
• Follow-up period: 1 year
• Primary endpoint: incidence of biopsy-proven acute cellular rejection 1 year
following steroid withdrawal
Participants • Country: UK
• Setting: single centre
• First or second cadaveric or living kidney transplant with functioning graft > 1
year; < 10% rise in SCr within preceding 6 months; SCr < 200 µmol/L; < 15%
variability in CsA levels; CsA levels between 80 to 120 µg/L; aged 18 to 80 years
• Number: withdrawal group (44); maintenance group (48)
• Mean age ± SD (years): withdrawal group (44 ± 15); maintenance group (45 ± 13)
• Sex (female): withdrawal group (32%); maintenance group (40%)
• Donor source (living donor): withdrawal group (28%); maintenance group (25%)
• Exclusion criteria: malignancy; previous rejection on steroid withdrawal; history
of Addison’s disease; bilateral adrenalectomy; multi-organ transplant; recurrence of
focal and segmental glomerulosclerosis; treatment with Sandimmun; ischaemic heart
disease; malnutrition; recent severe infection
Interventions Treatment group
• Steroid withdrawal > 1 year after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: no further information provided
• AZA: no further information provided
• Steroids:
◦ Withdrawal group: steroids withdrawn at a rate of 1 mg/mo
◦ Maintenance group: prednisolone unchanged
Outcomes • Biopsy-proven acute cellular rejection
• SCr (µmol/L)
Notes • Screened for eligibility (572); randomised (92); did not reported number analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided.
Allocation concealment (selection bias) Low risk ’Using sealed envelopes’.
Blinding (performance bias and detection
bias)
All outcomes
High risk ’Patients were informed to which arm of
the trial they had been allocated.’
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Farmer 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “The patients randomised to the with-
drawal group were followed with more
frequent serum creatinine estimation.” A
rise in serum creatinine prompted kidney
biopsy to detect biopsy proven acute cellu-
lar rejection which is the primary endpoint
of this study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Total number of patients by group for out-
comes not reported. Number of patients
who were lost to follow up is unclear
Selective reporting (reporting bias) High risk Patient and graft survival are not reported
Other bias Unclear risk Time lead bias, because follow up started
with date steroids were completely with-
drawn in treatment group but with ran-
domisation for control group
Funding source not reported
FRANCIA Study 2007
Methods • Study design: parallel RCT
• Time frame: 2001 to 2005
• Follow-up period: 1 year
• Primary endpoint: acute rejection during first year after transplantation
Participants • Country: France
• Setting: multicentre (6 centres)
• First cadaveric kidney transplantation; aged 18 to 65 years
• Number (randomised/analysed): withdrawal group (98/103); maintenance group
103/99)
• Mean age, range (years): withdrawal group (48, 19 to 65); maintenance group
(48, 17 to 65)
• Sex (female): withdrawal group (28%); maintenance group (35%)
• Exclusion criteria: PRA > 20%; cold ischaemia time > 36 hours; malignancy;
immunosuppressive therapy before transplantation; wait listed for another transplant;
leucocytes < 2000/mm3; platelets < 50000/mm3 ; underlying kidney disease; focal and
segmental glomerular sclerosis
Interventions Treatment group
• Steroid withdrawal day 1 after transplantation
Control group
• Steroid maintenance until at least 6 months after transplantation, thereafter
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FRANCIA Study 2007 (Continued)
according to centre practice
Baseline immunosuppression
• ATG: day 0: 9 mg/kg; day 1, 3, 5, 7: 3 mg/kg
• CsA: starting on day 5 with 8 mg/kg/d, divided into 2 single doses, adjusted to
trough levels 150 to 200 ng/mL
• MMF: 1000 mg/d twice daily, adjusted to centre practice
• Steroids
◦ IV methylprednisone day 0: 500 mg
◦ Withdrawal group: no further steroids
◦ Maintenance group: prednisone: day 0 to 5: 1 mg/kg/d; day 6 to 10: 0.5 mg/
kg/d; day 11 to 15: 0.25 mg/kg/d; day 16 to 30: 0.2 mg/kg/d; day 31 to 180: 0.1 mg/
kg/d; after day 180 according to centre practice
Outcomes • Mortality
• Graft loss
• Acute rejection
• SCr (µmol/L)
Notes • Did not report number screened for eligibility
• Number of patients excluded from analysis: maintenance group (4) because of
substantial deviations from the immunosuppressant therapy protocol
• Number of patients discontinued study: 3 patients were excluded after
randomisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Eligible patients were assigned to CS or
non-CS treatment at a 1:1 ratio using block
randomization with stratification accord-
ing to the recipient’s age and cold ischaemia
time.’
Allocation concealment (selection bias) Low risk ’Treatment codes were provided in sealed
envelopes’.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints.
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FRANCIA Study 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; 4 patients in con-
trol group excluded from analysis for acute
rejection but included for patient and graft
survival analysis
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported.
Other bias High risk TAC, SRL, EVL, AZA could be introduced
according to centre practice
Steroid dosing after 6 months according
to centre practice, unclear whether patients
were withdrawn from steroids or main-
tained on steroids
Study was sponsored by the Nantes Uni-
versity Hospital
Statistical analysis of study data was sup-
ported by Fresenius Biotech GmbH, Ger-
many
FREEDOM Study 2008
Methods • Study design: parallel RCT
• Time frame: 2001 to 2005
• Follow-up period: 1 year
• Primary endpoint: eGFR at 1 year post-transplant
Participants • Country: North America, South Africa, Europe, Australia, Asia
• Setting: multicentre (40 centres)
• First cadaveric or living kidney transplantation; aged 18 to 75 years
• Number (randomised/analysed): treatment group 1 (112/111); treatment group 2
(116/115); control group (109/109)
• Mean age ± SD (years): treatment group 1 (43 ± 13); treatment group 2 (46 ± 12)
; control group (47 ± 13)
• Sex (female): treatment group 1 (35%); treatment group 2 (27%); control group
(36%)
• Donor source (living donor)
• Treatment group 1 (48%); treatment group 2 (30%); control group (41%)
• Exclusion criteria: donor age > 60 years; non heart beating donor; previous organ
transplant; current PRA > 20%; cold ischaemia time > 24 h
Interventions Treatment group 1
• No steroids at any time
Treatment group 2
• Steroid withdrawal day 7 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: day 0 and 4: 20 mg
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FREEDOM Study 2008 (Continued)
• CsA: starting within 24 h of transplantation with 10 mg/kg/d adjusted to C2
levels month 1: 1500 to 2000 ng/mL; month 2: 1300 to 1700 ng/mL; month 3: 1100
to 1500 ng/mL; month 4 to 6: 900 to 1300 ng/mL; thereafter: 800 to 1000 ng/mL
• EC-MPS: day 0: 720 to 1440 mg; thereafter 1440 mg/day divided in two doses
• Steroids (for treatment group 2 and control group)
◦ IV methyl prednisone: day 0: 500 mg; day 1: 250 mg; day 2: 125 mg
◦ Oral prednisolone: day 3: 60 mg; day 4: 40 mg; day 5: 30 mg; day 6: 20 mg
◦ Treatment group 2: no further steroids
◦ Control group: month 1: 10 to 30 mg; month 2: 10 to 20 mg; thereafter: 5
to 10 mg
Outcomes • Mortality
• Graft loss
• Biopsy-proven acute rejection
• NODAT
• Infection
• CMV infection
• Malignancy
• CrCl (mL/min)
• SCr (mg/dL)
Notes • Did not report number screened for eligibility
• Number of patients excluded from analysis
◦ Did not undergo transplantation: treatment group 1 (1); treatment group 2
(1); control group (0)
• Number of patients discontinued treatment: treatment group 1 (38, 25%);
treatment group 2 (34, 34%); 20 patients in control group (20, 20%)
• Number of patients discontinued study
◦ Treatment group 1 (8%): loss to follow-up (2), withdrawal of consent (2),
death (5)
◦ Treatment group 2 (10%):loss to follow-up (4), withdrawal of consent (5),
death (2)
◦ Control group (9%): loss to follow-up (3), withdrawal of consent (5), death
(2)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated ’Randomization was undertaken in
a 1:1:1 ratio using a validated system that
automates the random assignment of treat-
ment groups to randomization numbers.’
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
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FREEDOM Study 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all patients fol-
lowed up or accounted for
Selective reporting (reporting bias) Low risk Primary endpoints for this review reported
Other bias High risk The study was funded by Novartis Pharma
AG
Gulanikar 1991
Methods • Study design: parallel RCT
• Time frame: 1982 to 1992
• Follow-up period: 5 years
Participants • Country: Canada
• Setting: multicentre (14)
• First and subsequent cadaveric or living kidney transplant; functioning graft 90
days after transplantation, with SCr < 2.5 mg/d
• Number (randomised/analysed): withdrawal group (260/260); maintenance
group (263/263)
• Mean age ± SD (years): withdrawal group (39 ± 1); maintenance group (40 ± 1)
• Sex (female): withdrawal group (35%); maintenance group (41%)
• Donor source (% living donors): not reported
• Exclusion criteria: acute rejection in previous 2 weeks; malignancy
Interventions Treatment group
• Steroid withdrawal after at least 90 days
Control group
• Steroid maintenance
Baseline Immunosuppression
• CsA: twice daily adjusted to 12-h trough levels between 75 to 200 ng/mL
• Steroids
◦ Prednisone: from day 1 after transplantation 1 mg/kg on alternate days,
reduced by 5 mg (when clinical conditions allowed) until a dosage of 0.3 mg/kg
Outcomes • Mortality
• Graft loss
• NODAT
• Infection
• CMV infection
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Gulanikar 1991 (Continued)
• Malignancy
• Cardiovascular event
• SCr (mg/dL)
• CrCl (mL/min)
Notes • Did not report number screened for eligibility
• Number of patients discontinued treatment
◦ Withdrawal group: 143 patients; cessation by physician (45), decoded on
request (34), no test drug given (33), CsA stopped (15), noncompliance (15), technical
withdrawal (1)
◦ Maintenance group: 123 patients; because of cessation by physician (33),
decoded on request (32), no test drug given (25), CsA stopped (18), noncompliance
(14), technical withdrawal (1)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated ’randomised blocks of various sizes
were generated and used to attain a bal-
anced, restricted randomization according
to treatment centre. The order of random-
ization did not have a repeating sequence’
Allocation concealment (selection bias) Low risk Stated ’Physicians did not know the ran-
domization number until the patient was
enrolled, and the code was not broken until
the analysis’
Blinding (performance bias and detection
bias)
All outcomes
Low risk Stated ’...the code was not broken until the
analysis. Patients were randomly assigned
at 90 days to receive either a placebo or
prednisone by means of a process that pre-
vented prior knowledge of their treatment
group’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated ’The study was doubly blinded. The
placebo and prednisone were prepared in
an indistinguishable form and dispensed as
coded therapy’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded placebo controlled, out-
comes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk Stated ’No patients were excluded after en-
try (as distinct fromwithdrawals in the sur-
vival analysis) or lost to follow-up.’; ITT
analysis performed
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Gulanikar 1991 (Continued)
Selective reporting (reporting bias) High risk Acute rejection not reported
Other bias High risk This work was supported by Sandoz Ltd.
, Basel, Switzerland, Sandoz Canada Inc.
, Dorval, Que., Upjohn Ltd., Kalamazoo,
Mich., the Richard and Jean Ivey Fund,
London, Ont., the Michael Fung Endow-
ment Fund, London, Ont., the Claudine
Keown Endowment Fund, London, Ont.
, the University Hospital Transplant Re-
search Fund, London, Ont., Robarts Re-
search Institute endowment funds and the
City of London, Ont
Höcker 2009
Methods • Study design: parallel RCT
• Time frame: 2000 to 2006
• Follow-up period: 2 years
• Primary endpoint: standardised longitudinal growth
Participants • Country: Germany
• Setting: multicentre (8 centres)
• Aged < 18 years; 12 to 24 months after first or second cadaveric or living kidney
transplant; triple immunosuppression at study entry with CsA, MMF and steroids
• Number (analysed/randomised): withdrawal group (23/23); maintenance group
(19/17)
• Mean age ± SD (years): withdrawal group (10 ± 1); maintenance group (11 ± 1)
• Sex (female): withdrawal group (35%); maintenance group (32%)
• Donor source (living donors): withdrawal group (22%); maintenance group
(32%)
• Exclusion criteria: irreversible acute rejection of a previous graft; PRA > 80%
within 12 months before study entry; any previous steroid-resistant acute rejection; > 2
acute rejections; biopsy-proven acute rejection; GFR < 40 mL/min; SCr increase >
20% within the last 6 months before study entry; growth hormone therapy
Interventions Treatment group
• Steroid withdrawal 12 to 24 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: 5 to 10 mg/kg/d divided into 2 or 3 single doses adjusted to trough level 70
to 140 µg/L
• MMF: 1200 mg/m2 body surface area/d, divided into two single doses
• Steroids
◦ Either prednisone 5 mg/m2/d or methylprednisolone 4 mg/m2/d
⋄ Withdrawal group: tapered over 12 weeks by either 0.35 mg/m2/wk or
by 0.7 mg/m2/2 wk until withdrawal
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Höcker 2009 (Continued)
⋄ Maintenance group: unchanged
Outcomes • Mortality
• Graft loss
• Acute rejection
• Biopsy-proven acute rejection
• Infection
• CrCl (mL/min)
Notes • Did not report number screened for eligibility
• Number of patients discontinued treatment
◦ Withdrawal group: switched to different immunosuppression (mTOR-
inhibitor (2), TAC (2), MMF withdrawal (1))
◦ Maintenance group: withdrew MMF (1)
• Number of patients discontinued study
◦ Withdrawal group: were lost to follow-up (2)
◦ Maintenance group: withdrew consent after randomisation (2); received
growth hormone (1)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated ’central randomization by the prin-
cipal investigator’, stated ’block random-
ization stratified by pubertal status’
Allocation concealment (selection bias) Unclear risk Stated ’concealed allocation’ but not fur-
ther information provided
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all patients fol-
lowed up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
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Other bias Unclear risk ’Because recruitment of patients for this
study was more difficult than anticipated
(because some patient’s parents and cover-
ing physicians had a strong bias pro or con
steroid withdrawal, we performed an in-
terim analysis, which revealed a significant
difference in growth between both groups.
Hence, the study was finished prematurely.
’
Funding source not reported
INFINITY Study 2013
Methods • Study design: parallel RCT
• Time frame: not reported
• Follow-up period: 6 month
• Primary endpoint: Treatment failure (biopsy-proven acute rejection, graft loss,
death or loss to follow-up)
Participants • Country: France
• Setting: multicentre (number of centres not reported)
• De novo kidney transplant recipients at low immunological risk (PRA < 20%,
cold ischaemia time < 36 h)
• Number: 131 analysed, no further data available
• Age: not reported
• Mean age ± SD (years): not reported
• Sex (% female): not reported
• Donor source (% living donor): not reported
• Exclusion criteria: not reported
Interventions Treatment group
• Steroid avoidance, no further information provided
Control group
• Steroid maintenance, no further information provided
Baseline immunosuppression
• IL-2RA: no further information provided
• CsA: no further information provided
• Intensified enteric-coated mycophenolate sodium: 2160 mg/d to week 6; 1440
mg/d thereafter
• Steroids: no further information provided
Outcomes • Treatment failure (biopsy-proven acute rejection, graft loss, death or loss to
follow-up)
• Mortality
• Graft loss
• Biopsy-proven acute rejection
• CrCl (mL/min)
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Notes • Did not report number screened for eligibility or randomised
• Abstract-only publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if ITT analysis conducted
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias High risk Funding source not reported but authors
disclose ’Grant/Research Support, Novar-
tis (Myfortic)’, Co-authors affiliated with
Novartis Pharma SAS, Rueil-Malmaison,
France
Abstract data only
Lack of important information regarding
design and conduct of study
Isoniemi 1990
Methods • Study design: parallel RCT
• Time frame: 1986 to 1987
• Follow-up period: 4 years
• Primary endpoint: not reported
Participants • Country: Finland
• Setting: single centre
• First cadaveric kidney transplant
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• Number (randomised/analysed): withdrawal group (32/32); /maintenance group
(32/29)
• Mean age ± SD (years): withdrawal group (49 ± 13); maintenance group (47 ± 11)
• Sex (female): withdrawal group (53%); maintenance group (38%)
• Exclusion criteria: living donor kidney transplants; ineligibility for triple
immunosuppression with CsA + AZA + steroids
Interventions Treatment group
• Steroid withdrawal 10 weeks after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: day 0: 5 mg/kg; thereafter: 10 mg/kg/d adjusted to trough levels, but no
further information provided
• AZA: day 0 to 14: 2mg/kg/d
⋄ Withdrawal group: from day 15: 1 mg/kg/d but temporarily increased
to 2 mg/kg/d during steroid withdrawal and thereafter adjusted to WCC
⋄ Maintenance group: from day 15: 1 mg/kg/d
• Steroids:
◦ Methylprednisone: day 0: 1 mg/kg/d tapered in 3-day intervals to 0.25 mg/
kg by day 10
⋄ Withdrawal group: withdrawal over 1 to 2 weeks
⋄ Maintenance group: tapered to 4 to 12 mg/d during the first year
Outcomes • Mortality
• Graft loss
• Acute rejection
• Infection
• SCr (µmol/L)
Notes • Screened for eligibility: 184
• This had two additional arms (in total 128 patients randomised)
◦ Arm 3 with withdrawal of CsA (32 patients)
◦ Arm 4 with withdrawal of AZA (32 patients)
• Number of patients discontinued treatment
◦ Withdrawal group: switched immunosuppression within 2 year follow-up;
AZA withdrawn (7), CsA withdrawn (3), steroids reinitiated (3)
◦ Maintenance group: switched immunosuppression within 2 year follow-up;
AZA withdrawn (6), CsA withdrawn (3), steroids withdrawn (1)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided.
Allocation concealment (selection bias) Low risk Stated ’using the sealed envelope method’
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Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all patients fol-
lowed up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Low risk ’The study was supported by a grant from
the Sigrid Juselius Foundation.’
AZA dose was increased during and af-
ter steroid withdrawal in treatment group
while it remained unchanged in mainte-
nance group
Jankowska-Gan 2009
Methods • Study design: parallel RCT
• Time frame: 2002
• Follow-up period: 3 years
• Primary endpoint: incidence of allograft rejection (original primary endpoint:
graft function)
Participants • Country: USA
• Setting: single centre RCT
• Aged ≥ 55 years; living or cadaveric kidney transplantation > 1 year ago; CNI +
MMF + prednisone since transplantation; SCr < 1.8 mg/dL or CrCl > 55 mL/min;
stable cardiovascular function; HCT ≥ 32%; WCC ≥ 3.0 K/µL
• Number (randomised/analysed): withdrawal group (32/32); maintenance group
(10/10)
• Mean age (± SD): not reported
• Sex (female): withdrawal group (36%); maintenance group (10%)
• Donor source (% living donors): withdrawal group (60%); maintenance group
(60%)
• Exclusion criteria: acute rejection within past 12 months; > 1 rejection episode;
steroid dependency due to pre-existing disease; African-American
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Jankowska-Gan 2009 (Continued)
Interventions Treatment group
• Steroid withdrawal > 1 year after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CNI: no further information provided
• MMF: no further information provided
• Steroids
◦ Steroid withdrawal group: slow withdrawal during 3 months, then stopped
Outcomes • Mortality
• Graft loss
• Acute rejection
• SCr (mg/dL)
Notes • Did not report number screened for eligibility
• Enrolment lagged due to difficulty in enrolling older transplant patients and was
terminated at 32 (target was 75)
• Contact with study authors for additional information: authors contacted 4 July
2013; response received 5 September 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether ITT analysis performed;
number of patients by group not reported
for outcomes
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
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Other bias Unclear risk Funding source not reported
Patients in treatment group were enrolled
later after transplantation compared to
control group
Johnson 1989a
Methods • Study design: parallel RCT
• Time frame: started in 1981
• Follow-up period: 7 years
• Primary endpoint: not reported
Participants • Country: UK
• Setting: single centre RCT
• First or second cadaveric kidney transplantation
• Number (randomised): withdrawal group (376); maintenance group (182)
• Mean age ± SD (years): not reported
• Sex (female): not reported
• Exclusion criteria: diabetes mellitus, urine output < 50 mL/h within the first 6
hours after transplantation
Interventions Treatment group
• Steroid withdrawal day 1 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: started with 6 mg/kg IV over 12 hours until oral administration accepted;
oral: 15mg/kg/d in divided doses; reduced after 2 weeks or if signs of toxicity to achieve
target levels between 80 to 500 ng/mL before the end of the first month
• Steroids
◦ IV methylprednisone: during transplantation: 500 mg
◦ Withdrawal group: no further steroids
◦ Maintenance group: oral prednisone: 0.25 mg/kg, maximum 30 mg/d
Outcomes • Mortality
• Graft loss
• CMV infection
Notes • Screened for eligibility (700); did not report the number analysed
• This study had a third arm with AZA + steroids (112 patients)
• Number of patients discontinued treatment
◦ Withdrawal group: received steroids permanently (125); switched to AZA +
steroids (19); AZA added (27)
Risk of bias
Bias Authors’ judgement Support for judgement
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Johnson 1989a (Continued)
Random sequence generation (selection
bias)
Low risk ’The recipient was entered into the trial by
drawing a card to determine immunosup-
pressive therapy.’
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if ITT analysis performed; total
number of patients by group not reported
for outcomes, results presented as rates and
percentages
Selective reporting (reporting bias) High risk Acute rejection not reported
Other bias Unclear risk Funding sources not reported
465 patients included in first publication
(1989), 700 patients included in second
publication in (1990). Patients in third arm
(AZA + steroids) remained equal in size,
while the treatment group (steroid avoid-
ance = CsA monotherapy) gained most
of the additional patients, which was the
groupwith the better outcomes infirst pub-
lication
Immunosuppressive protocol differs be-
tween these two publications with lower
CsA target levels and more steroids in 2nd
publication
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Kacar 2004
Methods • Study design: parallel RCT
• Time frame: not reported, but before 2004
• Follow-up period: not reported
• Primary endpoint: not reported
Participants • Country: Turkey
• Setting: single centre
• Kidney transplantation > 2 years ago; stable kidney function
• Number (randomised/analysed): withdrawal group (31/31); maintenance group
(30/30)
• Mean age ± SD (years): not reported
• Sex (female): not reported
• Exclusion criteria: acute rejection within last 6 months
Interventions Treatment group
• Steroid withdrawal > 2 years after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• No further information provided
Outcomes • Mortality
• Graft loss
• Acute rejection
• SCr
Notes • Did not report number screened for eligibility
• Number of patients discontinued treatment
◦ Withdrawal group: reintroduced steroids because of discontinuation of
AZA, increase of SCr or acute rejection (7)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether ITT analysis performed;
total number of patients by group for out-
comes not reported
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Abstract-only publication
Kim 2002
Methods • Study design: parallel RCT
• Time frame: 1998 to 1999
• Follow-up period: 2 years
• Primary endpoint: not reported
Participants • Setting: multicentre (2 centres)
• Country: USA
• Cadaveric or living kidney transplant
• Number (randomised/analysed): withdrawal group (12/11); maintenance group
(12/12)
• Mean age (years): withdrawal group (48); maintenance group: (48)
• Sex (% female): not reported
• Donor source (% living donors): not reported
• Exclusion criteria: PRA > 5%
Interventions Treatment group
• Steroid withdrawal 4 days after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: day 0, 4: 20 mg
• CsA: 8 to 10 mg/kg/d
• MMF: 2 to 3 g/d
• Steroids
◦ IV methylprednisone: day 0: 500 mg; day 1: 250 mg; day 2: 125mg
◦ Withdrawal group: day 3: 60 mg; day 4: 30 mg
◦ maintenance group: day 3 to 21: tapered to 20 to 30 mg/d; day 22 to 91:
tapered to 5 to 10 mg/d
Outcomes • Mortality
• Graft loss
• Acute rejection
• Biopsy-proven acute rejection
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Kim 2002 (Continued)
• SCr (mg/dL)
Notes • Did not report number screened for eligibility
• 54% in withdrawal group (6/11 patients) off steroids at 2 years
• Loss to follow-up: withdrawal group (1/12)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised 1:1 ratio’ but no further
information provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk One patient lost to follow up in withdrawal
group (8%), unlikely to affect results; un-
clear if ITT analysis performed
Selective reporting (reporting bias) High risk Graft loss not reported
Other bias Unclear risk Funding source not reported
Abstract-only publication
Kumar 2005
Methods • Study design: parallel RCT
• Time frame: 2000 to 2002
• Follow-up period: 1 year
• Primary endpoint: not reported
Participants • Country: USA
• Setting single centre
• Age > 20 years; first cadaveric or living kidney transplant
• Number (randomised/analysed): withdrawal group (45/45); maintenance group
(32/32)
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Kumar 2005 (Continued)
• Mean age ± SD (years): withdrawal group (50 ± 13); maintenance group (54 ± 13)
• Sex (female): withdrawal group (28%); maintenance group (28%)
• Donor source (living donors): withdrawal group (18%); maintenance group (9%)
• Exclusion criteria: PRA > 10%; HIV seropositivity; HBsAG seropositivity
Interventions Treatment group
• Steroid withdrawal 7 days after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: days 0, 4: 20 mg
◦ Withdrawal group: the first 17 patients received additionally 20 mg on day
60 and 64
• CsA: starting day 1 with 2 to 5 mg/kg twice daily, adjusted to trough blood levels:
day 1 to 100: 250 to 300 ng/mL; day 101 to 365: 200 to 250ng/mL; thereafter: 150 to
200 ng/mL
• MMF: 2 to 3 g/d
◦ MMF intolerance: SRL: started with 5 mg/d adjusted to blood level 6 to 10
ng/mL
• Steroids:
◦ IV methylprednisone: day 0: 250 mg; day 1: 125 mg
◦ Oral prednisone
⋄ Withdrawal group: first 17 patients: day 2: 30 mg, tapered by 5 mg/d
until withdrawal on day 7; remaining 28 patients: no further steroids
⋄ Maintenance group: day 2: 30 mg; tapered to 5 mg/d at month 1
Outcomes • Mortality
• Graft loss
• Acute rejection
• NODAT
• SCr (mg/dL)
Notes • Did not report number screened for eligibility
• Study was closed after 77 patients were randomised, because patients refused to be
randomised in the maintenance group. Nevertheless 300 patients were enrolled
through patient’s choice. This systematic review only includes data on the randomised
first 77 patients
• 7 patients in withdrawal group and 3 patients in maintenance group received SRL
because of MMF intolerance
• Contact with study authors for additional information: authors contacted 5 July
2013; no response received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomization was completed using the
first generator plan from randomization.
com.’
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Kumar 2005 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all patients fol-
lowed up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias High risk First 17 patients (38%) in withdrawal
group received steroids until day 7 and two
additional doses of basiliximab, the remain-
ing 28 patients (62%) received steroids un-
til day 2 and no additional basiliximab
’The study was funded internally by clin-
ical revenue. The manuscript was support
by an unrestricted educational grant from
Novartis Pharm. Corp.’
Laftavi 2005
Methods • Study design: parallel RCT
• Time frame: 2002 to 2004
• Follow-up period: 1 year
• Primary endpoint: not reported
Participants • Country: USA
• Setting: single centre
• First cadaveric or living kidney transplant
• Number (randomised): withdrawal group (32); maintenance group (28)
• Mean age (± SD): withdrawal group (50 ± 13); maintenance group (51 ± 12)
• Sex (female): withdrawal group (35%); maintenance group (36%)
• Donor source (living donor): withdrawal group (16%); maintenance group (21%)
• Exclusion criteria: PRA > 30%
Interventions Treatment group
• Steroid withdrawal day 7 after transplantation
Control group
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Laftavi 2005 (Continued)
• Steroid maintenance
Baseline immunosuppression
• Rabbit ALG: 1mg/kg per day for 3 to 5 doses
• TAC: day 0: 0.5 to 1 mg twice daily adjusted to whole blood level: by day 7 to 10:
10 ng/mL; month 1 to 6: 10 to 15 ng/mL; thereafter: 8 to 10 ng/mL
• MMF: starting on day 0: 2 g/d divided in 2 to 4 doses.
• Steroids
◦ IV methylprednisone: day 0: 250 mg; day 1: 125mg
◦ Withdrawal group: prednisone: day 2: 30 mg/d; rapidly titrated down to a
dose of 5 mg/d and withdrawn on day 7
◦ Maintenance group: prednisone: day 2: 30 mg/d, rapidly titrated down to a
dose of 5 mg/d by end of month 1 and thereafter maintained at 5 mg/d
Outcomes • Acute rejection
• Biopsy-proven acute rejection
• CrCl (mL/min)
Notes • Did not report number screened for eligibility or number analysed
• Number of patients discontinued study
◦ Clinical adverse events, biopsy findings or subsequent pancreas
transplantation: withdrawal group (10); maintenance group (6)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Patients were randomised by a blinded
nurse coordinator according to random
numbers.’
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’A single pathologist who was blinded to
the treatment arms, evaluated biopsy spec-
imens for severity of rejection and fibrosis.
’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether ITT analysis performed.
In treatment group 16 of 32 patients and in
control group 14 of 28 patients completed
1 year follow-up
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Selective reporting (reporting bias) High risk Mortality and graft loss are not reported
Other bias Unclear risk Funding source not reported
Unclear whether groups were similar at
baseline, because ’steroid withdrawal pa-
tients were at greater risk for rejection, hav-
ing a higher average number of HLA mis-
matches and a greater number of African
American patients’
Lebranchu 1999
Methods • Study design: parallel RCT
• Time frame: 1996 to 1997
• Follow-up period: 12 months
• Primary endpoint: biopsy-proven acute rejection 6 months after transplantation
Participants • Country: Europe, Australia, South Africa
• Setting: multicentre (75 centres)
• First or second cadaveric or living kidney transplant; > 18 years
• Number (randomised/analysed): withdrawal group (252/252); maintenance
group (248/248)
• Mean age, range (years): withdrawal group (45, 18 to 69); maintenance group
(46, 18 to 71)
• Sex (female): withdrawal group (43%); maintenance group (41%)
• Donor source (living donor): withdrawal group (10%); maintenance group (8%)
• Exclusion criteria: immunosuppression other than CsA + MMF + steroids
(induction with OKT 3 and ATG was allowed); historical PRA ≥ 80%; seropositivity
for HTLV-1/HIV/HBsAG; WCC < 2.5 x 109/L; Hb < 5 g/dL; malignancy; systemic
infection; severe gastrointestinal disorders; psychiatric problems; substance use
Interventions Treatment group
• Steroid withdrawal 3 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: started with 5 to 15 mg/kg/d adjusted to normal trough levels for
participating centres
• MMF: 1000 mg twice daily
• Steroids
◦ IV prednisolone: preoperative and postoperative dose: 500 mg
◦ Withdrawal group: day 1 to 14: 15 mg; day 15 to 70: 10 mg; day 71 to 84: 5
mg; then no further steroids
◦ Maintenance group: day 1 to 14: 30 mg; day 15 to 56: 20 mg; day 57 to 70:
15 mg; beyond day 71: 10 mg
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Lebranchu 1999 (Continued)
Outcomes • Mortality
• Graft loss
• Acute rejection
• Biopsy-proven acute rejection
• Infection
• CMV infection
• SCr (µmol/L)
Notes • Did not report number screened for eligibility
• Number of patients discontinued study (at 12 months)
◦ Withdrawal group (25%): adverse events (35), unsatisfactory response to
study treatment (6), required prohibited medication (4), death (4), other reasons (14)
◦ Maintenance group (17%): adverse events (17), unsatisfactory response to
study treatment (3), required prohibited medication (1), death (5), other reasons (15)
• Completed 6 months follow-up double-blind period according to protocol:
withdrawal group (174); maintenance group (193)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’Patients were randomly assigned to
one of two treatment groups in a 1:1 ra-
tio, with stratification by cadaveric/ living
related donor transplant recipient and by
type of cyclosporine’ but random sequence
generation unclear
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Stated ’Treatment continued in a blinded
fashion for 6months, after which the study
was to be unblinded during a further 6
months, for a total study length of 1 year’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Stated ’Treatment continued in a blinded
fashion for 6months, after which the study
was to be unblinded during a further 6
months, for a total study length of 1 year’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether ITT analysis performed;
stated ’At 12 months 17% in the con-
trol group and 25% in the treatment
group were prematurely withdrawn from
90Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lebranchu 1999 (Continued)
the study’
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Maiorca 1988
Methods • Study design: parallel RCT
• Time frame: 1983 to 1986
• Follow-up period: 27 ± 9 months
• Primary endpoint: not reported
Participants • Country: Italy
• Setting: single centre
• First cadaveric kidney transplant; functioning graft 6 months after transplantation
• Number (randomised/analysed): withdrawal group (35/35): maintenance group
(31/31)
• Mean age ± SD (years): withdrawal group (33 ± 10); maintenance group (35 ± 9)
• Sex (female): withdrawal group (30%); maintenance group (29%)
• Exclusion criteria: not reported
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation (completed 13 months after
transplantation)
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: no further information provided
• Steroids
◦ Withdrawal group: prednisone: reduced by 2 mg/wk until complete
withdrawal 13 months after transplantation
◦ Maintenance group: prednisone: continued 8 mg/d
Outcomes • Mortality
• Graft loss
• Acute rejection
• NODAT
Notes • Did not report number screened for eligibility
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated’ randomised’ but no further infor-
mation provided
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Maiorca 1988 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All patients followed up or accounted for;
unclear if ITT analysis performed
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Matl 2000
Methods • Study design: parallel RCT
• Time frame: not reported, but before 2000
• Follow-up period: 1 year
• Primary endpoint: not reported
Participants • Country: Czech Republic
• Setting: single centre
• First cadaveric or living kidney transplant; stable graft function one year after
transplantation; 18 to 65 years
• Number (randomised/analysed): withdrawal group (46/45); maintenance group
(42/42)
• Mean age ± SD (years): withdrawal group (50 ± 9); maintenance group (47 ± 13)
• Sex (female): withdrawal group (45%); maintenance group (26%)
• Donor source (% living donors): not reported
• Exclusion criteria: SCr > 1.8 mg/dL
Interventions Treatment group
• Steroid withdrawal 1 year after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: adjusted to blood levels in the upper half of the therapeutic range
• AZA: minimum of 1.5 mg/kg/d
• Steroids
◦ Withdrawal group: gradually withdrawn over a period of 6 months
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◦ Maintenance group: unchanged, no further information provided
Outcomes • Mortality
• Graft loss
• Acute rejection
• SCr (mg/dL)
Notes • Did not report number screened for eligibility
• Number of patients discontinued study
◦ Withdrawal group: excluded after randomisation before steroid withdrawal
(1)
• Number of patients discontinued treatment
◦ Withdrawal group: did not withdraw steroids because of rejection (3),
leucopenia (1)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Patients were randomised according to the
month of birth
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients followed up or accounted for;
ITT analysis performed
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Low risk The studywas supported by grantN°3631-
3 awarded by the Internal Grant Agency of
the Ministry of Health of the Czech Re-
public
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Mericq 2013
Methods • Study design: parallel RCT
• Time frame: 2008 to 2009
• Follow-up period: 1 year
• Primary endpoint: stimulation of growth after 12 months
Participants • Country: Chile
• Setting: multicentre RCT (2 centres)
• First cadaveric or living kidney transplant; < 16 years with a bone age ≤ 15 years
in boys and ≤ 13 years in girls
• Number (randomised/analysed): withdrawal group (14/12); maintenance group
(16/12)
• Mean age ± SD (years) (only reported for prepubertal patients); withdrawal group
(6 ± 3); maintenance group (6 ± 4)
• Sex (female) (only for prepubertal patients reported): withdrawal group (50%);
maintenance group (42%)
• Donor source (% living donor) not reported
• Exclusion criteria: treatment with recombinant human growth hormone or
bisphosphonate
Interventions Treatment group
• Steroid withdrawal 6 days after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: days 0, 4: 20 mg/m2
• TAC: started with 0.15 mg/kg twice daily when creatinine < 2 mg/dL; adjusted to
basal levels until day 30: 10 to 15 ng/mL; thereafter: 5 to 7 ng/mL
• MMF: until day 30: 800 mg/m2/d; day 31 to month 3: 600 mg/m2/d; thereafter:
400 mg/m2/d
• Steroids
◦ Withdrawal group: methylprednisone: day 0 to 2: 2 mg/kg/d; prednisone:
day 3: 2 mg/kg/d; day 4: 1 mg/kg/d; day 5: 0.5 mg/kg/d; day 6: 0.25 mg/kg/d; then no
further steroids
◦ Maintenance group: methylprednisone: day 0 to 2: 2 mg/kg/d; prednisone:
day 3 and 4: 2 mg/kg/d; day 5 to month 1: 1.5 mg/kg/d; reduced to 0.12 mg/kg/d
until study end
Outcomes • Mortality
• Graft loss
• Acute rejection
Notes • Did not report number screened for eligibility
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated ’central randomization by the prin-
ciple investigator’
94Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mericq 2013 (Continued)
Allocation concealment (selection bias) Low risk Stated ’stratified treatment allocation on
the basis of block randomization carried
out by a statistician whowas not participat-
ing in this study using numbered contain-
ers by a computerized statistical program’
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether ITT analysis performed;
outcomes for prepubertal patients only re-
ported. Number of events and per group
not reported
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Low risk This study was supported by Fondecyt
1080166 (National Fund for Scientific and
Technological Development)
Montagnino 2005
Methods • Study design: parallel RCT
• Time frame: not reported, but before 2005
• Follow-up period: 3 years
• Primary endpoint: graft survival
Participants • Country: Italy
• Setting: multicentre (number of centres not reported)
• First and second cadaveric or living kidney transplant; 18 to 65 years
• Number (randomised/analysed): withdrawal group (65/65); maintenance group
(68/68)
• Mean age ± SD (years): withdrawal group (44 ± 10); maintenance group (46 ± 12)
• Sex (female): withdrawal group (31%); maintenance group (38%)
• Donor source (living donors): withdrawal group (5%); maintenance group (6%)
• Exclusion criteria: ischaemia time > 40 hours; PRA > 50%
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Interventions Treatment group
• Steroid withdrawal 7 days after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: days 0 and 4: 20 mg
• CsA: twice daily 3 to 5 mg/kg adjusted to trough levels; week 1 to 4: 150 to 300
ng/mL; month 2 to 6: 100 to 250 ng/mL; thereafter: 100 to 200ng/mL
◦ Amendment to study protocol after availability of new evidence: CsA levels
< 100 ng/mL
• EVL: 1.5 mg twice daily
• Steroids
◦ Withdrawal group: prednisone: day 1 to 5: 20 mg/d; day 6: 5 mg; day 7: 5
mg; then stopped
◦ Maintenance group: prednisone: week 1 to 2: 20 mg/d; week 3 to 4: 15 mg/
d; week 5 to 6: 10 mg/d; week 7 to month 12: 5 to 10 mg/day; thereafter: 2.5 to 5 mg/d
Outcomes • Mortality
• Graft loss
• Biopsy-proven acute rejection
• NODAT
• Malignancy
• Infection
• CMV infection
• SCr (mg/dL)
• CrCl (mL/min)
Notes • Did not report number screened for eligibility
• Number of patients discontinued treatment
◦ Withdrawal group: reintroduced steroids (28)
• Contact with study authors for additional information: authors contacted 2
September 2013; no response received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised randomisation by a randomi-
sation list, stratified within centres using an
interactive voice-response system
Allocation concealment (selection bias) Low risk ’The sequence was concealed until inter-
ventions were assigned.’
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
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Montagnino 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients followed up or accounted for;
ITT analysis performed (’All the analy-
ses considered all the randomised patients,
grouped originally by randomised treat-
ment as per ITT concept.’)
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias High risk Supported by grant from Novartis
Nagib 2015
Methods • Study design: parallel RCT
• Time frame: 2003 to 2014
• Follow-up period: median follow-up was 66 ± 41 months
• Primary endpoint: incidence of a first biopsy-proven acute rejection (Banff type 1
or higher) within 36 months after transplantation
Participants • Country: Egypt
• Setting: single centre
• Primary kidney transplantation from living donors between 21 and 60 years of
age with compatible ABO blood groups
• Number (randomised): avoidance group (214); maintenance group (214)
• Age range: 5 to 62 years
• Mean age ± SD (years): avoidance group (30 ± 12); maintenance group (24 ± 13)
• Sex (female): avoidance group (24%); maintenance group (26%)
• Exclusion criteria: lost follow-up; pretransplantation diabetes mellitus; other
immunosuppressive protocols
Interventions Treatment group
• Steroid avoidance on day 4
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: days 0 and 4
• TAC: no further information provided
• MMF: no further information provided
• Steroids
◦ IV methylprednisone: days 0 and 1: 500 mg; day 2: 250 mg; day 3: 100 mg
◦ Avoidance group: steroids stopped at day 4 provided that an acceptable TAC
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Nagib 2015 (Continued)
level was achieved
◦ Maintenance group: 1.5 mg/kg/d methylprednisolone days tapered gradually
to 0.15 mg/kg/d by the 9 months post-transplantation
Outcomes • Mortality
• Graft loss
• Biopsy-proven acute rejection
• SCr (µmol/L)
Notes • Did not report number screened for eligibility or analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’...patients were randomised to receive...’
but no further information provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Unclear if ITT analysis performed; total
number of patients by group for outcomes
not reported
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
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Nematalla 2007
Methods • Study design: parallel RCT
• Time frame: 2004 to 2005
• Follow-up period: 1 year
• Primary endpoint: incidence of biopsy-proven acute rejection within 12 months
after transplantation
Participants • Country: Egypt
• Setting: single centre
• First living kidney transplant; recipient age 22 to 56 years; donor age 21 to 60
years
• Number (randomised/analysed): withdrawal group (50/50); maintenance group
(50/50)
• Mean age ± SD (years): withdrawal group (30 ± 11); maintenance group (29 ± 10)
• Sex (female): withdrawal group (20%); maintenance group (36%)
• Exclusion criteria: mismatch at HLA-DR locus
Interventions Treatment group
• Steroid withdrawal day 4 after transplantation (if TAC levels in target range)
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: day 0 and 4: 20 mg
• TAC: starting on day -2 with 0.1 mg/kg/d adjusted to trough levels week 1 to 2:
10-15 ng/mL; thereafter: 5 to 10 ng/mL
• MMF: week 1 to 2: 1000 mg twice daily; thereafter 750 mg twice daily
• Steroids
◦ IV methylprednisone: day 0: 500 mg
◦ Withdrawal group: methylprednisone: day 1: 500 mg; day 2: 250 mg; day 3:
100 mg; thereafter no further steroids
◦ Maintenance group: methylprednisone: day 1, 3, 7, 14: 3.5 mg/kg/d;
followed by gradual tapering to 0.15 mg/kg/d by month 9
Outcomes • Mortality
• Graft loss
• Biopsy-proven acute rejection
• NODAT
• Infection
• CMV infection
• SCr (µmol/L)
• eGFR (mL/min)
Notes • Did not report number screened for eligibility
• Contact with study authors for additional information: authors contacted 9 July
2013; no response received
Risk of bias
Bias Authors’ judgement Support for judgement
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Nematalla 2007 (Continued)
Random sequence generation (selection
bias)
Low risk ’100 similar closed opaque envelopes were
made, each containing a slip of opaque pa-
per with the type of maintenance immuno-
suppression. Therefore, 50 envelopes were
with steroid and the rest were without. All
envelopes were kept closed until the morn-
ing of the transplant day, when one enve-
lope was selected for each patient’
Allocation concealment (selection bias) Low risk ’Similar closed opaque envelopes, each con-
taining a slip of opaque paper’
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether ITT analysis performed;
number of patients in groups varies slightly
between reports
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Different protocol between groups for
steroid dosing before withdrawal
Funding source not reported
Nott 1985
Methods • Study design: parallel RCT
• Time frame: 1982
• Follow-up period: 14 to 39 months
• Primary endpoint: not reported
Participants • Country: UK
• Setting: single centre
• All ages; first or subsequent cadaveric or living kidney transplant
• Number (randomised): withdrawal group (59); maintenance group (58)
• Mean age (± SD): not reported
• Sex (% female): not reported
• Donor source (% living donors): 0.05%
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Nott 1985 (Continued)
• Exclusion criteria: none
Interventions Treatment group
• Steroid withdrawal day 1 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: 17 mg/kg/d divided in 2 doses, reduced by 2 mg/kg every 2 weeks adjusted
to whole blood level 250 to 700 ng/mL. Dose reduction to 15 mg/kg after the first 20
patients due to nephrotoxicity
• Steroids
◦ IV methylprednisone: day 0: 500 mg
◦ Oral prednisolone: starting on day 2 with 2 mg/kg/d; tapered to 0.15 mg/
kg/d by day 74
⋄ Withdrawal group: no further steroids
⋄ Maintenance group: from day 1: 0.3 mg/kg/d as divided dose; reduced
by 5 mg/mo to a maintenance dose of 10 to 15 mg/d
Outcomes • Mortality
• Graft loss
• Cardiovascular event
• Infection
• SCr (mmol/L)
Notes • Did not report number screened for eligibility or analysed
• Number of patients discontinued treatment
◦ Withdrawal group: switched to different immunosuppression (steroid added
(13), converted to AZA + steroids (19))
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was achieved by drawing a
card
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
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Nott 1985 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Total number of patients by group not
reported for outcomes; ITT analysis per-
formed
Selective reporting (reporting bias) High risk Acute rejection not reported
Other bias Unclear risk Immunosuppressive protocol differs be-
tween publications
No patient characteristics shown, unclear
whether the groups were similar at baseline
Funding source not reported
Park 1994
Methods • Study design: parallel RCT
• Time frame: not reported, but before 1994
• Follow-up period: 1 year (6 years for 68 patients)
• Primary endpoint: patient and graft survival rates
Participants • Country: Korea
• Setting: multicentre (number of centres not reported)
• First living kidney transplant; 18 to 65 years
• Number (randomised): withdrawal group (141); maintenance group (153)
• Mean age ± SD (years): not reported
• Sex (% female): not reported
• Exclusion criteria: SCr > 1.5 mg/dL 3 months after transplantation; active
hepatitis; HBsAG seropositivity
Interventions Treatment group
• Steroid withdrawal 3 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: day 0 to 2: 3 mg/kg IV; day 3: 10 mg/kg PO; reduced to 3 to 5 mg/kg/d
adjusted to trough levels: month 1 to 3: 200 to 400 ng/mL; thereafter: 100 to 200 ng/
mL
• Steroids
◦ IV methylprednisone: day 0: 1000 mg; day 1: 200 mg; reduced to 60 mg by
day 4
◦ Oral prednisone: day 5: 30 mg/d; reduced to 10 mg/d by end of month 3
⋄ Withdrawal group: prednisone reduced by 2.5 mg every 2 weeks until
complete withdrawal 6 to 8 weeks after randomisation
Outcomes • Mortality
• Graft loss
• Acute rejection
• NODAT
• Infection
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Park 1994 (Continued)
• SCr (mg/dL)
• CrCl (mL/min)
Notes • Did not report number screened for eligibility; randomised (294); analysed in
1998 (68)
• Number of patients discontinued study
◦ At 1 year 18 patients withdrawn from study because of regimen failure,
death, graft loss, compliance, adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided.
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of patients in which the outcome
was measured are not reported, survival
only reported as rates; unclear if ITT anal-
ysis performed
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
There’s a substantial difference between
number of participants in first published
report (1994) (294) and second report
(1998) (68) which is not explained
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Pelletier 2006
Methods • Study design: parallel RCT
• Time frame: 1997 to 2002
• Follow-up period: mean 3.7 years
• Primary endpoints: incidence of acute rejection, chronic rejection and graft loss
within 1 year of consent
Participants • Country: USA
• Setting: single centre
• First cadaveric or living kidney transplant; > 18 years; MMF > 2 g (unless
intolerant) and CsA > 2 mg/kg/d or trough levels > 150 ng/mL
• Number (randomised/analysed): withdrawal group (60/59); maintenance group
(60/59)
• Mean age ± SD (years): withdrawal group (45 ± 14); maintenance group (45 ± 14)
• Sex (female): withdrawal group (22%); maintenance group (31%)
• Donor source (living donors): withdrawal group (36%); maintenance group
(37%)
• Exclusion criteria: SCr > 2.5 mg/dL; previous acute rejection; proteinuria > 600
mg/24 h; presence of steroid treated disease
Interventions Treatment group
• Steroid withdrawal at different time points after transplantation (exact time point
of steroid withdrawal unclear, but all patients had steroids for > 14 days)
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab (54 patients): day 0 and 4: 20 mg
• OKT3 (40 patients): day 3 to 5: 5 mg/d
• Thymoglobulin (6 patients): day 3 to 5
• No induction: 14 patients
• CsA: starts with 5 to 6 mg/kg/d adjusted to trough levels: year 1: 250 ng/mL;
thereafter: 150
• MMF: 2 g/d
• Steroids
◦ Prednisone: starts with 2 mg/kg, tapered to 0.2 mg/kg at month 1; tapered
to 0.15 mg/kg at month 12
◦ Steroid withdrawal: reduced by 2.5 mg/2 wk
Outcomes • Mortality
• Graft loss
• Acute rejection
• SCr (mg/dL)
• NODAT
Notes • Did not report number screened for eligibility
• Number of patients discontinued study
◦ Withdrawal group: 1 patient
◦ Maintenance group: 1 patients withdrawn from study shortly after consent
because of proteinuria > 600 mg/24 h and non-compliance
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided.
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if ITT analysis performed
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Steroids have been withdrawn at different
time points after transplantation and the
time point of steroid withdrawal is unclear
Different induction treatments used, 14%
of patients did not receive any induction
treatment
Pisani 2001
Methods • Study design: parallel RCT
• Time frame: not reported
• Follow-up period: not reported
• Primary endpoint: incidence of acute rejection
Participants • Country: Italy
• Setting: single centre
• First or second kidney transplant
• Number (analysed): withdrawal group (15); maintenance group (15)
• Mean age: withdrawal group (41 years); maintenance group (45 years)
• Sex (female): withdrawal group (33%); maintenance group (30%)
• Donor source (% living donors): not reported
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Pisani 2001 (Continued)
• Exclusion criteria: not reported
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: day 0 and 4: 20 mg
• CsA: started with 8 mg/kg/d adjusted to blood levels in month 1 to 2: 350 to 400
ng/mL; month 3: 250 to 300 ng/mL
• MMF: 1500 mg/d
• Steroids
◦ IV methylprednisone day 0: 500 mg
◦ Oral prednisone: month 1: 20 mg/d; tapered to 5 mg/day at month 3
Outcomes • Mortality
• Graft loss
• Acute rejection
• SCr (µmol/L)
• NODAT
• Infection
• CMV infection
Notes • Did not report number screened for eligibility; randomised (46); analysed (30)
• Steroids withdrawn in 8/15 patients in withdrawal group at time of preliminary
report
• This study had a third arm with ’standard immunosuppression’ CsA + MMF +
steroids (17 patients)
• Contact with study authors for additional information: authors contacted 9 July
2013; no response received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided.
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
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Pisani 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether ITT analysis was per-
formed; number of patients per group and
in total vary between reports
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Abstract-only data
Lack of important information regarding
design and conduct of study
Ponticelli 1997
Methods • Study design: parallel RCT
• Time frame: 1990 to 1993
• Follow-up period: 9 years
• Primary endpoint: not reported
Participants • Country: Italy
• Setting multicentre (number of centres not reported)
• First or second cadaveric kidney transplant; 16 to 70 years
• Number (randomised): withdrawal group (115); maintenance group (117)
• Mean age ± SD (years): withdrawal group (41 ± 11); maintenance group (41 ± 11)
• Sex (female): withdrawal group (39%); maintenance group (32%)
• Exclusion criteria: PRA > 50%; acute rejection or need for dialysis within 5 days
after transplantation
Interventions Treatment group
• Steroid withdrawal day 5 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: day 0 and 1: 5 mg/kg IV; day 2 to 14: 12 mg/kg/d divided in two doses; day
15: 10 mg/kg then tapered every fortnight by 2 mg/kg to maintenance dose 4-5 mg/
kg/d; adjusted to target level: month 1 to 3: 175 to 400 ng/mL; month 4 to 6: 125 to
300 ng/mL; month 7 to 12: 100 to 225 ng/mL; thereafter: 75 to 200 ng/mL
• Steroids
◦ IV methylprednisone day 0: 500 mg; day 1: 200 mg; day 2: 50 mg
◦ Withdrawal group: day 3 and 4: 16 mg/d; then steroids withdrawn
◦ Maintenance group: month 1 to3: 16 mg/d; then gradually tapered to 8 mg/
d by end of month 6
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Ponticelli 1997 (Continued)
Outcomes • Mortality
• Graft loss
• Acute rejection
• Cardiovascular events
• NODAT
• Malignancy
• Infection
• CrCl (mL/min)
Notes • Number screened for eligibility: 547; did not report number analysed
• This study had a third arm with CsA + AZA + steroids (122 patients)
• Number of patients discontinued treatment
◦ Withdrawal group: switched to different immunosuppression: steroids added
(37), steroids + AZA added (20), AZA added (2), conversion to AZA + steroids (1)
◦ Maintenance group: switched to different immunosuppression: AZA added
(23), steroids withdrawn (1)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Random assignments were made accord-
ing to a randomization list balanced per
centre through a telephone call to the co-
ordinating centre.’
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all patients fol-
lowed up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Sandoz Prodotti Farmaceutici SpA pro-
vided logistic support for the SIMTRE
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group meetings
Ratcliffe 1993
Methods • Study design: parallel RCT
• Time frame: 1988 - 1991
• Follow-up period: 1 year (another 24 months uncontrolled)
Participants • Country: UK
• Setting: single centre
• First and second cadaveric kidney transplant; stable kidney function 1 to 6 years
after transplantation
• Number (randomised/analysed): withdrawal group (49/49); maintenance group
(51/51)
• Mean age ± SD (years): withdrawal group (48 ± 14); maintenance group (48 ± 14)
• Sex (female): withdrawal group (35%); maintenance group (31%)
• Exclusion criteria: not on triple immunosuppression; history of steroid resistant
rejection; rejection after the first year following transplantation or within 6 months of
eligibility assessment; SCr > 2.8 mg/dL
Interventions Treatment group
• Steroid withdrawal 1 to 6 years after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: no further information provided
• AZA: no further information provided
• Prednisone: no further information provided
Outcomes • Mortality
• Graft loss
• SCr (mg/dL)
• CrCl (mL/min)
Notes • Did not report number screened for eligibility
• Number of patients discontinued treatment
◦ Withdrawal group: did not stop steroids because of increased SCr (3), severe
myalgia (2), death (2)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided.
Allocation concealment (selection bias) Unclear risk Not reported
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Ratcliffe 1993 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients followed up or accounted for;
ITT analysis performed (”Unless otherwise
stated, data were analysed with groups as-
signed on the basis of “intention-to-treat”)
Selective reporting (reporting bias) High risk Acute rejection is not reported
Other bias Unclear risk Funding source not reported
Sandrini 2009
Methods • Study design: parallel RCT
• Time frame: 2002 to 2004
• Follow-up period: 4 years
• Primary endpoint: percentage of patients who could be successfully withdrawn
from steroids at 12 and 48 months
Participants • Country: Italy
• Setting: single centre
• First cadaveric kidney transplant; PRA < 50%; all ages
• Number (randomised/analysed): avoidance group (49/44); /withdrawal group
(47/46)
• Mean age ± SD (years): avoidance group (50 ± 11); withdrawal group (51 ± 11)
• Sex (% female): not reported
• Exclusion criteria: underlying disease requiring steroids; HIV seropositivity
Interventions Avoidance group
• Steroid withdrawal day 5 after transplantation
Withdrawal group
• Steroid withdrawal 6 months after transplantation
Baseline immunosuppression
• Basiliximab: day 0 and 4: 20 mg
• CsA: started on day 0 with 5 mg/kg/d divided into 2 doses, adjusted to C2 levels
month 1 to 6: 800 to 1000 g/L; month 7 to 12: 600 to 800 g/L; thereafter: 400 to 500
g/L
• Sirolimus: started on day 2 with 6 mg/d, then 2 mg/d, adjusted to blood levels 5
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to 10 ng/mL
• Steroids
◦ IV methylprednisone: day 0: 500 mg
◦ Avoidance group: methylprednisone: day 1: 200 mg; day 2: 100 mg; day 3:
50 mg; day 4: 20 mg; then no further steroids
◦ Withdrawal group: methylprednisone: day 1: 200 mg; day 2: 200 mg; day 3:
150 mg; day 4: 100 mg; day 5: 50 mg; day 6: 20 mg; day 7 to month 1: 16 mg; month
2: 12 mg; month 3 to 5: 8 mg; month 6: withdrawn but only in selected patients with
stable kidney function (proteinuria < 1g/d, SCr < 2.0 mg/dL, < 3 acute rejections)
Outcomes • Mortality
• Graft loss
• Acute rejection
• NODAT
• Malignancy
• Infection
• SCr (mg/dL)
Notes • Did not report number screened for eligibility
• Number of patients excluded from analysis
◦ Avoidance group protocol violation (continued to take steroids) (1)
• Number of patients discontinued study
◦ Avoidance group: lost to follow-up at 1 year (4)
◦ Withdrawal group: lost to follow-up at 1 year (1)
• Patients discontinued treatment
◦ Avoidance group: 38%
◦ Withdrawal group: not withdrawn from steroids at 1 year because of acute
rejection, delayed graft function, patient ’unsuitability’ (33%)
• Contact with study authors for additional information: authors contacted 14
January 2013; no response received.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label, primary study endpoint was
the percentage of patients who could be
successfully withdrawn from steroids at 1
and 4 years after transplantation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Stated ’ The results were analyzed on an
ITT basis’ but patients were excluded from
analysis due to protocol violation; reasons
for loss to follow-up not reported
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Lack of important information regarding
design and conduct of study
High percentage of protocol failure (38%
in avoidance group and 33% in withdrawal
group not withdrawn from steroids at 1
year after transplantation)
Schulak 1989
Methods • Study design: parallel RCT
• Time frame: 1987 to 1989
• Follow-up period: 2 years
Participants • Country: USA
• Setting: single centre
• First and second cadaveric or living kidney transplant
• Number (randomised/analysed): withdrawal group 32/32); maintenance group
(35/35)
• Mean age ± SD (years): withdrawal group (44 ± 13); maintenance group (43 ± 12)
• Sex (female): withdrawal group (50%); maintenance group (34%)
• Donor source (living donors): withdrawal group (16%); maintenance group (9%)
• Exclusion criteria: previous graft lost due to rejection; ongoing steroid therapy for
other diseases
Interventions Treatment group
• Steroid withdrawal after 6 to 20 days after transplantation (most had steroids < 14
days), steroids were withdrawn shortly after CsA initiation
Control group
• Steroid maintenance
Baseline immunosuppression
• ALG: 10 mg/kg day 1; 20 mg/kg day 5 to 12 depending on graft function
• CsA: starting on last day of ALG administration with 10 mg/kg/d adjusted to
blood levels between 100 to 250 ng/mL during first 3 months; tapered to 3 to 5 mg/
kg/d by 6 months
• AZA: 5 mg/kg once prior to transplantation; 1.5 to 2.0 mg/kg daily after
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Schulak 1989 (Continued)
transplantation
• Steroids
◦ IV methylprednisone: day 0: 250 mg; day 1 to 3: tapered doses
◦ Oral prednisone: day 4: 1mg/kg/d; tapered to 30 mg/d by week 2; tapered to
15 mg/d at month 3 to 4
Outcomes • Mortality
• Graft loss
• Acute rejection
• Infection
• SCr (mg/dL)
Notes • Did not report number screened for eligibility
• Number of patients discontinued treatment
◦ Withdrawal group: returned to steroid maintenance (18)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Patients were randomised using a table of
random numbers’
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients followed up or accounted for;
ITT analysis performed
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Groups at baseline were different regard-
ing gender, race and causes of kidney fail-
ure with more females, less African-Amer-
icans, more diabetics in the steroid avoid-
ance group
Funding source not reported
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Methods • Study design: parallel RCT
• Time frame: 1997 to 1999
• Follow-up period: 18 months
• Primary endpoint: first biopsy-proven acute or chronic rejection between 6
months and 24 months after transplantation
Participants • Country: The Netherlands
• Setting: multicentre (3 centres)
• Cadaveric or living kidney transplant with stable graft function 6 months after
transplantation
• Number (randomised/analysed): withdrawal group (76/76); maintenance group
(73/73)
• Mean age, range (years): withdrawal group (52, 19 to 68); maintenance group
(51, 19 to 70)
• Sex (female): withdrawal group (32%); maintenance group (37%)
• Donor source (% living donor): not reported
• Exclusion criteria: ≥ 2 acute rejections; biopsy-proven acute vascular rejection;
proteinuria > 3 g/d; immunosuppression other than CsA + MMF + steroids
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: adjusted to trough levels: 125 to 175 ng/mL (from 3 months after
transplantation)
• MMF: 1000 mg twice daily
• Steroid:
◦ Prednisone: 0.1 mg/kg/d
◦ Withdrawal group: steroids tapered over 10 weeks and then withdrawn
◦ Maintenance group: no further details provided
Outcomes • Mortality
• Graft loss
• Biopsy-proven acute rejection
• Infection
• CMV infection
• Malignancy
• SCr (mg/dL)
• CrCl (mL/min)
Notes • Number screened for eligibility: 313
• This study had a third arm with CsA withdrawal (63 patients)
• Number of patients discontinued treatment
◦ Withdrawal group: never stopped steroids (1); returned to steroids (4)
• Contact with study authors for additional information: authors contacted 3
September 2013; no response received
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’Patients were randomly assigned to
one of the three treatment groups in a 1:
1:1 ratio, with stratification for cadaveric/
living related transplant, for centre, and for
the number of acute rejections during the
first 6mo after transplantation’ but random
sequence generation not reported
Allocation concealment (selection bias) Low risk Stated ’Randomization was carried out by
opening a sealed envelope with the lowest
available study number’
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all patients fol-
lowed up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias High risk The study was supported by Roche Phar-
maceuticals, Mijdrecht, the Netherlands
Sola 2002
Methods • Study design: parallel RCT
• Time frame: not reported, but before 2002
• Follow-up period: 2 years
• Primary endpoint: acute rejection and kidney function 2 years after steroid
withdrawal
Participants • Country: Spain
• Setting: single centre
• Cadaver kidney transplant; stable kidney function 3 months after transplantation
• number (randomised): withdrawal group (46); maintenance group (46)
• Mean age (± SD): not reported
• Sex (% female): not reported
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• Exclusion criteria: PRA > 50%; previous acute rejection
Interventions Treatment group
• Steroid withdrawal after 3 months
Control group
• Steroid maintenance
Baseline Immunosuppression
• TAC: day 0 to 15: 10 to 15 ng/mL; from day 16: 5 to 10 ng/mL
• MMF: 1 g/d
• Steroids
◦ IV methylprednisone day 0: 500 mg; day 1: 125 mg
◦ Oral prednisone: day 2 to month 2: 20 to 25 mg/d; month 2 to month 3:
tapered to 5 mg/d
Outcomes • Mortality
• Graft loss
• Acute rejection
• NODAT
• SCr (mg/dL)
• CrCl (mL/min)
Notes • Did not report number screened for eligibility or analysed
• 28/120 were not randomised
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of events and number of patients
analysed not reported; unclear if ITT anal-
ysis performed
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Sola 2002 (Continued)
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Stiller 1983
Methods • Study design: parallel RCT
• Time frame: 1982 to 1983
• Follow-up period: not reported
• Primary endpoint: not reported
Participants • Country: Canada
• Setting: multicentre (9 centres)
• First or subsequent cadaveric or living kidney transplant; > 12 years
• Number (randomised): no steroids group (33); maintenance group (36)
• Mean age: no steroids group (35 years); maintenance group (35 years)
• Sex (female): no steroids group (33%); maintenance group (36%)
• Donor source (living donor): no steroids group (18%); maintenance group (36%)
• Exclusion criteria: acute or progressive liver disease; previous generalised or
metastatic malignancy; localised malignancy within the previous year; disease requiring
maintenance steroid
Interventions Treatment group
• No steroids at any time
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: prior to transplantation: 15 mg/kg, thereafter 7.5 mg/kg twice daily adjusted
to trough levels: day 1 to 60: 100 to 300 ng/mL; thereafter: 50 to 200 ng/mL
• Steroids
◦ Maintenance group: prednisone: 1 mg/kg alternate day reduced by 5 mg
every other day to 0.3 mg/kg/d
Outcomes • Mortality
• Graft loss
• Acute rejection
• Infection
• CMV infection
• Malignancy
• SCr (mg/dL)
Notes • Did not report number screened for eligibility or analysed
• Number of patients discontinued treatment
◦ No steroids group: switched to different immunosuppression: AZA +
steroids (6), steroids added (12)
◦ Maintenance group: switched to AZA + steroids (3)
Risk of bias
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Stiller 1983 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’A computer-derived randomised blocks of
varying size was generated and noted in a
series of opaque envelopes held by the re-
search pharmacist at each participating cen-
tre.’
Allocation concealment (selection bias) Low risk Stated ’opaque envelopes’
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether ITT analysis performed
andwhether all patients have been followed
up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias High risk The study was supported by Medical Re-
search Council of Canada; Richard and
Jean Ivey Fund, London, Ontario; San-
doz Ltd, Basel; the Micheal Fung Endow-
ment Fund, London, Ontario; the Uni-
versityHospital Transplant Research Fund,
London, Ontario
THOMAS Study 2002
Methods • Study design: parallel RCT
• Time frame: 1998 to 2000
• Follow-up period: 6 months
• Primary endpoint: not reported
Participants • Country: 11 European countries
• Setting: multicentre (47 centres)
• First or second cadaveric or living kidney transplant; adults
• Number (randomised/analysed): withdrawal group (281/279); maintenance
group (279/277)
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THOMAS Study 2002 (Continued)
• Mean age: withdrawal group (46 years); maintenance group (47 years)
• Sex (female): withdrawal group (33%): maintenance group (38%)
• Donor source (living donor): withdrawal group (8%); maintenance group (8%)
• Exclusion criteria to enter study: previous organ transplant other than kidney
transplantation; loss of a previous kidney transplant due to early acute rejection; PRA
≥ 50%; requirement for immunosuppression besides kidney transplantation; HIV
seropositivity; familial hypercholesterolaemia; malignancy; ongoing infection
• Exclusion criteria to enter steroid withdrawal phase after 3 months: steroid
resistant rejection; graft loss; dose of steroids or MMF modified > 10 consecutive days;
stopped TAC < 1 day; protocol violation during the first 3 months
Interventions Treatment group
• Steroid withdrawal 3 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• TAC: started with 0.2 mg/kg/d divided in two doses adjusted to trough levels day
0 to 14: 10 to 20 ng/mL; thereafter: 5 - 15 ng/mL
• MMF: 1000 mg daily divided in two doses
• Steroids
◦ IV methylprednisone: day 0: 500 mg or less; day 1: 125 mg
◦ Prednisone: day 2 to 14: 20 mg; day 15 to 28: 15 mg; day 29 to 92: 10 mg
◦ Withdrawal group: steroids tapered over 2 weeks and then withdrawn
◦ Maintenance group: steroids maintained with 10 mg
Outcomes • Mortality
• Graft loss
• Acute rejection
• Biopsy-proven acute rejection
• NODAT
• Infection
• CMV infection
• SCr (mg/dL)
Notes • Did not report number screened for eligibility; 446 entered steroid withdrawal
phase (221/225)
• This study had a third arm with MMF withdrawal (278 patients)
• Number of patients excluded from analysis: 2 patients in withdrawal group and 2
patients in maintenance group because they did not undergo transplantation
• Number of patients discontinued study (before the steroid withdrawal phase)
◦ Withdrawal group: steroid resistant acute rejection (11), graft loss (13),
protocol violation (14), other reasons (18); withdrawn from study in the steroid
withdrawal phase because of protocol violation (10), other reasons (11)
◦ Maintenance group: steroid resistant acute rejection (16), graft loss (6),
protocol violation (13), other reasons (14); withdrawn from study in the steroid
withdrawal phase because of protocol violation (6), other reasons (5)
Risk of bias
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THOMAS Study 2002 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’Randomization (1:1:1) was strati-
fied by centre and donor type’ but random
sequence generation not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Stated ’The investigators were blinded with
respect to randomization until the month-
3 visit.’ which is the time before start of
the intervention, but thereafter investiga-
tors were unblinded, thus this is an open-
label study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Stated ’The investigators were blinded with
respect to randomization until the month-
3 visit.’ which is the time before start of
the intervention, but thereafter investiga-
tors were unblinded, thus this is an open-
label study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all patients fol-
lowed-up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias High risk Unclear whether the rather short follow-up
period allows sufficient time for endpoints
to occur
This study was supported by Fujisawa
GmbH, Munich, Germany
Vincenti 2003a
Methods • Study design: parallel RCT
• Time frame: not reported but before 2003
• Follow-up period: 12 months
• Primary endpoint: incidence of biopsy-proven acute rejection episodes within the
first 12 months
Participants • Country: not reported
• Setting: multicentre (5 centres)
• First cadaveric or living kidney transplant; 18 to 70 years
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Vincenti 2003a (Continued)
• Number (randomised/analysed) withdrawal group (40/40); maintenance group
(43/43)
• Mean age ± SD (years): withdrawal group (49 ± 11); maintenance group (49 ± 12)
• Sex (female): withdrawal group (55%); maintenance group (28%)
• Donor source (living donor): withdrawal group (55%); maintenance group (44%)
• Exclusion criteria: previous or multiple organ transplant; non-heart beating
cadaveric donor; PRA > 50%; planned induction with an antilymphocyte preparation;
malignancy within five years; medical conditions likely to affect the safety of the subject
Interventions Treatment group
• Steroid withdrawal day 5 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: day 0 and 4: 20mg
• CsA: started on day 1 with 4 to 5 mg/kg twice daily adjusted to trough levels
week 1 to 2: 150 - 450 ng/mL; week 3 to 12: 150 to 300 ng/mL; thereafter: 150 to 250
ng/mL (for patients with delayed graft function CsA was started with 3 mg/kg twice
daily or delayed for up to 48 h)
• MMF: 2000 mg daily divided in two doses (African-Americans and patients
during delayed graft function received 3000 mg/d)
• Steroids
◦ IV methylprednisone: day 0: 500 mg; day 1: 250 mg; day 2: 125 mg
◦ Withdrawal group: prednisone or methylprednisone: day 3: 60 mg; day 4 or
until CsA levels in target range: 30 mg; then no further steroids (steroid withdrawal
delayed in patients with delayed graft function until SCr < 50% of pretransplant value)
◦ Maintenance group: prednisone: day 3 to 21: tapered to 20 to 30 mg; day 22
to 90: tapered to 5 to 20 mg day 91 to 180: 5 to 10 mg
Outcomes • Mortality
• Graft loss
• Acute rejection
• Biopsy-proven acute rejection
• Infection
• SCr (mg/dL)
Notes • Did not report number screened for eligibility
• Number of patients discontinued treatment: 28% of patients in withdrawal group
were not withdrawn from steroids at 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided
Allocation concealment (selection bias) Unclear risk Not reported
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Vincenti 2003a (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all patients fol-
lowed up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias High risk The study was supported byNovartis Phar-
maceuticals Corporation, East Hanover,
NJ
Woodle 2005
Methods • Study design: parallel RCT
• Time frame: 1999 to 2007
• Follow-up period: 5 years
• Primary endpoint: treatment failure defined as composite of death, graft loss or
acute rejection at 5 years
Participants • Country: USA
• Setting: multicentre (26 centres)
• First or subsequent cadaveric or living kidney transplant; during days 3 to 7
decrease in SCr ≥ 30% from pretransplant value; 18 to 70 years
• Number (randomised/analysed): withdrawal group (197/191); maintenance
group (200/195)
• Mean age (± SD): withdrawal group (47 ± 12); maintenance group (46 ± 13)
• Sex (female): withdrawal group (31%); maintenance group (36%)
• Donor source (living donor): withdrawal group (57%); maintenance group (57%)
• Exclusion criteria: acute rejection within the first 7 days after transplantation;
current PRA ≥ 25%; peak PRA ≥ 50%; cold ischaemia time > 36 hours; multiple
organ transplant; non heart beating donor; paediatric donor; dual kidney transplant;
reasons for loss of previous kidney transplant other than technical reasons or recurrence
of disease with low risk of recurrence; dialysis post-transplant; requirement for
systematic steroids for other disease; HIV seropositivity
Interventions Treatment group
• Steroid withdrawal day 8 after transplantation
Control group
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Woodle 2005 (Continued)
• Steroid maintenance
Baseline immunosuppression
• Antilymphocytic or anti-IL2 antibodies according to centre preference
• TAC: started within 72 hours post-transplant with 0.15 to 0.2 mg/kg divided in
two doses, adjusted to blood levels by day 7 to 90: 10 to 20 ng/mL; thereafter: 5 to 15
ng/mL
• MMF: day 0: 1000 mg; day 1: 2000 mg, day 2 to 14: 3000 mg, thereafter: 2000
mg
• Steroids
◦ IV corticosteroid: day 0: 10 mg/kg (max 500 mg); day 1: 5 mg/kg (max 500
mg); day 2: 3 mg/kg (max 300 mg)
◦ Corticosteroid: day 3: 2 mg/kg (max 200 mg); day 4: 1 mg/kg (max 100 mg)
; day 5: 0.7 mg/kg (max 70 mg); day 6: 0.5 mg/kg (max 50 mg); day 7: 0.4 mg/kg
(max 40 mg)
◦ Withdrawal group: no further steroids
◦ maintenance group: day 8 to 14: 0.4 mg/kg; day 15 to 29: 0.3 mg; day 30 to
89: 0.2 mg/kg; day 90 to 119: 0.15 mg/kg; thereafter: 0.1 mg/kg
Outcomes • Mortality
• Graft loss
• Biopsy-proven acute rejection
• New-onset of diabetes after transplantation
• Infection
• CMV infection
• Malignancy
• Cardiovascular event
• SCr (mg/dL)
• CrCl (mL/min)
Notes • Did not report number screened for eligibility
• Induction treatment
◦ Withdrawal group: thymoglobulin (65%); basiliximab (31%); daclizumab
(3%)
◦ Maintenance group: thymoglobulin (70%); basiliximab (27%); daclizumab
(3%)
• Number of patients excluded from analysis
◦ Withdrawal group: rejection or dialysis within the first 7 days (3),
withdrawal of consent (1), did not meet eligibility criteria (2)
◦ Maintenance group : rejection or dialysis within the first 7 days (2), protocol
violation (1), did not meet eligibility criteria (2)
• Number of patients discontinued treatment
◦ Withdrawal group: 67 patients (35%)
◦ Maintenance group: 73 patients (37%)
• Number of patients discontinued study
◦ Withdrawal group: 25 patients were lost to follow-up or withdrew consent
(13%)
◦ Maintenance group: 31 patients were lost to follow-up or withdrew consent
(16%)
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Woodle 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated ’Randomization was based on a per-
muted block design with block sizes of 6
within each clinical site. Randomization
was performed using a central random-
ization service at the EMMES Corpora-
tion (Potomac,Md,US). Patients were ran-
domised 1:1 stratified by race and donor
type’
Allocation concealment (selection bias) Low risk Stated ’The EMMES Corporation gener-
ated the allocation sequence and main-
tained the allocation code. The random-
ization order did not have a repeating se-
quence, and the randomization code was
not broken or revealed to patients/investi-
gators until subjects completed study’
Blinding (performance bias and detection
bias)
All outcomes
Low risk Stated ’Patients received a blinded study
drug beginning on posttransplant day 8’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated ’Study subjects, investigators, study
personnel, and those assessing outcomes re-
mained blinded throughout 5-year dura-
tion of the study, unless medical necessity
to unblind occurred’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated ’Study subjects, investigators, study
personnel, and those assessing outcomes re-
mained blinded throughout 5-year dura-
tion of the study, unless medical necessity
to unblind occurred’
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed; all patients fol-
lowed up or accounted for
Selective reporting (reporting bias) Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
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Zhu 2008a
Methods • Study design: parallel RCT
• Time frame: 2003 to 2005
• Follow-up period: 2 years
• Primary endpoint: not reported
Participants • Country: China
• Setting: single centre
• Cadaveric kidney transplant
• Number (randomised): 45 total
• Median age (range): 44 (26 to 65) years
• Sex (% female): not reported
• Exclusion criteria: PRA > 10%; multi-organ transplantation; serious infections (e.
g. AIDS); malignancy
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation
Control group
• Steroid maintenance
Baseline Immunosuppression
• TAC: day 0 to 14: adjusted to blood levels between 10 to 20 ng/mL; thereafter: 5
to 15 ng/mL
• MMF: 1.5 to 2.0 g/d
• Steroids
◦ IV methylprednisone: day 0: 500 mg; day 1: 300mg; day 2: 200 mg
◦ Oral prednisone: day 3 to 14: 20 mg/d; day 15 to 28: 15 mg/d
◦ Withdrawal group: day 29 to 92: tapered to 5 mg/d; withdrawn on day 183
◦ Maintenance group: day 29 to study end: 10 mg/d
Outcomes • Mortality
• Acute rejection
• NODAT
• Infection
• SCr (µmol/L)
Notes • Did not report number screened for eligibility or analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated ’randomised’ but no further infor-
mation provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
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Zhu 2008a (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of patients and number of events
per group not reported; unclear whether
ITT analysis was performed. Number of
patients lost to follow up not reported
Selective reporting (reporting bias) High risk Graft loss not reported
Other bias Unclear risk Funding source not reported
It was not reported how many of the par-
ticipants were randomised to either group,
whether the timing of outcome assessment
is similar in all groups, whether the groups
were similar at baseline, whether co-inter-
ventions were avoided or similar
Important information on design and con-
duct of study not reported
ALG - anti-lymphocyte globulin; ATG - anti-thymocyte globulin; AZA - azathioprine; CMV - cytomegalovirus; CNI - calcineurin
inhibitor; CrCl - creatinine clearance; CsA - cyclosporin; EC-MPS - enteric-coated mycophenolate sodium; eGFR - estimated
glomerular filtration rate; EVL - everolimus; GFR - glomerular filtration rate; HBsAG - hepatitis B surface antigen; HCT -
haematocrit; HIV - human immunodeficiency virus; HLA - human leukocyte antigen; HTLV-1 - human T-lymphotropic virus type
1; IL-2RA - interleukin 2 receptor antagonist; ITT - intention-to-treat analysis; IV - intravenous; MMF - mycophenolate mofetil;
NODAT-new-onset diabetes post transplant; PO - oral; PRA - panel reactive antibodies; PTLD -Post-transplant lymphoproliferative
disease; RCT - randomised controlled trial; SCr - serum creatinine; SD - standard deviation; SRL - sirolimus; TAC - tacrolimus;
WCC - white cell count
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alexander 2006 Wrong co-intervention
Anil Kumar 2005 Wrong co-intervention
Axelrod 2005 Not RCT
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(Continued)
Berney 2004 Pancreatic islet transplantation
Birkeland 1998b Not RCT
Birkeland 2002 Pancreatic islet transplantation
Budde 2001 Wrong co-intervention
PLEASE ADD REASON FOR EXCLUSION
CAMPASIA Study 2005 Wrong co-intervention
CARMEN Study 2005 Wrong co-intervention
Citterio 2002 Wrong co-intervention
CORRETA Study 2008 No steroid withdrawal or avoidance
Curtis 1982 No steroid withdrawal or avoidance
Daniel 1985 No steroid withdrawal or avoidance
De Backer 1992 No steroid withdrawal or avoidance
de Sandes Freitas 2011 Wrong co-intervention
Delucchi 2006 Difference in co-intervention
ECSEL Study 2008 Wrong co-intervention
Hibbs 2010 Not RCT
Hilbrands 1993 Not RCT
Hodson 1989 Not RCT
Hricik 1993a Not RCT
Hricik 1993b Not RCT
John 2005 Not RCT
Juarez 2006 Not steroid withdrawal or avoidance
Kim 2004 Wrong co-intervention
Kim 2005 Not RCT
Lehmann 2004 Pancreatic islet transplantation
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(Continued)
Li 2011a Not steroid withdrawal or avoidance
Morris 1982 Not steroid withdrawal or avoidance
MYSS Study 2004 Wrong co-intervention
NCT00089947 Wrong co-intervention
Nori 2008 Wrong co-intervention
Paczek 2003a Wrong co-intervention
Papadakis 1982 Not steroid withdrawal or avoidance
Reed 1991 Wrong co-intervention
Remport 2001 Not steroid withdrawal or avoidance
Robertson 1980 Not RCT
Sarwal 2012 Wrong co-intervention
SENIOR Study 2009 Wrong co-intervention
Shapiro 1993 Wrong co-intervention
Silverstein 2005 Not RCT
SOCRATES Study 2014 Not steroid withdrawal or avoidance
Tarantino 1991 Wrong co-intervention
Teplan 2003 Not RCT
ter Meulen 2002 Wrong co-intervention
TRIMS Study 2010 Wrong co-intervention
TWIST Study 2010 Wrong co-intervention
Weimert 2008 Wrong co-intervention
RCT - randomised controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
Newstead 1989
Methods Unclear if this was a RCT
Participants Kidney transplant recipients not further specified, unclear time frame, but before 1989
Interventions Steroid withdrawal versus steroid maintenance plus CsA
Outcomes Serum creatinine and acute rejection
Notes Abstract-only data; unable to contact authors
CsA - cyclosporin; RCT - randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Steroid withdrawal versus steroid maintenance
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death and graft loss 15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death up to one year 10 1913 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.36, 1.30]
1.2 Death one to five years 7 1118 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.73, 2.17]
1.3 Graft loss including death
up to one year
8 1817 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.64, 1.49]
1.4 Graft loss including death
one to five years
7 1092 Risk Ratio (M-H, Random, 95% CI) 1.41 [1.00, 2.01]
1.5 Graft loss excluding death
up to one year
8 1817 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.72, 1.92]
1.6 Graft loss excluding death
one to five years
7 1092 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.98, 2.64]
2 Rejection 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Acute rejection up to one
year
10 1913 Risk Ratio (M-H, Random, 95% CI) 1.77 [1.20, 2.61]
2.2 Biopsy-proven acute
rejection up to one year
5 1292 Risk Ratio (M-H, Random, 95% CI) 1.32 [0.78, 2.22]
3 New-onset diabetes after
transplantation and
cardiovascular events
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 New onset diabetes after
transplantation up to five years
6 1439 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.49, 1.21]
3.2 Cardiovascular events up
to five years
2 607 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.42, 2.33]
4 Infection and malignancy 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Infection (all) up to five
years
5 1819 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.84, 1.22]
4.2 CMV infection up to five
years
5 1758 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.80, 1.36]
4.3 Malignancy up to five
years
3 756 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.41, 1.46]
5 Kidney function 8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Serum creatinine (mg/dL)
up to one year
4 644 Std. Mean Difference (IV, Random, 95% CI) -0.04 [-0.21, 0.13]
5.2 Serum creatinine (mg/dL)
one to five years
5 762 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.06, 0.23]
5.3 Creatinine clearance
(mL/min) up to one year
2 215 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.35, 0.21]
5.4 Creatinine clearance
(mL/min) one to five years
3 669 Std. Mean Difference (IV, Random, 95% CI) -0.21 [-0.56, 0.13]
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Comparison 2. Steroid avoidance versus steroid maintenance
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death and graft loss 13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death up to one year 10 1462 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.52, 1.80]
1.2 Death one to five years 7 1201 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.32, 1.01]
1.3 Graft loss including death
up to one year
7 1211 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.72, 1.62]
1.4 Graft loss including death
one to five years
7 1245 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.53, 1.18]
1.5 Graft loss excluding death
up to one year
7 1211 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.64, 1.86]
1.6 Graft loss excluding death
one to five years
7 1245 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.66, 1.45]
2 Rejection 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Acute rejection up to one
year
7 835 Risk Ratio (M-H, Random, 95% CI) 1.58 [1.08, 2.30]
2.2 Biopsy-proven acute
rejection up to one year
6 1073 Risk Ratio (M-H, Random, 95% CI) 1.94 [1.26, 2.98]
3 New-onset diabetes after
transplantation and
cardiovascular events
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 New onset diabetes after
transplantation up to five years
9 1618 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.51, 1.10]
3.2 Cardiovascular events up
to five years
4 1013 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.30, 1.05]
4 Infection and malignancy 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Infection (all) up to five
years
9 1833 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.84, 1.03]
4.2 CMV Infection up to five
years
6 1454 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.70, 1.31]
4.3 Malignancy up to five
years
7 1635 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.61, 1.52]
5 Kidney function 10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Serum creatinine (mg/dL)
up to one year
5 735 Std. Mean Difference (IV, Random, 95% CI) 0.02 [-0.12, 0.17]
5.2 Serum creatinine (mg/dL)
one to five years
3 688 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.16, 0.14]
5.3 Creatinine clearance
(mL/min) up to one year
6 1104 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.23, 0.08]
5.4 Creatinine clearance
(mL/min) one to five years
3 563 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.25, 0.08]
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Comparison 3. Steroid avoidance versus steroid withdrawal
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death and graft loss 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death up to one year 1 222 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.08, 1.98]
1.2 Death one to five years 2 152 Risk Ratio (M-H, Random, 95% CI) 2.67 [0.63, 11.32]
1.3 Graft loss including death
up to one year
1 222 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.32, 2.29]
1.4 Graft loss including death
one to five years
2 152 Risk Ratio (M-H, Random, 95% CI) 2.44 [0.89, 6.70]
1.5 Graft loss excluding death
up to one year
1 222 Risk Ratio (M-H, Random, 95% CI) 1.64 [0.40, 6.68]
1.6 Graft loss excluding death
one to five years
2 152 Risk Ratio (M-H, Random, 95% CI) 1.91 [0.48, 7.67]
2 Rejection 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Acute rejection up to one
year
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Biopsy-proven acute
rejection up to one year
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 New-onset diabetes after
transplantation, infection,
malignancy
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 New onset diabetes after
transplantation up to five years
3 351 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.36, 1.09]
3.2 Infection (all) up to five
years
3 374 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.76, 1.50]
3.3 CMV Infection up to five
years
2 284 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.30, 0.92]
3.4 Malignancy up to five
years
1 90 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.28, 8.94]
4 Kidney function 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Serum creatinine (mg/dL)
up to one year
2 88 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.47, 0.37]
4.2 Creatinine clearance
(mL/min) up to one year
2 206 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.41, 0.14]
Comparison 4. Steroid withdrawal versus maintenance in children
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death and graft loss 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death up to five years 2 174 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.02, 1.35]
1.2 Graft loss including death
up to five years
2 174 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.01, 0.69]
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1.3 Graft loss excluding death
up to five years
2 174 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.00, 1.64]
2 Rejection, malignancy 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Acute rejection up to one
year
2 174 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.13, 1.02]
2.2 Biopsy-proven acute
rejection up to one year
1 42 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.01, 3.27]
2.3 Malignancy (PTLD) up
to five years
1 132 Risk Ratio (M-H, Random, 95% CI) 1.89 [0.51, 6.98]
3 Kidney function 1 Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Creatinine clearance
(mL/min) up to five years
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Publication bias
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Funnel plots 20 5288 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [1.15, 1.62]
1.1 Death, steroid withdrawal
versus maintenance
10 1913 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.39, 1.29]
1.2 Acute rejection steroid
withdrawal versus maintenance
10 1913 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [1.28, 1.87]
1.3 Death, steroid avoidance
versus maintenance
10 1462 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.52, 1.63]
133Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 1 Death and graft
loss.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 1 Steroid withdrawal versus steroid maintenance
Outcome: 1 Death and graft loss
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Death up to one year
Ahsan 1999 0/134 1/132 4.0 % 0.33 [ 0.01, 7.99 ]
Bouma 1996 0/42 1/42 4.1 % 0.33 [ 0.01, 7.96 ]
del Castillo 2005 1/70 0/72 4.1 % 3.08 [ 0.13, 74.46 ]
Isoniemi 1990 3/32 4/32 20.5 % 0.75 [ 0.18, 3.09 ]
Lebranchu 1999 4/252 8/248 29.1 % 0.49 [ 0.15, 1.61 ]
Maiorca 1988 0/35 1/31 4.1 % 0.30 [ 0.01, 7.02 ]
Matl 2000 1/45 0/42 4.1 % 2.80 [ 0.12, 67.00 ]
Pelletier 2006 1/59 0/59 4.1 % 3.00 [ 0.12, 72.18 ]
Pisani 2001 1/15 0/15 4.2 % 3.00 [ 0.13, 68.26 ]
THOMAS Study 2002 3/279 6/277 21.7 % 0.50 [ 0.13, 1.97 ]
Subtotal (95% CI) 963 950 100.0 % 0.68 [ 0.36, 1.30 ]
Total events: 14 (Withdrawal), 21 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.51, df = 9 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
2 Death one to five years
Boletis 2001 0/36 0/36 Not estimable
Gulanikar 1991 14/260 12/263 52.4 % 1.18 [ 0.56, 2.50 ]
Isoniemi 1990 5/32 5/32 22.8 % 1.00 [ 0.32, 3.12 ]
Pelletier 2006 5/59 2/59 11.6 % 2.50 [ 0.50, 12.38 ]
Ratcliffe 1993 2/49 1/51 5.3 % 2.08 [ 0.19, 22.23 ]
Smak Gregoor 1999 2/76 2/73 7.9 % 0.96 [ 0.14, 6.64 ]
Sola 2002 0/46 0/46 Not estimable
Subtotal (95% CI) 558 560 100.0 % 1.26 [ 0.73, 2.17 ]
Total events: 28 (Withdrawal), 22 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 4 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
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(. . . Continued)
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Graft loss including death up to one year
Ahsan 1999 2/134 3/132 5.8 % 0.66 [ 0.11, 3.87 ]
Bouma 1996 1/42 1/42 2.4 % 1.00 [ 0.06, 15.47 ]
del Castillo 2005 5/70 5/72 12.8 % 1.03 [ 0.31, 3.40 ]
Isoniemi 1990 3/32 6/32 10.8 % 0.50 [ 0.14, 1.83 ]
Lebranchu 1999 14/252 18/248 39.9 % 0.77 [ 0.39, 1.50 ]
Matl 2000 1/45 1/42 2.4 % 0.93 [ 0.06, 14.45 ]
Pelletier 2006 1/59 1/59 2.4 % 1.00 [ 0.06, 15.61 ]
THOMAS Study 2002 15/279 7/277 23.4 % 2.13 [ 0.88, 5.14 ]
Subtotal (95% CI) 913 904 100.0 % 0.97 [ 0.64, 1.49 ]
Total events: 42 (Withdrawal), 42 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.73, df = 7 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
4 Graft loss including death one to five years
Boletis 2001 0/36 0/36 Not estimable
Gulanikar 1991 45/260 29/263 65.0 % 1.57 [ 1.02, 2.42 ]
Isoniemi 1990 7/32 8/32 15.5 % 0.88 [ 0.36, 2.13 ]
Maiorca 1988 2/35 1/31 2.2 % 1.77 [ 0.17, 18.60 ]
Pelletier 2006 8/59 4/59 9.3 % 2.00 [ 0.64, 6.28 ]
Ratcliffe 1993 2/49 1/51 2.2 % 2.08 [ 0.19, 22.23 ]
Smak Gregoor 1999 3/76 4/73 5.7 % 0.72 [ 0.17, 3.11 ]
Subtotal (95% CI) 547 545 100.0 % 1.41 [ 1.00, 2.01 ]
Total events: 67 (Withdrawal), 47 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.65, df = 5 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.052)
5 Graft loss excluding death up to one year
Ahsan 1999 2/134 2/132 6.4 % 0.99 [ 0.14, 6.89 ]
Bouma 1996 1/42 0/42 2.4 % 3.00 [ 0.13, 71.61 ]
del Castillo 2005 4/70 5/72 14.9 % 0.82 [ 0.23, 2.94 ]
Isoniemi 1990 0/32 2/32 2.7 % 0.20 [ 0.01, 4.01 ]
Lebranchu 1999 12/252 11/248 37.8 % 1.07 [ 0.48, 2.39 ]
Matl 2000 0/45 1/42 2.4 % 0.31 [ 0.01, 7.44 ]
Pelletier 2006 0/59 1/59 2.4 % 0.33 [ 0.01, 8.02 ]
THOMAS Study 2002 15/279 7/277 31.1 % 2.13 [ 0.88, 5.14 ]
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Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 913 904 100.0 % 1.17 [ 0.72, 1.92 ]
Total events: 34 (Withdrawal), 29 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.08, df = 7 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
6 Graft loss excluding death one to five years
Boletis 2001 0/36 0/36 Not estimable
Gulanikar 1991 31/260 17/263 76.6 % 1.84 [ 1.05, 3.25 ]
Isoniemi 1990 2/32 3/32 8.3 % 0.67 [ 0.12, 3.73 ]
Maiorca 1988 2/35 0/31 2.7 % 4.44 [ 0.22, 89.16 ]
Pelletier 2006 3/59 2/59 8.0 % 1.50 [ 0.26, 8.65 ]
Ratcliffe 1993 0/49 0/51 Not estimable
Smak Gregoor 1999 1/76 2/73 4.3 % 0.48 [ 0.04, 5.18 ]
Subtotal (95% CI) 547 545 100.0 % 1.61 [ 0.98, 2.64 ]
Total events: 39 (Withdrawal), 24 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.67, df = 4 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Chi2 = 6.11, df = 5 (P = 0.30), I2 =18%
0.005 0.1 1 10 200
Favours withdrawal Favours maintenance
136Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 2 Rejection.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 1 Steroid withdrawal versus steroid maintenance
Outcome: 2 Rejection
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acute rejection up to one year
Ahsan 1999 26/134 7/132 12.5 % 3.66 [ 1.65, 8.14 ]
Bouma 1996 11/42 1/42 3.3 % 11.00 [ 1.49, 81.44 ]
del Castillo 2005 17/70 13/72 15.4 % 1.35 [ 0.71, 2.56 ]
Isoniemi 1990 6/32 1/32 3.1 % 6.00 [ 0.77, 47.05 ]
Lebranchu 1999 76/252 52/248 22.8 % 1.44 [ 1.06, 1.95 ]
Maiorca 1988 16/35 3/31 8.1 % 4.72 [ 1.52, 14.69 ]
Matl 2000 3/45 2/42 4.2 % 1.40 [ 0.25, 7.97 ]
Pelletier 2006 3/59 3/59 5.0 % 1.00 [ 0.21, 4.75 ]
Pisani 2001 1/15 2/15 2.6 % 0.50 [ 0.05, 4.94 ]
THOMAS Study 2002 67/279 60/277 22.8 % 1.11 [ 0.82, 1.51 ]
Subtotal (95% CI) 963 950 100.0 % 1.77 [ 1.20, 2.61 ]
Total events: 226 (Withdrawal), 144 (Maintenance)
Heterogeneity: Tau2 = 0.15; Chi2 = 19.74, df = 9 (P = 0.02); I2 =54%
Test for overall effect: Z = 2.89 (P = 0.0039)
2 Biopsy-proven acute rejection up to one year
Bouma 1996 9/42 1/42 5.7 % 9.00 [ 1.19, 67.93 ]
del Castillo 2005 16/70 12/72 23.7 % 1.37 [ 0.70, 2.69 ]
Farmer 2006 1/6 2/4 5.6 % 0.33 [ 0.04, 2.56 ]
Lebranchu 1999 63/252 36/248 32.7 % 1.72 [ 1.19, 2.49 ]
THOMAS Study 2002 42/279 47/277 32.3 % 0.89 [ 0.61, 1.30 ]
Subtotal (95% CI) 649 643 100.0 % 1.32 [ 0.78, 2.22 ]
Total events: 131 (Withdrawal), 98 (Maintenance)
Heterogeneity: Tau2 = 0.18; Chi2 = 11.38, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 0.79, df = 1 (P = 0.37), I2 =0.0%
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Analysis 1.3. Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 3 New-onset
diabetes after transplantation and cardiovascular events.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 1 Steroid withdrawal versus steroid maintenance
Outcome: 3 New-onset diabetes after transplantation and cardiovascular events
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 New onset diabetes after transplantation up to five years
Bouma 1996 8/42 6/42 22.0 % 1.33 [ 0.51, 3.51 ]
Gulanikar 1991 9/260 15/263 31.6 % 0.61 [ 0.27, 1.36 ]
Maiorca 1988 0/35 0/31 Not estimable
Pelletier 2006 4/59 6/59 14.0 % 0.67 [ 0.20, 2.24 ]
Sola 2002 2/46 2/46 5.6 % 1.00 [ 0.15, 6.80 ]
THOMAS Study 2002 8/279 12/277 26.7 % 0.66 [ 0.27, 1.59 ]
Subtotal (95% CI) 721 718 100.0 % 0.77 [ 0.49, 1.21 ]
Total events: 31 (Withdrawal), 41 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.81, df = 4 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
2 Cardiovascular events up to five years
Bouma 1996 4/42 6/42 52.6 % 0.67 [ 0.20, 2.19 ]
Gulanikar 1991 6/260 4/263 47.4 % 1.52 [ 0.43, 5.31 ]
Subtotal (95% CI) 302 305 100.0 % 0.98 [ 0.42, 2.33 ]
Total events: 10 (Withdrawal), 10 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.62), I2 =0.0%
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Analysis 1.4. Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 4 Infection and
malignancy.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 1 Steroid withdrawal versus steroid maintenance
Outcome: 4 Infection and malignancy
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Infection (all) up to five years
Ahsan 1999 49/134 42/132 21.0 % 1.15 [ 0.82, 1.61 ]
Bouma 1996 13/42 20/42 9.6 % 0.65 [ 0.37, 1.13 ]
Gulanikar 1991 106/260 110/263 37.1 % 0.97 [ 0.79, 1.20 ]
Lebranchu 1999 18/252 22/248 8.3 % 0.81 [ 0.44, 1.46 ]
THOMAS Study 2002 68/221 55/225 24.0 % 1.26 [ 0.93, 1.70 ]
Subtotal (95% CI) 909 910 100.0 % 1.02 [ 0.84, 1.22 ]
Total events: 254 (Withdrawal), 249 (Maintenance)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.69, df = 4 (P = 0.22); I2 =30%
Test for overall effect: Z = 0.17 (P = 0.87)
2 CMV infection up to five years
Gulanikar 1991 10/260 13/263 11.1 % 0.78 [ 0.35, 1.74 ]
Lebranchu 1999 55/252 54/248 65.3 % 1.00 [ 0.72, 1.40 ]
Pisani 2001 3/15 1/15 1.6 % 3.00 [ 0.35, 25.68 ]
Smak Gregoor 1999 1/76 2/73 1.3 % 0.48 [ 0.04, 5.18 ]
THOMAS Study 2002 24/279 18/277 20.8 % 1.32 [ 0.74, 2.38 ]
Subtotal (95% CI) 882 876 100.0 % 1.04 [ 0.80, 1.36 ]
Total events: 93 (Withdrawal), 88 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.53, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
3 Malignancy up to five years
Bouma 1996 3/42 6/42 23.4 % 0.50 [ 0.13, 1.87 ]
Gulanikar 1991 12/260 13/263 69.4 % 0.93 [ 0.43, 2.01 ]
Smak Gregoor 1999 1/76 2/73 7.2 % 0.48 [ 0.04, 5.18 ]
Subtotal (95% CI) 378 378 100.0 % 0.77 [ 0.41, 1.46 ]
Total events: 16 (Withdrawal), 21 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.81, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.75, df = 2 (P = 0.69), I2 =0.0%
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Analysis 1.5. Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 5 Kidney function.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 1 Steroid withdrawal versus steroid maintenance
Outcome: 5 Kidney function
Study or subgroup Withdrawal Maintenance
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Serum creatinine (mg/dL) up to one year
del Castillo 2005 65 1.7 (0.8) 67 1.6 (0.5) 22.0 % 0.15 [ -0.19, 0.49 ]
Isoniemi 1990 28 1.6 (0.7) 26 1.5 (0.6) 9.6 % 0.15 [ -0.38, 0.69 ]
Lebranchu 1999 162 1.5 (0.5) 180 1.6 (0.6) 48.8 % -0.18 [ -0.39, 0.03 ]
Pelletier 2006 57 1.6 (0.5) 59 1.6 (0.5) 19.6 % 0.0 [ -0.36, 0.36 ]
Subtotal (95% CI) 312 332 100.0 % -0.04 [ -0.21, 0.13 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.35, df = 3 (P = 0.34); I2 =11%
Test for overall effect: Z = 0.47 (P = 0.64)
2 Serum creatinine (mg/dL) one to five years
Burke 2000 14 1.7 (0.5) 15 1.5 (0.5) 3.7 % 0.39 [ -0.35, 1.13 ]
Gulanikar 1991 260 2 (0.82) 263 2 (0.83) 68.9 % 0.0 [ -0.17, 0.17 ]
Isoniemi 1990 25 1.5 (0.5) 24 1.4 (0.5) 6.4 % 0.20 [ -0.36, 0.76 ]
Pelletier 2006 35 1.9 (0.5) 29 1.7 (0.6) 8.2 % 0.36 [ -0.14, 0.86 ]
Ratcliffe 1993 47 1.7 (0.5) 50 1.6 (0.4) 12.7 % 0.22 [ -0.18, 0.62 ]
Subtotal (95% CI) 381 381 100.0 % 0.08 [ -0.06, 0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.38, df = 4 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
3 Creatinine clearance (mL/min) up to one year
Bouma 1996 42 66 (33) 41 63 (20) 39.7 % 0.11 [ -0.32, 0.54 ]
del Castillo 2005 65 59.1 (21.3) 67 62.9 (19.4) 60.3 % -0.19 [ -0.53, 0.16 ]
Subtotal (95% CI) 107 108 100.0 % -0.07 [ -0.35, 0.21 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.10, df = 1 (P = 0.29); I2 =9%
Test for overall effect: Z = 0.48 (P = 0.63)
4 Creatinine clearance (mL/min) one to five years
Gulanikar 1991 260 54.5 (30.44) 263 54.6 (29.78) 47.2 % 0.00 [ -0.17, 0.17 ]
Isoniemi 1990 25 57 (20) 24 62 (19) 22.0 % -0.25 [ -0.81, 0.31 ]
Ratcliffe 1993 47 47 (17) 50 56 (18) 30.7 % -0.51 [ -0.91, -0.10 ]
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(. . . Continued)
Study or subgroup Withdrawal Maintenance
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 332 337 100.0 % -0.21 [ -0.56, 0.13 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 5.43, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Chi2 = 3.29, df = 3 (P = 0.35), I2 =9%
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Analysis 2.1. Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 1 Death and graft loss.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 2 Steroid avoidance versus steroid maintenance
Outcome: 1 Death and graft loss
Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Death up to one year
ATLAS Study 2005 3/151 0/147 4.4 % 6.82 [ 0.36, 130.81 ]
De Vecchi 1986 0/25 4/26 4.7 % 0.12 [ 0.01, 2.04 ]
FRANCIA Study 2007 1/98 3/103 7.7 % 0.35 [ 0.04, 3.31 ]
FREEDOM Study 2008 7/226 2/109 16.0 % 1.69 [ 0.36, 7.99 ]
Kumar 2005 0/45 0/32 Not estimable
Montagnino 2005 0/65 1/68 3.8 % 0.35 [ 0.01, 8.40 ]
Nematalla 2007 0/50 0/50 Not estimable
Nott 1985 8/59 8/58 46.6 % 0.98 [ 0.40, 2.44 ]
Schulak 1989 3/32 2/35 13.0 % 1.64 [ 0.29, 9.20 ]
Vincenti 2003a 0/40 1/43 3.8 % 0.36 [ 0.01, 8.54 ]
Subtotal (95% CI) 791 671 100.0 % 0.96 [ 0.52, 1.80 ]
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Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 22 (Avoidance), 21 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.22, df = 7 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
2 Death one to five years
ATLAS Study 2005 3/139 5/139 16.2 % 0.60 [ 0.15, 2.46 ]
De Vecchi 1986 0/25 5/26 4.0 % 0.09 [ 0.01, 1.62 ]
Kim 2002 0/11 1/12 3.3 % 0.36 [ 0.02, 8.04 ]
Montagnino 2005 0/65 2/68 3.5 % 0.21 [ 0.01, 4.27 ]
Nematalla 2007 0/49 0/49 Not estimable
Ponticelli 1997 3/115 9/117 19.6 % 0.34 [ 0.09, 1.22 ]
Woodle 2005 11/191 13/195 53.3 % 0.86 [ 0.40, 1.88 ]
Subtotal (95% CI) 595 606 100.0 % 0.57 [ 0.32, 1.01 ]
Total events: 17 (Avoidance), 35 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.90, df = 5 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
3 Graft loss including death up to one year
ATLAS Study 2005 9/151 6/147 16.3 % 1.46 [ 0.53, 4.00 ]
FRANCIA Study 2007 5/98 7/103 13.3 % 0.75 [ 0.25, 2.29 ]
FREEDOM Study 2008 13/226 5/109 16.4 % 1.25 [ 0.46, 3.43 ]
Kumar 2005 2/45 1/32 3.0 % 1.42 [ 0.13, 15.02 ]
Nematalla 2007 0/50 0/50 Not estimable
Nott 1985 17/59 16/58 49.4 % 1.04 [ 0.59, 1.86 ]
Vincenti 2003a 0/40 1/43 1.6 % 0.36 [ 0.01, 8.54 ]
Subtotal (95% CI) 669 542 100.0 % 1.08 [ 0.72, 1.62 ]
Total events: 46 (Avoidance), 36 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.37, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
4 Graft loss including death one to five years
ATLAS Study 2005 11/139 15/139 18.9 % 0.73 [ 0.35, 1.54 ]
De Vecchi 1986 1/25 7/26 3.7 % 0.15 [ 0.02, 1.12 ]
Montagnino 2005 3/65 10/68 8.7 % 0.31 [ 0.09, 1.09 ]
Nematalla 2007 0/49 0/49 Not estimable
Ponticelli 1997 18/115 24/117 26.5 % 0.76 [ 0.44, 1.33 ]
Schulak 1989 9/32 8/35 16.5 % 1.23 [ 0.54, 2.80 ]
Woodle 2005 22/191 20/195 25.7 % 1.12 [ 0.63, 1.99 ]
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Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 616 629 100.0 % 0.79 [ 0.53, 1.18 ]
Total events: 64 (Avoidance), 84 (Maintenance)
Heterogeneity: Tau2 = 0.08; Chi2 = 7.39, df = 5 (P = 0.19); I2 =32%
Test for overall effect: Z = 1.16 (P = 0.25)
5 Graft loss excluding death up to one year
ATLAS Study 2005 7/151 6/147 24.6 % 1.14 [ 0.39, 3.30 ]
FRANCIA Study 2007 5/98 5/103 19.2 % 1.05 [ 0.31, 3.52 ]
FREEDOM Study 2008 6/226 3/109 15.0 % 0.96 [ 0.25, 3.78 ]
Kumar 2005 2/45 1/32 5.0 % 1.42 [ 0.13, 15.02 ]
Nematalla 2007 0/50 0/50 Not estimable
Nott 1985 9/59 8/58 36.1 % 1.11 [ 0.46, 2.67 ]
Vincenti 2003a 0/40 0/43 Not estimable
Subtotal (95% CI) 669 542 100.0 % 1.09 [ 0.64, 1.86 ]
Total events: 29 (Avoidance), 23 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 4 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
6 Graft loss excluding death one to five years
ATLAS Study 2005 9/139 10/139 20.4 % 0.90 [ 0.38, 2.15 ]
De Vecchi 1986 1/25 2/26 2.8 % 0.52 [ 0.05, 5.38 ]
Montagnino 2005 3/65 8/68 9.4 % 0.39 [ 0.11, 1.41 ]
Nematalla 2007 0/49 0/49 Not estimable
Ponticelli 1997 15/115 15/117 34.6 % 1.02 [ 0.52, 1.98 ]
Schulak 1989 6/32 6/35 14.7 % 1.09 [ 0.39, 3.05 ]
Woodle 2005 11/191 7/195 18.0 % 1.60 [ 0.64, 4.05 ]
Subtotal (95% CI) 616 629 100.0 % 0.98 [ 0.66, 1.45 ]
Total events: 45 (Avoidance), 48 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.42, df = 5 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Chi2 = 4.33, df = 5 (P = 0.50), I2 =0.0%
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Analysis 2.2. Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 2 Rejection.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 2 Steroid avoidance versus steroid maintenance
Outcome: 2 Rejection
Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acute rejection up to one year
ATLAS Study 2005 60/151 19/147 18.8 % 3.07 [ 1.93, 4.89 ]
De Vecchi 1986 19/25 13/26 19.2 % 1.52 [ 0.98, 2.37 ]
FRANCIA Study 2007 25/98 13/99 15.5 % 1.94 [ 1.06, 3.57 ]
Kumar 2005 7/45 4/32 7.6 % 1.24 [ 0.40, 3.90 ]
Laftavi 2005 4/32 3/28 5.6 % 1.17 [ 0.29, 4.77 ]
Stiller 1983 25/33 24/36 22.5 % 1.14 [ 0.84, 1.54 ]
Vincenti 2003a 8/40 8/43 10.7 % 1.08 [ 0.45, 2.59 ]
Subtotal (95% CI) 424 411 100.0 % 1.58 [ 1.08, 2.30 ]
Total events: 148 (Avoidance), 84 (Maintenance)
Heterogeneity: Tau2 = 0.14; Chi2 = 16.23, df = 6 (P = 0.01); I2 =63%
Test for overall effect: Z = 2.39 (P = 0.017)
2 Biopsy-proven acute rejection up to one year
ATLAS Study 2005 48/151 12/147 22.5 % 3.89 [ 2.16, 7.03 ]
FRANCIA Study 2007 17/98 7/99 15.8 % 2.45 [ 1.06, 5.65 ]
FREEDOM Study 2008 65/226 16/109 25.7 % 1.96 [ 1.19, 3.22 ]
Laftavi 2005 4/32 3/28 7.5 % 1.17 [ 0.29, 4.77 ]
Nematalla 2007 8/50 8/50 14.4 % 1.00 [ 0.41, 2.46 ]
Vincenti 2003a 8/40 7/43 14.0 % 1.23 [ 0.49, 3.08 ]
Subtotal (95% CI) 597 476 100.0 % 1.94 [ 1.26, 2.98 ]
Total events: 150 (Avoidance), 53 (Maintenance)
Heterogeneity: Tau2 = 0.12; Chi2 = 9.08, df = 5 (P = 0.11); I2 =45%
Test for overall effect: Z = 3.01 (P = 0.0026)
Test for subgroup differences: Chi2 = 0.50, df = 1 (P = 0.48), I2 =0.0%
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Analysis 2.3. Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 3 New-onset diabetes
after transplantation and cardiovascular events.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 2 Steroid avoidance versus steroid maintenance
Outcome: 3 New-onset diabetes after transplantation and cardiovascular events
Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 New onset diabetes after transplantation up to five years
ATLAS Study 2005 6/127 4/126 8.1 % 1.49 [ 0.43, 5.15 ]
FRANCIA Study 2007 6/98 15/103 13.3 % 0.42 [ 0.17, 1.04 ]
FREEDOM Study 2008 19/227 16/109 21.6 % 0.57 [ 0.31, 1.06 ]
Kumar 2005 0/30 3/23 1.7 % 0.11 [ 0.01, 2.04 ]
Montagnino 2005 6/65 4/68 8.4 % 1.57 [ 0.46, 5.31 ]
Nematalla 2007 2/50 8/50 5.9 % 0.25 [ 0.06, 1.12 ]
Nott 1985 1/59 2/58 2.5 % 0.49 [ 0.05, 5.27 ]
Ponticelli 1997 9/115 9/117 13.7 % 1.02 [ 0.42, 2.47 ]
Woodle 2005 23/107 18/86 24.8 % 1.03 [ 0.59, 1.78 ]
Subtotal (95% CI) 878 740 100.0 % 0.75 [ 0.51, 1.10 ]
Total events: 72 (Avoidance), 79 (Maintenance)
Heterogeneity: Tau2 = 0.08; Chi2 = 10.51, df = 8 (P = 0.23); I2 =24%
Test for overall effect: Z = 1.49 (P = 0.14)
2 Cardiovascular events up to five years
ATLAS Study 2005 6/139 4/139 20.3 % 1.50 [ 0.43, 5.20 ]
Nott 1985 3/59 4/58 15.7 % 0.74 [ 0.17, 3.15 ]
Ponticelli 1997 6/115 18/117 33.1 % 0.34 [ 0.14, 0.82 ]
Woodle 2005 6/191 14/195 30.9 % 0.44 [ 0.17, 1.11 ]
Subtotal (95% CI) 504 509 100.0 % 0.56 [ 0.30, 1.05 ]
Total events: 21 (Avoidance), 40 (Maintenance)
Heterogeneity: Tau2 = 0.11; Chi2 = 4.02, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 1.81 (P = 0.071)
Test for subgroup differences: Chi2 = 0.57, df = 1 (P = 0.45), I2 =0.0%
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Analysis 2.4. Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 4 Infection and
malignancy.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 2 Steroid avoidance versus steroid maintenance
Outcome: 4 Infection and malignancy
Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Infection (all) up to five years
ATLAS Study 2005 30/139 26/139 4.4 % 1.15 [ 0.72, 1.85 ]
FRANCIA Study 2007 66/98 75/103 29.5 % 0.92 [ 0.77, 1.11 ]
FREEDOM Study 2008 144/227 71/109 34.0 % 0.97 [ 0.82, 1.15 ]
Montagnino 2005 9/65 13/68 1.6 % 0.72 [ 0.33, 1.58 ]
Nott 1985 5/59 15/58 1.1 % 0.33 [ 0.13, 0.84 ]
Ponticelli 1997 39/115 47/117 8.5 % 0.84 [ 0.60, 1.18 ]
Schulak 1989 8/32 7/35 1.2 % 1.25 [ 0.51, 3.06 ]
Vincenti 2003a 13/40 12/43 2.3 % 1.16 [ 0.60, 2.24 ]
Woodle 2005 75/191 86/195 17.3 % 0.89 [ 0.70, 1.13 ]
Subtotal (95% CI) 966 867 100.0 % 0.93 [ 0.84, 1.03 ]
Total events: 389 (Avoidance), 352 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.57, df = 8 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
2 CMV Infection up to five years
ATLAS Study 2005 25/151 17/147 29.5 % 1.43 [ 0.81, 2.54 ]
FRANCIA Study 2007 16/98 20/103 27.2 % 0.84 [ 0.46, 1.53 ]
FREEDOM Study 2008 20/227 9/109 17.1 % 1.07 [ 0.50, 2.27 ]
Montagnino 2005 1/65 2/68 1.7 % 0.52 [ 0.05, 5.63 ]
Nematalla 2007 1/50 3/50 1.9 % 0.33 [ 0.04, 3.10 ]
Woodle 2005 14/191 20/195 22.7 % 0.71 [ 0.37, 1.37 ]
Subtotal (95% CI) 782 672 100.0 % 0.96 [ 0.70, 1.31 ]
Total events: 77 (Avoidance), 71 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.04, df = 5 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
3 Malignancy up to five years
ATLAS Study 2005 4/139 6/139 13.2 % 0.67 [ 0.19, 2.31 ]
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Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FRANCIA Study 2007 0/98 5/103 2.5 % 0.10 [ 0.01, 1.70 ]
FREEDOM Study 2008 3/227 1/109 4.0 % 1.44 [ 0.15, 13.69 ]
Montagnino 2005 4/65 2/68 7.4 % 2.09 [ 0.40, 11.04 ]
Ponticelli 1997 5/115 3/117 10.3 % 1.70 [ 0.41, 6.93 ]
Stiller 1983 0/33 0/36 Not estimable
Woodle 2005 20/191 22/195 62.6 % 0.93 [ 0.52, 1.64 ]
Subtotal (95% CI) 868 767 100.0 % 0.97 [ 0.61, 1.52 ]
Total events: 36 (Avoidance), 39 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.47, df = 5 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Chi2 = 0.06, df = 2 (P = 0.97), I2 =0.0%
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Analysis 2.5. Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 5 Kidney function.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 2 Steroid avoidance versus steroid maintenance
Outcome: 5 Kidney function
Study or subgroup Avoidance Maintenance
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Serum creatinine (mg/dL) up to one year
ATLAS Study 2005 151 1.63 (0.93) 147 1.52 (0.81) 40.6 % 0.13 [ -0.10, 0.35 ]
FRANCIA Study 2007 98 1.8 (1.4) 99 1.9 (1.5) 26.9 % -0.07 [ -0.35, 0.21 ]
Kumar 2005 45 2 (0.8) 32 2.1 (1) 10.2 % -0.11 [ -0.57, 0.34 ]
Nematalla 2007 50 1.22 (0.51) 50 1.22 (0.5) 13.7 % 0.0 [ -0.39, 0.39 ]
Schulak 1989 30 1.8 (0.6) 33 1.8 (0.8) 8.6 % 0.0 [ -0.49, 0.49 ]
Subtotal (95% CI) 374 361 100.0 % 0.02 [ -0.12, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.56, df = 4 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Serum creatinine (mg/dL) one to five years
ATLAS Study 2005 139 1.6 (0.9) 139 1.57 (0.79) 40.4 % 0.04 [ -0.20, 0.27 ]
Montagnino 2005 53 1.8 (0.55) 49 1.95 (1.09) 14.8 % -0.17 [ -0.56, 0.21 ]
Woodle 2005 156 1.5 (0.6) 152 1.5 (0.7) 44.8 % 0.0 [ -0.22, 0.22 ]
Subtotal (95% CI) 348 340 100.0 % -0.01 [ -0.16, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
3 Creatinine clearance (mL/min) up to one year
ATLAS Study 2005 151 63.5 (21.7) 147 67.7 (24) 24.6 % -0.18 [ -0.41, 0.04 ]
FRANCIA Study 2007 98 58.19 (16.6) 99 57.84 (20.4) 19.5 % 0.02 [ -0.26, 0.30 ]
FREEDOM Study 2008 226 55.6 (23.4) 109 58.8 (20.5) 24.5 % -0.14 [ -0.37, 0.09 ]
Laftavi 2005 10 80.7 (29.3) 11 61.5 (25.6) 2.9 % 0.67 [ -0.21, 1.56 ]
Nematalla 2007 50 74.9 (23.1) 50 71.3 (10.9) 12.1 % 0.20 [ -0.20, 0.59 ]
Ponticelli 1997 76 58.9 (16.1) 77 64 (21.3) 16.4 % -0.27 [ -0.59, 0.05 ]
Subtotal (95% CI) 611 493 100.0 % -0.08 [ -0.23, 0.08 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 7.53, df = 5 (P = 0.18); I2 =34%
Test for overall effect: Z = 0.96 (P = 0.34)
4 Creatinine clearance (mL/min) one to five years
Montagnino 2005 53 52.3 (17.08) 49 52 (21.52) 18.1 % 0.02 [ -0.37, 0.40 ]
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Study or subgroup Avoidance Maintenance
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ponticelli 1997 76 57.3 (16.3) 77 61.2 (23.3) 27.1 % -0.19 [ -0.51, 0.12 ]
Woodle 2005 156 58.6 (17.9) 152 59.8 (20.5) 54.8 % -0.06 [ -0.29, 0.16 ]
Subtotal (95% CI) 285 278 100.0 % -0.08 [ -0.25, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 1.28, df = 3 (P = 0.73), I2 =0.0%
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Analysis 3.1. Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 1 Death and graft loss.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 3 Steroid avoidance versus steroid withdrawal
Outcome: 1 Death and graft loss
Study or subgroup Avoidance Withdrawal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Death up to one year
DOMINOS Study 2012 2/112 5/110 100.0 % 0.39 [ 0.08, 1.98 ]
Subtotal (95% CI) 112 110 100.0 % 0.39 [ 0.08, 1.98 ]
Total events: 2 (Avoidance), 5 (Withdrawal)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
2 Death one to five years
Boots 2002 2/28 0/34 23.2 % 6.03 [ 0.30, 120.75 ]
Sandrini 2009 4/44 2/46 76.8 % 2.09 [ 0.40, 10.85 ]
Subtotal (95% CI) 72 80 100.0 % 2.67 [ 0.63, 11.32 ]
Total events: 6 (Avoidance), 2 (Withdrawal)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
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Study or subgroup Avoidance Withdrawal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Graft loss including death up to one year
DOMINOS Study 2012 7/112 8/110 100.0 % 0.86 [ 0.32, 2.29 ]
Subtotal (95% CI) 112 110 100.0 % 0.86 [ 0.32, 2.29 ]
Total events: 7 (Avoidance), 8 (Withdrawal)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
4 Graft loss including death one to five years
Boots 2002 5/28 2/34 41.8 % 3.04 [ 0.64, 14.47 ]
Sandrini 2009 6/44 3/46 58.2 % 2.09 [ 0.56, 7.85 ]
Subtotal (95% CI) 72 80 100.0 % 2.44 [ 0.89, 6.70 ]
Total events: 11 (Avoidance), 5 (Withdrawal)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
5 Graft loss excluding death up to one year
DOMINOS Study 2012 5/112 3/110 100.0 % 1.64 [ 0.40, 6.68 ]
Subtotal (95% CI) 112 110 100.0 % 1.64 [ 0.40, 6.68 ]
Total events: 5 (Avoidance), 3 (Withdrawal)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
6 Graft loss excluding death one to five years
Boots 2002 3/28 2/34 65.5 % 1.82 [ 0.33, 10.15 ]
Sandrini 2009 2/44 1/46 34.5 % 2.09 [ 0.20, 22.25 ]
Subtotal (95% CI) 72 80 100.0 % 1.91 [ 0.48, 7.67 ]
Total events: 5 (Avoidance), 3 (Withdrawal)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 5.49, df = 5 (P = 0.36), I2 =9%
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Analysis 3.2. Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 2 Rejection.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 3 Steroid avoidance versus steroid withdrawal
Outcome: 2 Rejection
Study or subgroup Avoidance Withdrawal Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acute rejection up to one year
Sandrini 2009 22/44 14/46 1.64 [ 0.97, 2.78 ]
2 Biopsy-proven acute rejection up to one year
DOMINOS Study 2012 13/112 8/110 1.60 [ 0.69, 3.70 ]
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Analysis 3.3. Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 3 New-onset diabetes
after transplantation, infection, malignancy.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 3 Steroid avoidance versus steroid withdrawal
Outcome: 3 New-onset diabetes after transplantation, infection, malignancy
Study or subgroup Avoidance Withdrawal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 New onset diabetes after transplantation up to five years
Boots 2002 2/25 10/33 15.0 % 0.26 [ 0.06, 1.10 ]
DOMINOS Study 2012 9/103 13/100 47.1 % 0.67 [ 0.30, 1.50 ]
Sandrini 2009 7/44 9/46 37.9 % 0.81 [ 0.33, 1.99 ]
Subtotal (95% CI) 172 179 100.0 % 0.63 [ 0.36, 1.09 ]
Total events: 18 (Avoidance), 32 (Withdrawal)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.79, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.099)
2 Infection (all) up to five years
Boots 2002 26/28 24/34 39.3 % 1.32 [ 1.03, 1.67 ]
DOMINOS Study 2012 68/112 78/110 42.3 % 0.86 [ 0.71, 1.04 ]
Sandrini 2009 14/44 13/46 18.3 % 1.13 [ 0.60, 2.12 ]
Subtotal (95% CI) 184 190 100.0 % 1.07 [ 0.76, 1.50 ]
Total events: 108 (Avoidance), 115 (Withdrawal)
Heterogeneity: Tau2 = 0.06; Chi2 = 7.96, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 0.37 (P = 0.71)
3 CMV Infection up to five years
Boots 2002 2/28 6/34 13.4 % 0.40 [ 0.09, 1.85 ]
DOMINOS Study 2012 14/112 25/110 86.6 % 0.55 [ 0.30, 1.00 ]
Subtotal (95% CI) 140 144 100.0 % 0.53 [ 0.30, 0.92 ]
Total events: 16 (Avoidance), 31 (Withdrawal)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.025)
4 Malignancy up to five years
Sandrini 2009 3/44 2/46 100.0 % 1.57 [ 0.28, 8.94 ]
Subtotal (95% CI) 44 46 100.0 % 1.57 [ 0.28, 8.94 ]
Total events: 3 (Avoidance), 2 (Withdrawal)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Chi2 = 6.08, df = 3 (P = 0.11), I2 =51%
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Analysis 3.4. Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 4 Kidney function.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 3 Steroid avoidance versus steroid withdrawal
Outcome: 4 Kidney function
Study or subgroup Avoidance Withdrawal
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Serum creatinine (mg/dL) up to one year
Boots 2002 18 1.4 (0.3) 28 1.4 (0.5) 51.2 % 0.0 [ -0.59, 0.59 ]
DOMINOS Study 2012 20 1.53 (0.42) 22 1.62 (1.15) 48.8 % -0.10 [ -0.71, 0.51 ]
Subtotal (95% CI) 38 50 100.0 % -0.05 [ -0.47, 0.37 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Creatinine clearance (mL/min) up to one year
Boots 2002 18 55.3 (21.6) 28 53.2 (17.9) 21.6 % 0.11 [ -0.49, 0.70 ]
DOMINOS Study 2012 79 56 (18) 81 60 (22) 78.4 % -0.20 [ -0.51, 0.11 ]
Subtotal (95% CI) 97 109 100.0 % -0.13 [ -0.41, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 4.1. Comparison 4 Steroid withdrawal versus maintenance in children, Outcome 1 Death and graft
loss.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 4 Steroid withdrawal versus maintenance in children
Outcome: 1 Death and graft loss
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Death up to five years
Benfield 2005 1/73 5/59 100.0 % 0.16 [ 0.02, 1.35 ]
Ho¨cker 2009 0/23 0/19 Not estimable
Subtotal (95% CI) 96 78 100.0 % 0.16 [ 0.02, 1.35 ]
Total events: 1 (Withdrawal), 5 (Maintenance)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.092)
2 Graft loss including death up to five years
Benfield 2005 1/73 9/59 100.0 % 0.09 [ 0.01, 0.69 ]
Ho¨cker 2009 0/23 0/19 Not estimable
Subtotal (95% CI) 96 78 100.0 % 0.09 [ 0.01, 0.69 ]
Total events: 1 (Withdrawal), 9 (Maintenance)
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
3 Graft loss excluding death up to five years
Benfield 2005 0/73 4/59 100.0 % 0.09 [ 0.00, 1.64 ]
Ho¨cker 2009 0/23 0/19 Not estimable
Subtotal (95% CI) 96 78 100.0 % 0.09 [ 0.00, 1.64 ]
Total events: 0 (Withdrawal), 4 (Maintenance)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi2 = 0.18, df = 2 (P = 0.91), I2 =0.0%
0.002 0.1 1 10 500
Favours withdrawal Favours maintenance
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Analysis 4.2. Comparison 4 Steroid withdrawal versus maintenance in children, Outcome 2 Rejection,
malignancy.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 4 Steroid withdrawal versus maintenance in children
Outcome: 2 Rejection, malignancy
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acute rejection up to one year
Benfield 2005 4/73 9/59 80.9 % 0.36 [ 0.12, 1.11 ]
Ho¨cker 2009 1/23 2/19 19.1 % 0.41 [ 0.04, 4.21 ]
Subtotal (95% CI) 96 78 100.0 % 0.37 [ 0.13, 1.02 ]
Total events: 5 (Withdrawal), 11 (Maintenance)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.054)
2 Biopsy-proven acute rejection up to one year
Ho¨cker 2009 0/23 2/19 100.0 % 0.17 [ 0.01, 3.27 ]
Subtotal (95% CI) 23 19 100.0 % 0.17 [ 0.01, 3.27 ]
Total events: 0 (Withdrawal), 2 (Maintenance)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
3 Malignancy (PTLD) up to five years
Benfield 2005 7/73 3/59 100.0 % 1.89 [ 0.51, 6.98 ]
Subtotal (95% CI) 73 59 100.0 % 1.89 [ 0.51, 6.98 ]
Total events: 7 (Withdrawal), 3 (Maintenance)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Chi2 = 4.53, df = 2 (P = 0.10), I2 =56%
0.005 0.1 1 10 200
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Analysis 4.3. Comparison 4 Steroid withdrawal versus maintenance in children, Outcome 3 Kidney function.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 4 Steroid withdrawal versus maintenance in children
Outcome: 3 Kidney function
Study or subgroup Withdrawal Maintenance
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Creatinine clearance (mL/min) up to five years
Ho¨cker 2009 23 95.5 (23.9792) 17 94.4 (28.4494) 1.10 [ -15.60, 17.80 ]
-20 -10 0 10 20
Favours withdrawal Favours maintenance
Analysis 5.1. Comparison 5 Publication bias, Outcome 1 Funnel plots.
Review: Steroid avoidance or withdrawal for kidney transplant recipients
Comparison: 5 Publication bias
Outcome: 1 Funnel plots
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Death, steroid withdrawal versus maintenance
Ahsan 1999 0/134 1/132 0.8 % 0.33 [ 0.01, 7.99 ]
Bouma 1996 0/42 1/42 0.8 % 0.33 [ 0.01, 7.96 ]
del Castillo 2005 1/70 0/72 0.3 % 3.08 [ 0.13, 74.46 ]
Isoniemi 1990 3/32 4/32 2.1 % 0.75 [ 0.18, 3.09 ]
Lebranchu 1999 4/252 8/248 4.2 % 0.49 [ 0.15, 1.61 ]
Maiorca 1988 0/35 1/31 0.8 % 0.30 [ 0.01, 7.02 ]
Matl 2000 1/45 0/42 0.3 % 2.80 [ 0.12, 67.00 ]
Pelletier 2006 1/59 0/59 0.3 % 3.00 [ 0.12, 72.18 ]
Pisani 2001 1/15 0/15 0.3 % 3.00 [ 0.13, 68.26 ]
0.005 0.1 1 10 200
Favours withdrawal Favours maintenance
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(. . . Continued)
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
THOMAS Study 2002 3/279 6/277 3.1 % 0.50 [ 0.13, 1.97 ]
Subtotal (95% CI) 963 950 12.8 % 0.70 [ 0.39, 1.29 ]
Total events: 14 (Withdrawal), 21 (Maintenance)
Heterogeneity: Chi2 = 4.51, df = 9 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.25)
2 Acute rejection steroid withdrawal versus maintenance
Ahsan 1999 26/134 7/132 3.7 % 3.66 [ 1.65, 8.14 ]
Bouma 1996 11/42 1/42 0.5 % 11.00 [ 1.49, 81.44 ]
del Castillo 2005 17/70 13/72 6.6 % 1.35 [ 0.71, 2.56 ]
Isoniemi 1990 6/32 1/32 0.5 % 6.00 [ 0.77, 47.05 ]
Lebranchu 1999 76/252 52/248 27.2 % 1.44 [ 1.06, 1.95 ]
Maiorca 1988 16/35 3/31 1.6 % 4.72 [ 1.52, 14.69 ]
Matl 2000 3/45 2/42 1.1 % 1.40 [ 0.25, 7.97 ]
Pelletier 2006 3/59 3/59 1.6 % 1.00 [ 0.21, 4.75 ]
Pisani 2001 1/15 2/15 1.0 % 0.50 [ 0.05, 4.94 ]
THOMAS Study 2002 67/279 60/277 31.2 % 1.11 [ 0.82, 1.51 ]
Subtotal (95% CI) 963 950 75.0 % 1.55 [ 1.28, 1.87 ]
Total events: 226 (Withdrawal), 144 (Maintenance)
Heterogeneity: Chi2 = 19.74, df = 9 (P = 0.02); I2 =54%
Test for overall effect: Z = 4.58 (P < 0.00001)
3 Death, steroid avoidance versus maintenance
ATLAS Study 2005 3/151 0/147 0.3 % 6.82 [ 0.36, 130.81 ]
De Vecchi 1986 0/25 4/26 2.3 % 0.12 [ 0.01, 2.04 ]
FRANCIA Study 2007 1/98 3/103 1.5 % 0.35 [ 0.04, 3.31 ]
FREEDOM Study 2008 7/226 2/109 1.4 % 1.69 [ 0.36, 7.99 ]
Kumar 2005 0/45 0/32 Not estimable
Montagnino 2005 0/65 1/68 0.8 % 0.35 [ 0.01, 8.40 ]
Nematalla 2007 0/50 0/50 Not estimable
Nott 1985 8/59 8/58 4.2 % 0.98 [ 0.40, 2.44 ]
Schulak 1989 3/32 2/35 1.0 % 1.64 [ 0.29, 9.20 ]
Vincenti 2003a 0/40 1/43 0.8 % 0.36 [ 0.01, 8.54 ]
Subtotal (95% CI) 791 671 12.2 % 0.92 [ 0.52, 1.63 ]
Total events: 22 (Withdrawal), 21 (Maintenance)
Heterogeneity: Chi2 = 6.22, df = 7 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.78)
Total (95% CI) 2717 2571 100.0 % 1.36 [ 1.15, 1.62 ]
0.005 0.1 1 10 200
Favours withdrawal Favours maintenance
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(. . . Continued)
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 262 (Withdrawal), 186 (Maintenance)
Heterogeneity: Chi2 = 35.73, df = 27 (P = 0.12); I2 =24%
Test for overall effect: Z = 3.59 (P = 0.00033)
Test for subgroup differences: Chi2 = 8.15, df = 2 (P = 0.02), I2 =75%
0.005 0.1 1 10 200
Favours withdrawal Favours maintenance
A D D I T I O N A L T A B L E S
Table 1. Steroid withdrawal versus steroid maintenance - stratified subgroup and sensitivity analysis for death, graft loss and
acute rejection up to one year after transplantation
Death Graft loss Acute rejection Biopsy-proven acute rejection
Studies RR 95% CI Studies RR 95% CI Studies RR 95% CI Studies RR 95% CI
Publication status
Peer re-
viewed
journal
8 0.60 0.31 to
1.17
7 1.25 0.73 to
2.13
8 2.02 1.23 to 3.
23
4 1.32 0.66 to 2.66
Ab-
stract
only
2 3.04 0.33 to
28.29
1 0.82 0.23 to
2.94
2 1.25 0.67 to 2.
32
1 1.37 0.70 to 2.69
ITT analysis
ITT
analysis
used
6 0.69 0.30 to
1.61
6 1.31 0.69 to
2.46
6 2.07 1.10 to 3.
91
3 1.37 0.64 to 2.94
ITT
anal-
ysis not
used/
unclear
4 0.67 0.25 to
1.81
2 1.00 0.46 to
2.17
4 1.65 0.81 to 3.
36
2 1.04 0.24 to 4.59
Calcineurin inhibitor
CsA 9 0.75 0.36 to
1.54
7 0.90 0.50 to
5.14
9 2.08 1.29 to 3.
35
4 1.60 0.87 to 2.92
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Table 1. Steroid withdrawal versus steroid maintenance - stratified subgroup and sensitivity analysis for death, graft loss and
acute rejection up to one year after transplantation (Continued)
TAC 1 0.50 0.13 to
1.97
1 2.13 0.88 to
5.14
1 1.11 0.82 to 1.
51
1 0.89 0.61 to 1.30
Antimetabolite
MMF
or EC-
MPS
6 0.67 0.31 to
1.47
5 1.25 0.75 to
2.08
6 1.41 1.02 to 1.
94
3 1.27 0.81 to 2.00
AZA 2 0.93 0.26 to
3.40
2 0.25 0.03 to
2.18
2 2.61 0.62 to
10.91
1 0.33 0.04 to 2.56
MMF
or EC-
MPS or
AZA
8 0.73 0.38 to
1.43
7 1.15 0.70 to
1.89
8 1.46 1.07 to 1.
98
4 1.19 0.75 to 1.90
none 2 0.31 0.03 to
2.95
1 3.00 0.13 to
71.61
2 5.80 2.16 to
15.57
1 9.00 1.19 to 67.93
Induction treatment
Induc-
tion
(yes)
2 3.00 0.32 to
27.87
1 0.33 0.01 to
8.02
2 0.80 0.22 to 2.
91
NA -- --
Induc-
tion
(no)
8 0.60 0.31 to
1.17
7 1.21 0.74 to
1.99
8 1.93 1.26 to 2.
94
NA -- --
AZA - azathioprine; CI - confidence interval; CsA - cyclosporin A; EC-MPS - enteric-coated mycophenolate sodium; ITT - intention
to treat; MMF - mycophenolate mofetil; NA - not available; RR - risk ratio; TAC - tacrolimus
Table 2. Steroid avoidance versus steroid maintenance - stratified subgroup and sensitivity analysis for death, graft loss and
acute rejection up to one year after transplantation
Death Graft loss Acute rejection Biopsy-proven acute rejection
Studies RR 95% CI Studies RR 95% CI Studies RR 95% CI Studies RR 95% CI
ITT analysis
ITT
analysis
used
7 1.16 0.48 to
2.83
5 1.09 0.56 to
2.11
4 1.92 1.18 to 3.
14
4 2.31 1.47 to 3.63
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Table 2. Steroid avoidance versus steroid maintenance - stratified subgroup and sensitivity analysis for death, graft loss and
acute rejection up to one year after transplantation (Continued)
ITT
anal-
ysis not
used/
unclear
3 0.51 0.07 to
3.83
2 1.11 0.46 to
2.67
3 1.24 0.97 to 1.
59
2 1.05 0.49 to 2.23
Calcineurin inhibitor
CsA 8 0.88 0.47 to
1.66
5 1.08 0.59 to
1.99
5 1.31 1.05 to 1.
63
3 1.89 1.29 to 2.79
TAC 2 6.82 0.36 to
130.81
2 1.14 0.39 to
3.3
2 2.40 1.05 to 5.
49
3 1.81 0.66 to 4.99
Antimetabolite
MMF
or EC-
MPS
6 1.15 0.36 to
3.69
6 1.09 0.56 to
2.11
5 1.87 1.20 to 2.
91
6 1.94 1.26 to 2.98
AZA 1 1.64 0.29 to
9.2
NA -- -- NA -- -- NA -- --
MMF
or EC-
MPS or
AZA
8 1.16 0.48 to
2.83
NA -- -- NA -- -- NA -- --
None 2 0.51 0.07 to
3.83
1 1.11 0.46 to
2.67
2 1.26 0.95 to 1.
65
NA -- --
Induction treatment
Induc-
tion
(yes)
7 0.97 0.38 to
2.48
5 1.06 0.45 to
2.46
4 1.50 0.97 to 2.
32
5 1.67 1.19 to 2.36
Induc-
tion
(no)
3 0.92 0.17 to
5.01
2 1.12 0.57 to
2.2
3 1.72 0.89 to 3.
32
1 3.89 2.16 to 7.03
AZA - azathioprine; CI - confidence interval; CsA - cyclosporin A; EC-MPS - enteric-coated mycophenolate sodium; ITT - intention
to treat; MMF - mycophenolate mofetil; NA - not available; RR - risk ratio; TAC - tacrolimus
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. Kidney Transplantation [MESH]
2. kidney transplant*
3. 1 or 2
4. (avoid* or minim* or free* or withdraw* or spar* or discontinu* or taper* or conversion* or convert*) near25
(predniso* or corticosteroid* or steroid*)
5. 3 and 4
MEDLINE 1. Kidney Transplantation/
2. ((avoid$ or minim$ or free$ or withdraw$ or spar$ or discontinu$ or taper$ or conversion$ or convert$) adj25
(predniso$ or corticosteroid$ or steroid$)).tw.
3. and/1-2
EMBASE 1. exp kidney transplantation/
2. Drug Withdrawal/
3. ((avoid$ or minim$ or free$ or withdraw$ or spar$ or discontinu$ or taper$ or conversion$ or convert$) adj25
(predniso$ or corticosteroid$ or steroid$)).tw.
4. or/2-3
5. and/1,4
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias:Randomisation method described that would not
allow investigator/participant to know or influence intervention
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(Continued)
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
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(Continued)
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
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(Continued)
High risk of bias:Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
WH A T ’ S N E W
Last assessed as up-to-date: 15 February 2016.
Date Event Description
15 February 2016 New search has been performed New studies included (20)
15 February 2016 New citation required and conclusions have changed New studies added; paediatric studies included
H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 1, 2009
Date Event Description
14 July 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
• MCH: performed study selection, data extraction, risk of bias assessment, data entry, data analyses and wrote the manuscript.
• AR: performed study selection, data extraction, risk of bias assessment, reviewed results and manuscript.
• EVN: performed study selection, resolved disagreement, reviewed results and manuscript and provided senior methodological
support.
• JP: resolved disagreement, reviewed results and manuscript and provided senior expert support.
• ACW: resolved disagreement, reviewed results and manuscript and provided senior expert support.
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D E C L A R A T I O N S O F I N T E R E S T
• MCH: none known
• AR: none known
• EVN: none known
• JP: none known
• ACW: none known
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• ERBP-Fellowship to assist guideline development process (Ghent University, Renal Division, Belgium), Belgium.
Dr Maria C. Haller and Dr Evi V. Nagler are ERBP research fellows. European Renal Best Practice (ERBP) is the official guidance
issuing body of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the earlier version of this review (Pascual 2009), we did not specifically include CMV infection as an outcome. Recent publications
include reporting of CMV infection as a specific outcome, and this has been translated to our review.
Since this review was last published (in 2009), the Cochrane risk of bias tool has been updated, and the current tool has been used in
assessments for this update.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Graft Rejection [immunology; ∗prevention & control]; Graft Survival [drug effects; immunology]; Immunosuppression; Immuno-
suppressive Agents [∗administration & dosage; adverse effects]; Kidney Transplantation [∗immunology; mortality]; Randomized Con-
trolled Trials as Topic; Steroids [∗administration & dosage; adverse effects]
MeSH check words
Humans
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